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Abstract 
Gene therapy has shown potential in alleviating a wide range of diseases, ranging from 
viral infections to autosomal diseases. One of the obstacles to gene therapy reaching its full 
potential is the inadequacy of methods to deliver therapeutic nucleic sequences. Current 
delivery of gene therapy entails use of viral and non-viral vectors. Viral vectors are however 
associated with drawbacks such as potential toxicity, high cost and labour-intensive 
production. Thus non-viral delivery alternatives are being developed in an attempt to 
overcome difficulties associated with nucleic acid delivery for gene therapy. Virus-like 
particles are potentially very useful delivery vehicles as their production is simple and cost 
effective, the particle surface is amenable to modification and the capsid interior can be 
altered to accommodate a variety of cargoes. One such particle is the recombinant HBV 
capsid, which comprises a single species of protein and is tolerant of amino acid 
substitutions on the surface exposed immunodominant loops. This study aimed to enhance 
the vector-like properties of the HBV virus-like particle by including amino acid substitutions 
on the particle surface. These substituted residues in turn provided a conjugation site for 
tropic and immuno evasive moieties. It was found that lysine substitutions resulted in poor 
conjugation to the capsid surface, whereas substituted cysteine residues resulted in almost 
all protein-moiety conjugates forming. In order to introduce lysine and cysteine 
substitutions, a novel method of cloning into the HBV was generated. In doing so, 
complicated procedures associated with cloning into the immunodominant loop of the HBV 
capsid have been alleviated. Ligands containing galactose were utilised on the surface of 
both the HBV capsid and liposomes to confer hepatotropism. The presence of the galactose 
moieties on the surface of the HBV capsid prevented indiscriminate cellular uptake in 
cultured cells, however did not improve hepatotropism. Galactose ligands on the surface of 
liposomes did improve transfection efficiency, however they required a short linker distance 
between liposome surface and galactose group. The inclusion of galactose in liposome 
formulations also provided a means to deliver siRNA to the liver of transgenic HBV mice. It is 
believed that with alterations to the ligand structure, it is possible to provide HBV capsids 
with hepatotropism in future experimentation. This study demonstrated that the exposed 
external surface of the HBV capsid is amenable to convenient conjugation, which potentially 
facilitates immune evasion and conferring of defined tropism. 
Page | vi  
 
Acknowledgements 
1) I would like to extend my heart-felt gratitude to my supervisor, Patrick Arbuthnot, 
who has played a significant part in sculpting the researcher who I am today 
2) Thanks go to my colleagues of AGTRU for the help and support during the course of 
the degree. A special thanks to Tristan Scott and Liam Thompson for providing the 
thought provoking conversations. 
3) I would like to thank Abdullah Ely, Carol Crowther and Gladys Gagliardi for assisting 
with in vivo experimentation. 
4) I would like to thank the members of the Wits Chemistry department, Charles de 
Koning, Willem van Otterlo, Rafique Islam and Santanu Chakraborty for the synthesis 
of the lipid-based compounds used in this study. I would also like to thank Prof. Injae 
Shin and colleagues (National Creative Research Initiative Center for Biofunctional 
Molecules, Department of Chemistry, Yonsei University, Korea) for the synthesis of 
maleimide-based carbohydrate compounds. 
5) I would like to acknowledge Dr. Michael Nassal for the plasmid pCH-9/3091. 
6) I would sincerely like to thank the funding bodies for support during the course of 
this work. The Postgraduate Merit Award, the Paul and Stella Loewenstein Charitable 
and Educational Trust, the Poliomyelitis Research Foundation, the National Research 
Foundation (Nanotechnology Flagship Program and Scarce Skills), Faculty Research 
Committee grant, the Sixth Research Framework Programme of the European Union, 
Project RIGHT (LSHB- CT-2004-005276) 
7) To Goonaseelan Pillai and Nicole Meisner for organising and hosting me during an 
internship based within Novartis, Basel. 
 
 
 
 
Page | vii  
 
Table of Contents 
Modification to the immunodominant loop of hepatitis B virus core protein to enhance vector 
properties of virus-like particles .............................................................................................................. i 
Declaration .............................................................................................................................................. ii 
Dedication .............................................................................................................................................. iii 
Publications related to thesis ................................................................................................................. iv 
Abstract ................................................................................................................................................... v 
Acknowledgements ................................................................................................................................ vi 
List of Figures ........................................................................................................................................ xii 
List of Tables ......................................................................................................................................... xv 
List of Abbreviations .............................................................................................................................xvi 
List of Symbols ...................................................................................................................................... xix 
Chapter 1: Introduction .......................................................................................................................... 1 
Brief overview of gene therapy .................................................................................................... 1 
Popular forms of gene therapy .................................................................................................... 2 
Prominent viral vectors in gene therapy ...................................................................................... 6 
Liposomes and lipoplexes as gene therapy vectors ..................................................................... 9 
Virus-like particles as gene therapy vectors ............................................................................... 10 
Chapter 2: The influence of galactose linker length on liposomal hepatotropic transfection efficiency
 .............................................................................................................................................................. 12 
2.1. Introduction ......................................................................................................................... 12 
2.2. Results ................................................................................................................................. 23 
2.2.1. Initial liposome formulation with monosaccharide-cholesterol conjugates................ 23 
2.2.2. Determination of DNA to lipid charge neutralising ratios by mobility shift assay ....... 23 
Page | viii  
 
2.2.3 Assessment of the transfection efficiency of MCC-containing liposomes .................... 25 
2.2.4 Determination of MCC concentration for optimal transfection in Huh7 cells. ............. 26 
2.2.5 Comparison of SLC P-Gal and Lipofectamine2000 transfection efficiency. .................. 28 
2.2.6 In vivo delivery of anti-HBV siRNAs using hepatotropic liposomes .............................. 28 
2.3. Discussion ............................................................................................................................ 34 
2.4. Materials and methods ....................................................................................................... 36 
2.4.1 Formulation and lipoplexing .......................................................................................... 36 
2.4.2 Mobility Shift Assay ....................................................................................................... 37 
2.4.3 Transfections and Luciferase Assays ............................................................................. 37 
2.4.4 In vivo assessment of hepatotropic delivery of liposomes in transgenic mice ............. 37 
2.4.5 Statistical analysis .......................................................................................................... 38 
Chapter 3: Amino acid substitutions to the immunodominant loop of the HBV capsid to generate 
ligand conjugation sites as a means of improving vector-like properties. ........................................... 39 
3.1. Introduction ......................................................................................................................... 39 
3.1.1 Composition of the hepatitis B virus capsid and applicability as a vector for gene 
therapy. ........................................................................................................................ 44 
3.2.1. Generation of HBV capsid library with modifications to the protamine domain. ....... 53 
3.2.2. Capsid yield is impacted by the position of lysine residue substitutions within the 
immunodominant loop ................................................................................................. 55 
3.2.3 Development of the core ‘Snap-in’ system as a means to simplify cloning into the IL 
region. ........................................................................................................................... 60 
3.2.4. Introduction of lysine and cysteine residues into the IL with minimal impact on 
electrostatic potential .................................................................................................. 62 
3.3. Discussion ............................................................................................................................ 70 
3.4. Materials and methods ....................................................................................................... 72 
Page | ix  
 
3.4.1. Cloning of recombinant c140, c149, c160, c170 and c183 cassette constructs ........... 72 
3.4.2 Cloning of core D78K S81K mutant and core LinkedLys mutants ................................. 75 
3.4.3 Generation of the IL ‘Snap-in’ system in pTZ57R. ......................................................... 79 
3.4.3. Core protein expression in Rosetta II bacteria ............................................................. 82 
3.4.4 Agarose gel and polyacrylamide gel analysis and staining ............................................ 84 
3.4.5 Electrostatic modelling. ................................................................................................. 84 
Chapter 4: Modification of recombinant HBV capsids using functional moiety-IL conjugation or 
liposome encapsulation. ....................................................................................................................... 85 
4.1 Introduction .......................................................................................................................... 85 
4.2 Results .................................................................................................................................. 91 
4.2.1 Assessment of lysine-N-hydroxysuccinimide-based conjugation of scPEG to capsids 
containing R82K and A80K R82K .................................................................................. 91 
4.2.2 Maleimide-based ligand conjugation to inserted cysteine residues of S81C and L76C 
S81C .............................................................................................................................. 95 
4.2.3 Increased incubation time results in malPEG conjugation to c160 L76C S81C and c170 
L76C S81C. .................................................................................................................... 97 
4.2.4 Cysteine-maleimide conjugation of functional ligands to c149 L76C S81C and c160 
L76C S81C ..................................................................................................................... 99 
4.2.5. Assessment of VLP liposome envelopment using mobility shift assay analysis ......... 105 
4.2.6. Particle size analysis of capsids, liposomes and enveloped virus-like particles ......... 107 
4.2.7. Particle analysis by electron microscopy .................................................................... 108 
4.3. Discussion .......................................................................................................................... 110 
4.4 Materials and methods ...................................................................................................... 113 
4.4.1 Recombinant capsid preparation ................................................................................ 113 
4.4.2 Conjugation of ligands to capsid surface ..................................................................... 113 
Page | x  
 
4.4.3 Molecular modelling .................................................................................................... 114 
4.4.4 Complexing of virus-like particles with liposomes ...................................................... 114 
4.4.5 Particle sizing ............................................................................................................... 114 
4.4.5 Mobility shift assays .................................................................................................... 114 
4.4.6 Electron Microscopy .................................................................................................... 115 
Chapter 5: Assessment of the decorated and loaded capsid hepatotropic properties with cultured 
cells ..................................................................................................................................................... 116 
5.1 Introduction ........................................................................................................................ 116 
5.2 Results ................................................................................................................................ 120 
5.2.1 Encapsidation of radio-labelled oligonucleotides by c183 .......................................... 120 
5.2.2 In vitro cellular uptake assessment of decorated, loaded c160 L76C S81C ................ 121 
5.2.4 Comparison of ligand linker lengths suggests why poor delivery occurred in ............ 126 
5.3 Discussion ........................................................................................................................... 127 
5.4 Materials and methods ...................................................................................................... 131 
5.4.1 Recombinant capsid preparation ................................................................................ 131 
5.4.2 Capsid dissociation and re-association ........................................................................ 131 
5.4.3 32P-labelling of oligonucleotides .................................................................................. 131 
5.4.4 Imaging with the Phosphorimager .............................................................................. 131 
5.4.5 Cell Culture and VLP inoculations ................................................................................ 132 
5.4.6 Microscopy and imaging .............................................................................................. 132 
Chapter 6: Conclusion ......................................................................................................................... 133 
Appendix 1 ................................................................................................................................ 135 
Primer sequences ................................................................................................................. 135 
Oligonucleotides ................................................................................................................... 136 
Page | xi  
 
Appendix 2 ................................................................................................................................ 137 
Reagent recipes .................................................................................................................... 137 
Appendix 3 – Standard Laboratory Protocols ........................................................................... 142 
A3.1 Chemically competent bacteria ................................................................................... 142 
A3.2 Transformation of chemically competent bacteria ...................................................... 142 
A3.3 Blue-white screening .................................................................................................... 142 
A3.4 Plasmid extraction ........................................................................................................ 143 
A3.4 Phenol-chloroform extraction ...................................................................................... 144 
A3.5 Agarose and polyacrylamide gel staining to detect recombinant HBV capsids ........... 144 
Appendix 4 ................................................................................................................................ 145 
A4.1 Example calculation to determine lysine:ligand mole ratio for conjugation ............... 145 
A4.2 Example calculation to determine cysteine:ligand mole ratio for conjugation ........... 145 
A4.3 Calculation to determine oligonucleotides (25-mer) required per g of capsid ......... 146 
References .......................................................................................................................................... 147 
 
Page | xii  
 
List of Figures 
Figure 1.1 .......................................................................................................................................... 5 
Figure 1.2 .......................................................................................................................................... 8 
Figure 2.1.1 ..................................................................................................................................... 14 
Figure 2.1.2 ..................................................................................................................................... 18 
Figure 2.1.3 ..................................................................................................................................... 19 
Figure 2.1.4: .................................................................................................................................... 20 
Figure 2.1.5: .................................................................................................................................... 21 
Figure 2.2.1 ..................................................................................................................................... 24 
Figure 2.2.2: .................................................................................................................................... 26 
Figure 2.2.3: .................................................................................................................................... 27 
Figure 2.2.4: .................................................................................................................................... 28 
Figure 2.2.5: .................................................................................................................................... 29 
Figure 2.2.6: .................................................................................................................................... 31 
Figure 2.2.7: .................................................................................................................................... 32 
Figure 2.2.8: .................................................................................................................................... 33 
Figure 3.1.1: .................................................................................................................................... 42 
Figure 3.1.2: .................................................................................................................................... 43 
Figure 3.1.3: .................................................................................................................................... 46 
Figure 3.1.4: .................................................................................................................................... 47 
Figure 3.1.5: .................................................................................................................................... 48 
Figure 3.1.7: .................................................................................................................................... 51 
Figure 3.2.1: .................................................................................................................................... 54 
Page | xiii  
 
Figure 3.2.2 ..................................................................................................................................... 57 
Figure 3.2.3: .................................................................................................................................... 57 
Figure 3.2.4: .................................................................................................................................... 59 
Figure 3.2.5: .................................................................................................................................... 60 
Figure 3.2.6: .................................................................................................................................... 61 
Figure 3.2.7: .................................................................................................................................... 62 
Figure 3.2.8: .................................................................................................................................... 63 
Figure 3.2.9: .................................................................................................................................... 64 
Figure 3.2.10: .................................................................................................................................. 65 
Figure 3.2.11: .................................................................................................................................. 67 
Figure 3.2.12: .................................................................................................................................. 68 
Figure 3.2.13: .................................................................................................................................. 69 
Figure 3.4.1: .................................................................................................................................... 77 
Figure 3.4.2: .................................................................................................................................... 78 
Figure 3.4.3: .................................................................................................................................... 80 
Figure 3.4.4: .................................................................................................................................... 81 
Figure 4.1.1: .................................................................................................................................... 88 
Figure 4.1.2: .................................................................................................................................... 89 
Figure 4.2.1: .................................................................................................................................... 93 
Figure 4.2.2: .................................................................................................................................... 93 
Figure 4.2.3: .................................................................................................................................... 94 
Figure 4.2.4: .................................................................................................................................... 96 
Figure 4.2.5: .................................................................................................................................... 97 
Page | xiv  
 
Figure 4.2.6: .................................................................................................................................... 98 
Figure 4.2.7: .................................................................................................................................. 100 
Figure 4.2.8: .................................................................................................................................. 101 
Figure 4.2.9: .................................................................................................................................. 104 
Figure 4.2.10: ................................................................................................................................ 105 
Figure 4.2.11: ................................................................................................................................ 106 
Figure 4.2.12: ................................................................................................................................ 108 
Figure 4.2.13: ................................................................................................................................ 109 
Figure 5.2.2: .................................................................................................................................. 122 
Figure 5.2.3: .................................................................................................................................. 124 
Figure 5.2.4: .................................................................................................................................. 125 
Figure 5.2.6: .................................................................................................................................. 127 
 
 
 
 
 
 
 
 
 
 
Page | xv  
 
List of Tables 
Table 2.1.1 ...................................................................................................................................... 13 
Page | xvi  
 
List of Abbreviations 
3D – Three dimensional 
aa – Amino acid 
AAV – Adeno-associated virus 
Ac – Acetyl group 
Ad – Adenovirus 
ADA-SCID – adenosine deaminase severe combined immuno-deficiency 
ALT – Alanine aminotransferase 
ANA – Altritol nucleic acids 
ASGPr – Asialoglycoprotein receptor 
AST – Aspartate transaminase 
bp – Base pair 
BSA – Bovine serum albumin 
c(140, 149, 160, 170, 183) – core protein variant 
CK – Creatine phosphokinase 
CL19 – Cationic lipid 19 
cp – core protein 
DC Chol - 3β-[N-(Dimethylaminoethane)carbamoyl]cholesterol 
DMEM - Dulbecco’s Modified Eagle’s Medium 
DNA – deoxyribonucleic acid 
DOPE – 1,2-dioleyl-sn-glycero-3-phosphoethanolamine 
ds – Double stranded 
DTT – Dithiothreitol  
e1 – epitope 1 
e2 – epitope 2 
eGFP – Enhanced green fluorescent protein 
ELISA – Enzyme-linked immunosorbent assay 
F5M – Fluorescein-5-maleimide 
FCS – Foetal calf serum 
FITC – Fluorescein isothiocyanate 
Gal – Galactose 
Page | xvii  
 
GalNAc – N-acetylgalactosamine 
glu – Glucose 
HBcAg – Hepatitis B core antigen 
HBsAg – Hepatitis B surface antigen 
HBV – Hepatitis B virus 
HEK293 – Human embryonic kidney 293 
HeLa – Henrietta Lacks 
HIV – Human immunodeficiency virus 
Huh7 – Human hepatocellular carcinoma 7 
IL – Immunodominant loop 
IPTG – Isopropyl -D-1-thiogalactopyranoside 
kb – kilobase 
LacZ – -galactosidase 
LB – Lysogeny broth 
LDH – Lactate dehydrogenase  
LLC – Long linker chain 
LNA – Locked nucleic acid 
mal – Maleimide 
MCC – Monosaccharide-cholesterol conjugates 
-mer – Oligomer 
min - Minute 
miRNA – MicroRNA 
MLC – Medium linker chain 
MOI – Multiplicity of infection 
NHS – N-hydroxysuccinimidyl 
ORF – Open reading frame 
OspA – Outer surface lipoprotein A 
P-Gal – Protected galactose 
PCR – Polymerase chain reaction 
pDNA – Plasmid DNA 
PEG – polyethylene glycol 
pH – Power of hydrogen 
Page | xviii  
 
Pol – RNA polymerase 
PS – Phosphatidyl serine 
pgRNA – Pregenomic RNA 
RISC – RNA induced silencing complex 
RNA – Ribonucleic acid 
RNAi – RNA interference 
sc – Succinimidyl carbonate 
SEC – Size exclusion-based chromatography 
SEM – standard error of the mean 
SDS-PAGE – Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SFDA – China’s State Food and Drug Administration 
siRNA – short interfering RNA 
SLC – Short linker chain 
TALEN – Transcription activator-like effector nucleases 
TCEP – Tris(2-carboxyethyl)phosphine 
UnP-Gal – Unprotected galactose 
UV – Ultra violet 
VLP – Virus-like particle 
wt – Wild type 
X-gal – 5-bromo-4-chloro-indolyl-galactopyranoside 
X-SCID – X-linked severe combined immunodeficiency 
 
Page | xix  
 
List of Symbols 
Å – Angstrom 
 – alpha 
 - beta 
oC – centigrade 
Ci - Curie 
Da – Dalton 
g – local gravitational field 
g – gram 
HII – Inverted hexagonal phase 
IU – International units 
L(l) – litre 
- - micro- 
k- - kilo- 
m- - milli- 
M- - Mega 
m – meter 
M – molar 
mol – mole 
n- – nano- 
n – experimental number 
p- – pico- 
P – Packing parameter 
T – triangulation number 
w – weight 
 
 
 
 
Page | 1  
 
Chapter 1: Introduction 
Brief overview of gene therapy 
The twenty first century is an exciting age in which medicine will see the full realisation 
of gene therapy. Since its initial conception in the mid twentieth century the field of gene 
therapy has flourished into a multitude of applications. Typically gene therapy involves the 
introduction of exogenous nucleic acids to a cell to correct a diseased state of the host. In 
doing so, diseases including cancer, autosomal and viral in origin have the potential to be 
treated. A popular means to introduce exogenous DNA in vivo is through the use of 
recombinant viral vectors. The concept of gene transfer using viruses initiated with humble 
beginnings, without therapeutic objectives in mind.  Viral gene transfer was first observed to 
occur from bacteriophages to host bacteria [1]. Although bacteriophage to bacteria gene 
transfer does not constitute gene therapy, it did suggest that gene transfer from one 
organism to another was possible. In a related experiment, gene transfer was identified to 
occur between Rous sarcoma virus and cultured chicken cells [2]. This observation further 
supported the idea that viruses could be utilised as vehicles to transfer genetic material, 
however the molecular biology tools required to implement gene transfer were 
undeveloped. The first human gene therapy experiment was performed in the 1970s using 
wild-type Shope papilloma virus on two individuals suffering from a urea cycle disorder [3, 
4]. It was shown that the Shope papilloma virus induced arginase production in virus-
induced papillomas on the skin of rabbits. It was known that the Shope papilloma virus was 
also capable of infecting human cells, and initial in vitro experiments suggested that infected 
cultured skin fibroblasts produced virally induced arginase. The escalated human trial was 
unsuccessful; the authors suggest this resulted from immune clearance of the virus or poor 
quality of virus administered.  
It was only in the 1990s that gene therapy gained momentum, targeting a variety of 
diseases [5-8]. It was also required to develop vehicles/vectors for delivery of therapeutic 
sequences in vivo. Ideally the viral vectors would be non-replicative recombinant viruses 
with the capability to deliver therapeutic cargo to specific cell types without stimulating a 
significant immune response. During the 1990s it was unfortunate that one individual died 
of a severe immune response to the administered viral vector, and three children from 
leukaemia-related malignancies caused by random integration of the recombinant virus. 
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However this significantly contributed to the development and understanding of viral 
vectors for gene therapy [9]. Alternative means for delivery were also sought, employing the 
use of synthetic compounds and structures to deliver remedial nucleic acids. Ideally the 
synthetic vectors would overcome the toxicity associated with viral vectors, as well as 
significantly decrease the cost of vector production. Synthetic delivery systems may consist 
of lipids and liposomes, polymers, modified nucleic acids or virus-like particles (VLPs). For 
the purposes of this work a distinction between viral vectors and VLPs is required. Viral 
vectors are defined as bearing a large degree in similarity to their wild type counterparts. 
Often structure, genome size and mode of infectivity remain the same. VLPs may resemble 
viral structures, may not contain viral-related nucleic acids, generally are non-infectious and 
are often recombinantly expressed and produced.  
Popular forms of gene therapy 
Various forms of gene therapy have been developed, each remediating disease at the 
DNA, RNA or protein level. Typically the introduction of a gene cassette to a host cell is 
responsible for expression of the therapeutic product. Integration of the cassette into host 
chromosomal material may result in stable expression of the transgene; whereas episomal 
constructs tend toward transient expression. For the purposes of brevity, four forms of gene 
therapy are highlighted.  
Introduction of a corrective gene to replace the effects of a dysfunctional gene 
This means of correction has been used to treat several autosomal diseases such as 
adenosine deaminase severe combined immuno-deficiency (ADA-SCID) [10], Duchenne 
muscular dystrophy [11] and lysosomal storage disease [12, 13]. In each of the 
aforementioned states, the disease was alleviated by the introduction of a functional gene, 
typically delivered by a recombinant virus (Figure 1.1A). Presence of the gene could be 
transient or permanent, both associated with benefits and shortfalls. Transient gene 
expression has been demonstrated to be stable for up to two years in mice and seven years 
in dogs and rhesus monkeys [14-16]. Unfortunately, if the autosomal condition is not 
permanently corrected, multiple instances of vector re-administration will be required, 
which may lead to immuno-stimulatory complications. Permanent inclusion of the 
therapeutic sequence requires insertion into the host genetic material, which may lead to 
undesired mutagenesis [17].  
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Introduction of a gene to induce toxicity within diseased cells 
Certain therapeutic approaches may introduce a gene product that induces a toxic state 
within targeted cells (Figure 1.1A). In doing so it is possible to destroy a particular 
population of cells, for example cancerous cells. Cellular death can be brought about by the 
conversion of a prodrug to a toxic product by the expressed therapeutic enzyme. There are 
several varieties of enzymes that have been assessed to induce cellular toxicity, including 
thymidine kinase [18-20], cytosine deaminase [21, 22] and nitroreductase [23, 24]. This form 
of therapy has seen successful clinical trial outcomes, and is described later in this chapter. 
Introduction of a gene to down-regulate the expression of a disease causing gene  
The advent of RNA interference (RNAi) has allowed for the extensive research into gene 
regulation, spanning from viral to host regulatory genes [25]. RNAi is a natural post-
transcriptionally based regulatory system that utilises short (21-23 nucleotide) RNA 
sequences to target and degrade or sequester complementary RNA. This regulatory 
pathway can be manipulated to target specific RNA sequences at various entry points, by 
the introduction of therapeutic primary microRNAs, short hairpin RNAs or short interfering 
RNAs (Figure 1.1B). The field of RNAi contains numerous reviews, and has been thoroughly 
described elsewhere [26, 27].  
Introduction of a corrective gene to disrupt genes causing a diseased state 
Typically this form of therapy involves the introduction of a site-directed nuclease to 
create double stranded DNA breaks. Initially accomplished by using zinc finger nucleases 
[28] and meganucleases [29], recent discovery has led to the further development of 
designer nucleases known as transcription activator-like effector nucleases (TALENs) [30-32] 
and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas (CRISPR 
associated proteins) [33-35]. Disruption of target sequences is a powerful technology, as it 
allows for the treatment of chronic infections caused by viruses such as hepatitis B virus, by 
targeting the episomal viral covalently closed circular DNA [36]. In addition, homology 
directed repair of the cell can be utilised to repair double stranded breaks to remediate 
single nucleotide polymorphisms and short regions of mutations (Figure 1.1C). 
Introduction of a gene to induce a immuno-stimulatory response 
Vaccinology by gene therapy requires the introduction and expression of immunogenic 
proteins to induce an immune response against disease causing agents (Figure 1.1A).  
Recently, this form of treatment made an impact within the field of HIV vaccinology [37]. 
Hansen and colleagues described a gene therapy vaccine capable of generating an immune 
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response against SIV in macaque monkeys over several months. Ideally this method of 
vaccinating against HIV will translate with equivalent efficacy in humans. These vaccines are 
not limited to viral infections but can also be applied to cancer. There are several reports 
indicating the potential to introduce a foreign protein to cancerous cells, causing their 
recognition and destruction by the immune system [38-40]. 
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Figure 1.1: A diagrammatic comparison of gene therapy methodologies currently researched to treat various diseases. (A) Introduction of exogenous genes may result in 
dysfunctional gene correction or cellular toxicity. Typically corrective sequences are introduced by viral vectors, which deliver their cargo to the nucleus. Transient 
corrections are introduced by the presence of episomal structures. Stable transformations occur as a result of insertion of therapeutic sequence into host chromosome. (B) 
The natural RNA interference pathway, with entry points of potentially therapeutic mimics indicated. Mimics are introduced using viral transduction, lipid-based 
transfection or as naked, chemically modified siRNA structures. (C) TALEN mediated disruption of target sequence. After the selective binding to a target site, endonuclease 
FokI, causes a single stranded nick in the sequence. Strand breakage is caused by the binding and cleavage of dimer TALENs. I) Non-homologous end joining may result in 
the insertion or deletion of nucleotides at the cleaved site. II) Including a donor sequence allows for the correction of SNPs and nucleotides by homology-direct repair.  
C B A 
I 
II 
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Prominent viral vectors in gene therapy 
Currently there are three viral families which make up the majority of viral vectors for 
gene therapy: adenoviruses (Ads), adeno-associated viruses (AAVs) and retroviruses (which 
encompass lentiviruses). Each provides a variety of unique advantages and drawbacks. Ads 
were one of the few viruses to show clinical success in the early 1990s, and subsequently 
have been included in a large number of viral vector-based clinical trials (over 430 trials, 
constituting 23% of viral vector trials) [41]. These vectors have the ability to deliver 
transgene sizes of up to 32 kb into both dividing and non-dividing cell lines. Furthermore 
Ads display a large variety of serotype dependent tissue tropism, rarely integrate into host 
chromosomes and can be produced at high titres [42-44]. Unfortunately Ads are associated 
with innate and pre-existing adaptive immunity, which is especially common amongst 
populations of developing countries. The immune response may significantly reduce the 
delivery efficacy of the vector and in severe cases result in toxicity or even death. Strategies 
to avoid immunostimulation have been employed, such as the conjugation of polymers (e.g. 
PEG) to the Ad surface [45]. Treatment with recombinant Ads has resulted in variable 
efficacy, attributed to both virus-host interaction and therapeutic cassette expression [44, 
46]. Nonetheless, successful treatment with recombinant Ads does result in prolonged 
therapeutic effect [47-49]. In particular, the use of third generation/gutless Ads has shown 
continued transgene expression of two and up to seven years (and ongoing) in primates 
[50]. Therapeutic Ads face certain hurdles that have to be overcome prior to their successful 
use as prominent gene therapy vectors. Other than the previously described immunologic 
hurdles, recombinant Ads are also costly and labour intensive to produce. Implementation 
of therapeutic Ads in developing countries may not be immediately feasible, and thus 
requires the development of alternative vector strategies.   
Adeno-associated viruses contain a 4.7 kb single stranded DNA genome, a considerable 
contrast to the larger genome of Ads [51]. Despite their small genome size, recombinant 
AAVs (rAAVs) can be used effectively to express RNAi effector molecules, including 
polycistronic sequences and poly-cassette constructs [52]. Furthermore rAAVs display broad 
tissue tropism with low immunogenicity, episomal persistence after infecting both dividing 
and non-diving cells and the episomal genome/transgene construct has a low chance of 
integrating into the host genome [53-56]. rAAVs are also capable of combining with other 
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serotypes to generate chimaeras with enhanced/altered tissue tropism and immuno-evasive 
properties. Chen and colleagues were able to generate a pseudotyped rAAV2/8 which 
effectively delivered therapeutic cargo to the murine liver [57]. Pseudotyping a second 
variety of rAAV, AAV2/9 was able to evade to immune response generated against AAV8 
and again deliver the therapeutic cargo to diseased murine hepatocytes [58]. rAAVs have 
several desirable properties of a gene therapy vector, however they exhibit similar 
difficulties to Ads in their implementation in developing countries. Production cost, 
scalability and labour intensity of producing rAAVs are all factors which encourage the 
further development of alternative delivery vectors such as non-viral vectors.  
Retroviral vectors were the first described vector to be used in clinical trials [59]. 
Retroviral vectors have shown promise over the past two decades in the reversal of 
inherited diseases such as severe combined immuno-deficiency (SCID) [60], ADA-SCID [10] 
and X-linked chronic granulomatous disease (X-CGD) [61]. Treatments were accomplished 
by the stable integration of the transgene into host chromosomes which allows for the 
sustained expression of the therapeutic transgene. Unfortunately difficulties have been 
encountered in which transgene insertion may result in harmful mutagenesis, or transgene 
expression becomes variegated. Attempts to improve transgene expression have 
incorporated the use of lentiviruses, which display the capacity to transduce dividing and 
non-dividing cell types and readily insert into the host chromosome to provide long term 
transgene expression [62, 63]. Gene therapy with lentiviruses has also found application in 
ex vivo transduction, as therapeutic cells are generated in vitro and re-introduced to in vivo 
systems [63-65]. Retro- and lentiviruses encounter similar production difficulties as Ads and 
AAVs. Currently there are no clinically approved lentiviral therapeutics available, 
consequently implementation of these products in developing countries such as Africa does 
not appear to be feasible. Considering the difficulties encountered by all three viral vectors, 
it is imperative that attention is also given to the non-viral delivery systems.   
Viral vectors are used in ±69% of the 1800 active clinical trials that use gene therapy to 
combat disease [41]. Approximately 60% of these trials are directed against cancer, followed 
by monogenetic and infectious diseases (Figure 1.2). Despite the huge number of trials 
being conducted, only a handful of gene therapy products have received approval for 
distribution, some controversial in nature. One of the first products on the market was 
Gendicine, a recombinant Ad used to treat head and neck squamous cell carcinoma [66, 67]. 
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Gendicine was approved by China’s State Food and Drug Administration (SFDA) for patient 
use prior to completion of phase III clinical trials, causing controversy surrounding its 
administration [68]. Two years after approval of Gendicine, the SFDA approved a second 
gene therapy product, Oncorine. Oncorine is a recombinant Ad developed to treat late-
stage refractory nasopharyngeal cancer [69]. The only Ad vector to have completed phase III 
clinical trials to date and approved for administration is Cerepro [19]. An interesting 
chimeric vector, Cerepro consists of an Ad exterior and encodes the Herpes simplex virus 
thymidine kinase gene. The fourth and last approved gene therapy product is Glybera, an 
AAV to treat severe lipoprotein lipase deficiency by expressing lipoprotein lipase within 
muscle tissue [70]. There are several promising therapies being evaluated in late-stage 
clinical trials against Leber’s congenital amaurosis [71], X-linked severe combined 
immunodeficiency (X-SCID) [72], Wiskott-Aldrich syndrome [73], -thalassemia [74] and 
severe protein lipase deficiency [70].    
 
Figure 1.2: Diseases targeted by gene therapy in clinical trials. Adapted from 
http://www.abedia.com/wiley/indications.php [41]. 
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Liposomes and lipoplexes as gene therapy vectors 
Liposomes are synthetic constructs used to deliver a variety of molecules, such as 
nucleic acids and drugs. Liposomes are generally composed of lipid bilayers. The outer 
hydrophilic surface associates with the therapeutic cargo, and the hydrophobic 
intramembrane region anchors moieties and ligands displayed on the liposome surface [75]. 
The most successful means of delivering nucleic acids is by the use of cationic liposomes. 
Cationic liposomes were first utilised in 1987 by Felgner and colleagues, who demonstrated 
the delivery and expression of DNA to cultured cells [76]. Liposomes offer several benefits 
as gene therapy vectors, as their synthesis is scalable and cost effective, are potentially not 
as immuno-stimulatory as viral vectors and importantly have the capacity to bind and 
deliver RNA sequences to cells. Liposome transfection efficacy is influenced by several 
factors, all of which have to be designed for optimal cellular uptake, interaction and 
eventual cargo release. The factors include lipoplex size [77, 78], the amount of lipid 
required for cargo binding, lipid/nucleic acid charge ratios [79], structure of lipid species 
within the liposome [80, 81], the type of cell targeted [82] and whether those cells are 
actively dividing [83]. Liposomes do however have several short comings that need to be 
overcome before their successful application within a clinical setting. Liposomes display 
decreased levels of cellular tropism compared to viral vectors, susceptibility to cargo 
degradation by nucleases, may induce cellular toxicity, be negatively affected by plasma 
components and stimulate innate immune responses [84]. Efforts to overcome these 
hurdles are under continual refinement, thus enhancing liposome delivery, stability and 
safety. 
Currently twelve liposomal based formulations have been approved for clinical use [85]. 
Formulations such as Doxil, Myocet and DaunoXome were used to target AIDS-related 
Kaposi’s sarcoma, and metastatic breast cancer [86]. Others include formulations against 
fungal infections (AmBisome) [87], age-related macular degeneration (Visudyne) [88] and 
hepatitis A virus (Epaxal) [89, 90] and influenza (Inflexal V) vaccines [91]. There are several 
ongoing clinical trials utilising liposome-based formulations to deliver a variety of drugs to 
diseased tissue. Improvement on the aforementioned difficulties may provide liposomes the 
means to become effective therapeutic vectors. As a whole, synthetic vectors are not as 
effective in delivery as viruses, however are easier and cheaper to produce, may be less 
toxic, and can easily be manipulated to avoid immuno-stimulation.  
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Virus-like particles as gene therapy vectors 
VLPs are considered part of the non-viral vectors. Derived from viral capsids, VLPs are 
biological objects such as empty viral structures, non-infectious self-assembled recombinant 
gene products and uncharacterised virus-like structures [92]. Furthermore, as a result of 
their simple nature, VLPs can be produced en masse in bacterial [93] or plant expression 
systems [94], in a scalable cost effective manner. Similarly, many synthetic vectors such as 
liposomes, synthetic nanoparticles and dendrimers are readily synthesised, however all are 
not as effective in delivering nucleic acids as viral vectors. Both viral and non-viral vectors 
offer benefits and drawbacks; ideally the combination of the particle properties could 
generate a cost effective, scalable, efficient delivery vector for application in resource poor 
regions like Africa. 
There has been a marked increase in the amount of research performed on VLPs, 
increasing from 15 700 publication in 1995 to 102 000 in 2012 [92]. Initially VLPs were used 
as agents for vaccinology, notably utilising the hepatitis B virus and human papilloma virus 
capsid structures to deliver exposed epitopes. To this day, VLPs are still being developed and 
tested in clinical trials for vaccines [95]. VLPs may offer benefits to the field of gene therapy, 
as they have the capacity to deliver a variety of therapeutic agents. Additional benefits 
include:  
1) VLPs present as a variety of nano-sized containers, in diverse shapes.  
2) In comparison to viruses, VLPs are simple, scalable and cost effective to produce.  
3) The VLP surface (both interior and exterior) is amenable to modifications in the 
forms of amino acid exchange and ligand conjugation to the capsid surface.  
4) Availability of known 3D structure.  
5) VLPs generally assemble with structural uniformity.  
Interestingly, VLPs have seen development in a variety of fields, including chemistry, 
physics and engineering [96]. Since the 1980s over 100 VLPs have been characterised, the 
first of these structures was the HBV capsid [97]. HBV capsids are easily expressed as 
recombinant structures within Escherichia coli, which may have facilitated the early 
characterisation.  
The HBV capsid offers several features compared to viral vectors that make it a 
candidate for VLP gene therapy vectorology. Production is simplified compared to viral 
vectors, as capsids are easily produced in recombinant E. coli and the production is cost 
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effective and scalable. The HBV capsid is amenable to amino acid changes on its surface, 
allowing for the introduction of functional residues. As demonstrated for the first time in 
this study it is possible to conjugate ligands to the HBV surface. Decoration of the capsid 
surface is necessary as un-enveloped viral particles lose their hepatotropism and are 
indiscriminately taken up by a variety of cell types [98, 99]. Indiscriminate cellular uptake is 
an undesirable feature for a gene therapy vector; useful properties of a vector include 
cellular tropism and immuno-evasion which can be introduced by the inclusion of functional 
ligands and chemical groups to the vector surface [45]. Lastly, a feature not always afforded 
to viral vectors is that capsids have the capacity to encapsidate choice therapeutic material 
post purification. This project aimed to contribute to the advancing field of gene therapy 
vectorology by developing the HBV capsid as a potential vehicle for therapeutic material. 
This was aided by the inclusion of liposomes within various aspects of the study. Liposomes 
offer an alternative platform to assess the effects of various ligands on the uptake behaviour 
of nanoparticles. It was established that the presence of galactose ligands on the surface of 
liposomes increased hepatotropic uptake in vitro, and permitted for hepatotropism in vivo. 
Similarly, galactose ligands were then conjugated to the surface of HBV capsids and 
hepatotropism was assessed in vitro. Despite HBV being hepatotropic, the viral capsid does 
not display any form of tropism. The addition of receptor-specific ligands to the capsid 
surface should enable targeted uptake into a variety of cell types. Galactose made for a 
suitable ligand as it is liver specific and could be chemically manipulated successfully to 
allow for inclusion on liposome and capsid surfaces. This proof of principle study was 
initiated by testing ligand-decorated capsid uptake into cultured liver cells. In principle, this 
approach could be employed with other cell types, provided a suitable tissue-tropic ligand 
was attached to the capsid surface. It was demonstrated in this study that:  
1) The HBV capsid is amenable to amino acid substitutions on its surface.  
2) The HBV capsid undergoes successful conjugation of ligands to its surface. 
3) Prevention of indiscriminate cellular uptake is possible with the addition of moieties 
to the capsid surface.  
Thus, future studies can focus on optimising the structure of the ligands conjugated to 
the capsid surface in order to enhance hepatotropism. In doing so it may be possible to 
address the deficits in current gene therapy vectorology to generate efficacious, cost 
effective non-viral gene therapy vectors for developing regions like Africa. 
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Chapter 2: The influence of galactose linker length on liposomal 
hepatotropic transfection efficiency   
 
2.1. Introduction 
The gene therapy field has undergone several improvements over the past decade, and 
continues to do so as our understanding of biological mechanisms and systems expands. 
One of the major challenges faced within gene therapy is delivery of therapeutic cargo, 
typically nucleic acids, to a target tissue/area.  Development of effective viral and non-viral 
vectors has become paramount within the field, as the full potential of gene therapy 
application cannot be realised without it. Synthetic/non-viral vectors offer several 
advantages over viral vectors, which include ease of in vitro modification and manipulation, 
lower cost of production, scalable production, low immunogenicity and enhanced stability 
(reviewed in [100-105]). One of the prominent forms of non-viral vectors is liposomal-based 
delivery. The design and synthesis of cationic liposomes has important hurdles that must be 
overcome to produce a successful correlation between lipoplex structure and transfection 
efficiency. Lipofection  in vitro and in vivo entails several potentially rate-limiting steps such 
as DNA lipoplexing [106], cellular binding (without cellular specificity targeting is 
electrostatically based), cellular uptake, endosomal escape [107], cytoplasmic 
transportation, nuclear entry and nucleic acid release from the lipoplex. For the purposes of 
this thesis, the above mentioned factors are collectively called transfection efficiency. Viral 
vectors experience the aforementioned rate-limiting steps to a far lesser extent, as their 
evolution has resulted in highly efficient nucleic acid delivery vehicles.  Viral vectors have 
shown in vivo success in inducing gene therapy [59, 60], however several safety concerns 
have been raised. Two children treated for X-linked severe combined immunodeficiency (X-
SCID) with retroviral vectors in 2002 developed leukaemia-like symptoms from random 
insertion events [108]. In 1999 an 18 year old patient treated for ornithine transcarbamylase 
deficiency with a recombinant adenovirus died as a result of a severe immune response 
resulting in multiple organ failure [9]. Despite the aforementioned risks, viral vectorology 
has seen drastic improvements over the past ten years and is still the preferred means of 
delivery for gene therapy as a result of enhanced tissue tropism and transgene expression 
[109]. Non-viral vectors have none the less made their mark in several phases of clinical 
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trials, summarised in Table 2.1.1. Liposomes primarily have the advantage of delivering 
either drugs or RNA sequences to targeted cells, a feature not available to viral-based 
vectors. 
Table 2.1.1 Gene therapy clinical trials using lipid-based vectors 
Disease Gene treatment Clinical phase Clinicaltrials.gov 
identifier 
Advanced head and neck cancer EGFR antisense DNA Phase I NCT00009841 
Cystic fibrosis pGT-1 gene Phase I NCT00004471 
Non-small-cell lung cancer Fus-1 gene Phase I NCT00059605 
Advanced pancreatic cancer Bik gene Phase I NCT00968604 
Cystic fibrosis CFTR gene Phase I/II NCT00789867 
Solid tumour cancers M2 subunit of ribonucleotide 
reductase siRNA 
Phase I NCT00689065 
Advanced solid tumours with liver 
involvement 
VEGF and KSP siRNA Phase I NCT00882180 
Advanced solid cancers PKN3 siRNA Phase I NCT00938574 
Respiratory syncytial virus 
infections 
Nucleocapsid N gene siRNA Phase II NCT01065935 
Transthyretin mediated 
amyliodosis 
Transthyretin gene siRNA Phase I NCT01148953 
Philadelphia Chromosome positive 
CML, AML, CLL and MDS 
Growth Factor Receptor Bound 
Protein-2  antisense DNA 
Unknown NCT01159028 
Advanced recurrent cancer EphA2 siRNA Not yet open NCT01591356 
Recurrent high-grade gliomas UGT1A1 siRNA Recruiting NCT00734682 
Adapted from Zhang et al.  2012 and sourced from www.chemicaltrials.gov (ALL – Acute lymphocytic 
leukaemia, CLL – Chronic lymphocytic leukaemia, CML – Chronic myelogenous leukaemia, EGFR – Epidermal 
growth factor receptor, EphA2 – Ephrin type-A receptor 2, KSP – Kinesin spindle protein, MDS – 
Myelodysplastic syndrome, PKN3 – Protein kinase N3, UGT1A1 – UDP glucuronosyltransferase 1 family, 
polypeptide A1, VEGF – Vascular endothelial growth factor) 
Liposomes are generally composed of amphiphilic molecules, comprising a hydrophilic 
cationic head group and a hydrophobic hydrocarbon group. The cationic head group 
provides solubility to the liposome within an aqueous environment, whereas the 
hydrophobic moiety forms the basis of the micelle or lamellar membrane.  The morphology 
of the liposome is related to the geometry of the amphiphilic molecules. This is of particular 
importance, as there are various morphological states of liposomes that can influence 
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transfection efficiency, endosomal escape and nucleic acid packing and protection [110-
112]. A means to assess morphology is by the packing parameter, P, which is used to 
determine whether liposomes will tend toward micelle, cylindrical micelle, lamellar, cubic or 
inverted hexagonal (HII) phases (Figure 2.1.1) [113, 114]. P is defined as the ratio of the 
hydrocarbon tail volume, v, to the product of  critical length of the lipid tail, lc, and effective 
head group area, a, as the following equation P=v/alc [115]. Thus this ratio describes the 
effect of the hydrophobic versus the hydrophilic volume of the amphiphilic molecule on 
liposome morphology. When the head group volume exceeds the hydrophobic tail group 
volume such that P < 0.5, liposomes will tend towards micellar-like structures. In particular, 
if P < 0.33 liposomes tend to form discreet micelles, whereas if 0.33 < P < 0.5 liposomes tend 
toward uniform cylindrical-like structures. If 0.5 < P ≤ 1 liposomes tend towards lamellar 
morphology and if P > 1 liposomes adopt the inverted hexagonal phase (Figure 2.1.1) [115].  
 
Salt concentration, pH and surface cationic charge play an important role in the 
determination of head group volume. A decrease in charge brought about by any of these 
factors will result in a smaller head group volume. This change promotes the conversion of 
liposomes from micellar/lamellar into the inverted hexagonal phase, an important step 
required for the release of nucleic acids from the endosomal pathway. Zwitterionic helper 
lipids such as 1,2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE) reduce the overall 
liposome surface potential by ionic interaction with the cationic head group [116]. This 
interaction facilitates the transition from micellar/lamellar to inverted hexagonal, especially 
Figure 2.1.1: Diagrammatic representation of 
liposomal phase morphology as a result of 
amphiphilic lipid packing parameter (P). 
Hydrophilic head groups (grey ball) with 
larger volume than hydrophobic tails tend 
toward cone-like geometry (P < 0.5). 
Amphiphiles with packing parameters 0.5 < P 
≤ 1 form lamellar bilayers. A packing 
parameter of P > 1, where the hydrophobic 
volume is larger than the hydrophilic, 
liposomes tend toward an inverted hexagonal 
morphology. Figure adapted from Wasungu 
and Hoekstra, 2006. 
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at lowered pH or physiological salt concentration. A difficulty encountered in the 
preparation of liposomes containing DOPE for in vivo application is the neutralisation of the 
surface potential at physiological salt concentrations. This neutralisation causes the 
transition from micellar/lamellar to inverted hexagonal phase, which results in the 
conglomeration and eventual precipitation of the liposomes [113]. DOPE also decreases the 
DNA binding capacity of the liposome, as a net decrease in cationic charge occurs [117]. 
However with a decrease in binding capacity an increase in liposome-DNA dissociation is 
also facilitated, allowing for the intracellular release of the liposome from bound DNA [103].   
An often overlooked aspect of lipoplexing is the effect of the liposome on the structural 
integrity of the cargo DNA. It has been suggested that poor packaging of DNA within the 
liposome, such that DNA protrusions are present, potentially allows for degradation by 
nucleases within circulation and the cytoplasm [118]. It has also been described that 
effective transfections require the disassociation of the lipid vector (or its components) from 
the DNA cargo once within a cellular environment. Hama et al.  reported that Lipofectamine 
Plus had significantly higher cellular entry, equivalent endosomal escape and slightly lower 
nuclear transfection compared to adenoviruses. The liposomal delivery system however 
required three times more DNA present within the nucleus to obtain comparable transgene 
expression. It was suggested by Hama and colleagues that transcription was affected by the 
poor dissociation of liposome and DNA within the nucleus. Supporting this finding, other 
instances of B-DNA structural changes have been found in which lipoplex-induced DNA 
compaction resulted in Z-DNA within anionic liposomes [119] and C-DNA in cationic 
liposomes [120]. Liposome-DNA interaction is also thought to be influenced by serum, thus 
affecting the overall transfection efficiency [121]. 
It is generally accepted that cationic liposomes interact with the cell surface in an 
electrostatic-based manner. The anionic cell surface charge is provided primarily by 
phospholipids; in addition the proteins heparin sulphate proteoglycan and integrin 
contribute to the anionic potential [122]. It is suggested that these proteins play an 
important role in lipofection, which may explain the variation in transfection efficiency seen 
between cell lines as a result of cell surface composition. Ligands present on the surface of 
liposomes provide means to bind and interact with the cell surface in a directed manner. 
Ligands such as antibodies/antibody fragments [123], steel factor [124], asialoglycoprotein 
(containing galactose or N-acetylgalactosamine) [125], mannose [126], lactose [127], folate 
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[128], integrin [129], transferrin [130] and epidermal growth factor [131] are examples used 
for the targeted delivery of liposomes to specific cell types. The asialoglycoprotein receptor 
(ASGPr) is a C-type Ca2+-dependent lectin found almost exclusively on the surface of 
parenchymal hepatocytes [132, 133], but is also found on Kupffer cells [134]. The ASGPr 
binds -D-galactose (Gal) or N-acetylgalactosamine (GalNAc) residues present of the surface 
glycoproteins, resulting in their clearance from circulation [133, 135]. The work described 
here made use of galactose tethered to the surface of liposomes to enhance cellular uptake 
and transfection efficiency in cultured hepatocytes and in a transgenic HBV murine model. 
The galactose affinity exhibited by the ASGPr can provide liposomes with hepatotropism by 
including galactose moieties within their composition. 
Generally the use of ligands results in particle uptake by receptor-mediated endocytosis, 
as opposed to the generic ionic pairing of ligand-less liposomes [82].  Passive fusion of the 
lipoplex with the cell surface has been shown to cause exclusion of the cargo DNA from the 
cell [136]. The five major routes of endocytic uptake (reviewed in [102, 137-142]) are:  
1 Phagocytosis – a process that generally occurs in neutrophils or macrophages. 
2 Macropinocytosis – this form of uptake requires cell membrane ruffling and 
liposome fusion, that results in large endocytic vesicles which fuse with the 
lysosome or are recycled and released at the cell surface.  
3 Clathrin-mediated endocytosis – a form of receptor mediated uptake by clathrin-
coated pits which form early endosomes.  
4 Caveolae-mediated endocytosis – caveolae are small sphingolipid and 
cholesterol-rich membrane invaginations, and are responsible for both 
endocytosis and signal transduction.  
5 Clathrin/caveolae-independent endocytosis – these uptake pathways are not 
well understood and are currently being investigated. Despite the presence of 
targeting ligands on liposomes, there is conflicting evidence for a generalised 
(clathrin-mediated) mechanism of uptake [82]. 
Following endocytosis, lipoplexes remain enveloped within early endosomes (Illustrated 
in Figure 2.1.2). It is crucial that the endosome contents are released into the cytosol, as 
lysosomal-based degradation or release at cell surface ensues. Several mechanisms have 
been suggested for the successful escape of lipoplexed cargo into the cytosol. The trans-
bilayer flip-flop mechanism causes anionic lipids such as phosphatidyl serine (PS) to 
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translocate from the outer to the inner leaflet of the endosome and interact with the 
lipoplex [143]. This causes destabilisation of the outer leaflet and rupture of the endosome. 
Alternatively PS interacts with the lipoplex surface, and the resultant ion pairing and charge 
neutralisation causes the liposome membrane to convert to the inverted hexagonal phase 
and fuse with the endosome [118, 144]. It is also possible that both mechanisms occur and 
contribute to endosomal instability. Helper lipids such as  DOPE are said to be of importance 
in the conversion of lipoplexes from lamellar to inverted hexagonal phases as endosomal 
acidification initiates phase conversion by charge neutralisation of DOPE and the cationic 
lipid [116, 118]. It has been questioned whether the inverted hexagonal phase-mediated 
endosomal fusion is of importance to the enhancement of transfection efficiency [111, 145]. 
Fasbender and colleagues described helper lipids that have varying effects on both uptake 
and transgene expression. Furthermore the type of cationic lipid and cell type influence 
helper lipid behaviour, indicating a complicated uptake and release behaviour [146].  
Polyethylene glycol (PEG) -like molecules have become indispensable within the field of 
liposome vectorology. Inclusion of PEG to liposome surfaces provides immuno-evasive 
properties and provides stability to the liposome structure. PEGylation of liposomes does 
however have a major impact on the endosomal release of lipoplexed DNA. Endosome and 
liposome membrane interaction responsible for membrane destabilisation and intracellular 
release is greatly diminished in the presence of PEG. As a result, endosome-responsive PEG 
in the form of exchangeable PEG-lipid analogues or pH-sensitive PEG analogues have been 
developed [147-149]. These PEG analogues undergo cleavage from the liposome surface 
within the endosome, allowing then for the ionic interaction between endosomal and 
liposomal membranes. 
Transport and entry into the nucleus of lipoplexed DNA is a critical but poorly 
understood process. The nucleus has a double membrane with selective pores 10 - 25 nm in 
diameter [150]. The pores are far smaller than condensed plasmid DNA, constituting a major 
barrier to plasmid entry. As a result of cytosolic nucleases, plasmid half-life in HeLa cells was 
estimated at 90 minutes, making nuclear entry a critical step in the transfection process 
[151, 152]. It has been estimated that DNA translocation occurs for every 1 of 1000 plasmids 
transfected [153]. Interestingly microinjection studies have shown that lipoplex injection 
into the cytoplasm does not result in transfection, whereas injection into the nucleus does. 
Similarly naked plasmid injection into the cytoplasm does not result in transfection. Only 
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when lipoplexed DNA is introduced to the cytoplasm via the endosome does transfection 
occur, indicating an unknown intracellular transport process after endosomal uptake [154]. 
 
Figure 2.1.2: Summary of lipofection and barriers of gene delivery. (1) Cellular binding mediated by 
electrostatic or receptor interaction. (2) Endocytosis established as the main mechanism of entry. (3) 
Endosomal escape of lipoplexes by various mechanisms before degradation. (4) Lipoplex or nucleic acid is 
required to be actively transported to the nucleus. (5) Nuclear entry by active transport. (6) Lipid dissociation 
from cargo DNA. (7) Lipoplexes unable to escape the endosome are degraded or recycled back to the surface. 
Innovative systems are under continuous development within the vectorology field. 
Improved receptor based targeting, immuno-evasion, improved DNA binding and release, 
enhanced endosomal escape are a few factors under development. In line with these 
factors, work described in this chapter aimed to combine hepatotropism and immuno-
evasive properties into one molecule, include it within a basic liposome and assess the 
effect on transfection efficiency. Monosaccharide-cholesterol conjugates (MCC) were 
synthesised such that galactose was tethered to a cholesterol moiety by a glycol-based 
linker of variable length. Two versions of the galactose ligand were assessed, in which 
hydroxyl groups were either acetylated (protected) or unacetylated (unprotected). The 
acetylation status of protected galactose (P-Gal) prevented the hydroxyl species from 
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undergoing unwanted reactions during compound synthesis. Removal of the acetyl groups 
results in an unprotected galactose moiety (UnP-Gal), similar to what would reside on 
asialoglycoproteins (Figure 2.1.3).   
 
Three glycol-based tethers, which varied in length, were used to link the galactose and 
cholesterol moieties. The shortest tether, short linker chain (SLC), comprised of 1 glycol link. 
Similarly medium linker chain (MLC) and long linker chain (LLC) included 4 and 11 glycol 
links, respectively. Figure 2.1.4 illustrates the structures of DC Chol and the compounds 
containing P-Gal or UnP-Gal and SLC, MLC or LLC. Ideally the short PEG-like linkers would 
provide immuno-evasive properties to the liposomes, and not interfere with liposome 
morphology, cell surface interaction or endosomal escape.  
Figure 2.1.3: Illustration of galactose 
moieties in the unprotected state 
(exposed hydroxyl groups) or protected 
state (acetyl groups). 
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Figure 2.1.4: Illustration of the various galactose-tethered cholesterol-based moieties included in the 
generation of liposomes. DC Chol is a commercially available cationic lipid capable of binding to anionic DNA. 
The remainder of the structures contain a protected (acetylated) galactose (P-Gal) or unprotected galactose 
(UnP-Gal), tethered to cholesterol by a short linker chain (SLC), medium linker chain (MLC) or long linker chain 
(LLC).  
+ 
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In a collaborative effort between the Antiviral Gene Therapy Research Unit 
(Johannesburg, South Africa) and the Rega Institute for Medical Research (Leuven, Belgium), 
in vivo delivery of hepatotropic liposomes loaded with modified siRNAs was assessed [155]. 
Liposomes were generated consisting of DOPE, SLC P-Gal and the novel cationic lipid, CL19 
(Figure 2.1.5). At the time of in vivo investigation, it was technically difficult to generate the 
unprotected variety of the galactose ligand, thus the protected variety was included instead. 
CL19 was generated during an earlier study to identify potential novel cationic lipids that 
allowed for in vivo delivery of siRNAs (data not included). Anti-HBV siRNAs included in the 
study contained altritol modifications (Figure 2.1.5) [156, 157]. Continual efforts to identify 
modifications to siRNAs which confer stability without affecting the targeting and off-
targeting capacity are underway, through which the altritol nucleic acids (ANA) were 
identified. ANAs contain a six membered sugar ring, derived from hexitol nucleic acids. The 
physicochemical properties of the ANA-siRNA helix induce the A-form, a property which is 
thought to improve the silencing capacity. In vitro assessment revealed that the 3’ 
positioning of the altritol modifications increased silencing efficacy compared to unmodified 
siRNAs. Together with in vitro transfection data, these findings prompted further 
investigation in an in vivo HBV transgenic murine model. 
   
Figure 2.1.5: Structural illustration of the cationic lipid CL19 and ANA-containing RNA moieties. 
 
+ 
+ 
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It was demonstrated that increasing linker length negatively impacts on the DNA binding 
capacity of the liposome. Increased linker length also decreased transfection efficiency in 
both targeted and non-targeted cell lines. Acetylation was shown to diminish transfection 
efficiency in a liver derived cell line. Despite the hepatotropism provided by galactose, it was 
demonstrated that commercially available transfection reagents have greater transfection 
efficiency in hepatocytes than liposomes containing MCC structures. In vivo studies suggest 
that the P-Gal liposomes are capable of delivering siRNAs to the hepatocytes of mice. It was 
demonstrated that the ANA-siRNAs induced knockdown of the HBV within the transgenic 
mouse model, with little to no liver damage and immunostimulation.  
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2.2. Results  
2.2.1. Initial liposome formulation with monosaccharide-cholesterol conjugates 
Liposomes were formulated comprising 60% cholesterol moiety and 40% neutral helper 
lipid (DOPE) (mole/mole) [158]. For the purposes of this study the 60:40 ratio comprised 60 
parts DC Chol and 40 parts DOPE. It was previously determined that liposomes required 16% 
P-Gal MCC for optimal transfection efficiency (mole/mole) [155]. This resulted in overall 
liposomal DC Chol content decreasing from 60% to 44%, as 36.4% of cholesterol species 
within the liposome were represented by MCC. Overall lipid composition of the liposomes is 
44% DC Chol, 40% DOPE and 16% MCC (also expressed as a ratio of 11:10:4) unless stated 
otherwise.  
2.2.2. Determination of DNA to lipid charge neutralising ratios by mobility shift 
assay 
Liposome to DNA ratios required for transfection were determined by mobility shift 
assays (Figure 2.2.1). DNA and liposomes were combined at specific ratios (w/w), allowed to 
lipoplex and subjected to agarose gel electrophoresis. Lipoplexed DNA lost mobility within 
the agarose gel and was trapped within the loading wells. Complete plasmid DNA (pDNA) 
sequestration was indicative of the DNA to lipid ratio required for efficient envelopment. 
The control liposome consisting of DC Chol and DOPE alone completely sequestered pDNA 
at a DNA to lipid ratio of 1:4. The introduction of MCC species into the liposome formulation 
caused a decrease in DNA binding, demonstrated by the increase in liposome required to 
sequester pDNA completely. Liposomes containing SLC UnP-Gal, SLC P-Gal, MLC UnP-Gal 
and MLC P-Gal required 6 parts lipid to 1 part pDNA for complete sequestration. The 
protection status of galactose did not significantly influence DNA-liposome binding. As the 
increase of 4 to 6 parts liposome was required for complete pDNA sequestration, a 
correlation was noted with the associated decrease in DC Chol. The 50% increase in 
liposome amount required for pDNA sequestration correlates to the 36.4% decrease in DC 
Chol present in the liposome formulations. The highest DNA to lipid binding ratio (1:8) 
occurred when using LLC P-Gal in liposome formulation. A trend of increased linker length 
and associated decrease in DNA binding capacity was noted in which it was possible that 
these PEG-like moieties shield the liposome surface from pDNA access. 
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Figure 2.2.1: DNA mobility shift assay to assess the effect of MCC with varying linker lengths on liposomal DNA 
binding. Liposomes comprised 60% cholesterol species and 40% DOPE. MCC-containing liposomes comprised 
44% DC Chol, 40% DOPE and 16% MCC (mole/mole). Increasing amounts of liposomes were lipoplexed with a 
constant amount of pDNA (w/w) and subjected to agarose gel electrophoresis. The lipofection ratio (DNA to 
liposome) was determined once charge neutralisation occurred, in which pDNA was sequestered within the gel 
well. (SLC – short linker chain, MLC – medium linker chain, LLC – long linker chain, UnP-Gal – unprotected 
galactose, P-Gal – acetyl-protected galactose). 
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2.2.3 Assessment of the transfection efficiency of MCC-containing liposomes  
DNA to liposome ratios determined by mobility shift assay were used for transfection in 
two immortalised cells lines, Human hepatocellular carcinoma (Huh7) and Human 
embryonic kidney cells (HEK293). The Huh7 cell line has been demonstrated to express the 
ASGPr on the cell surface [159]. The HEK293 cell line was used as a negative control in 
transfection experiments, as it did not contain the ASGPr and was incapable of binding 
galactose. Transfection efficiency was assessed by expressed luciferase luminescence 
intensity, an indication of the amount of luciferase-encoding pDNA (psi-Check2.2) delivered 
to and released within target cells. Despite not having tested the UnP-Gal species in cell 
culture, the previously determined [155] ratio of 16% monosaccharide-conjugated 
cholesterol (mole/mole) was used as a reference starting point for MCC-containing 
liposomes.  
Transfection efficiency was measured by the luciferase luminescence intensity, an 
indication of the amount of pDNA delivered and expressed in Huh7 (Figure 2.2.2A) and 
HEK293 (Figure 2.2.2B) cells. Inclusion of SLC UnP-Gal significantly increased the transfection 
efficiency by four-fold and SLC P-Gal by two-fold in Huh7 cells compared to liposomes 
without MCC (p < 0.005). It was anticipated that the protection status of the galactose 
would influence transfection efficiency, as the rate limiting step of acetyl group removal was 
required for asialoglycoprotein-receptor interaction. The MLC-containing liposomes (P-Gal 
and UnP-Gal) both resulted in a minor decrease in transfection efficiency, and LLC P-Gal 
decreased transfection efficiency by three fold in Huh7 cells. Unexpectedly SLC UnP-Gal 
containing liposomes resulted in an approximate 50% increase in transfection efficiency, 
whereas the remaining MCC-containing liposomes resulted in an equivalent or decreased 
transfection rate in HEK293 cells. These data suggest that protection of galactose 
significantly decreases transfection efficiency in Huh7 cells. Furthermore, an increase in 
linker length appears to correlate to a decrease in transfection efficiency.   
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Figure 2.2.2: Luciferase assay to evaluate the transfection efficiency of lipoplexed DNA using monosaccharide-
containing liposomes. The Huh7 cell line contains the ASGPr (A), and HEK293 (B) cell line is a negative control 
for the receptor. Liposomes contained 16% (mole/mole) MCC in a combination of SLC, MLC or LLC and either 
UnP-Gal or P-Gal. Transfection efficiency was compared to liposomes without galactose moieties (DC Chol). 
Statistical analysis done using the student t-test, number of replicates (n) = 3, SEM. **, P < 0.0001; *, P < 0.05 
2.2.4 Determination of MCC concentration for optimal transfection in Huh7 
cells. 
Having established that SLC UnP-GAL was the best candidate for transfection in Huh7 
cells, it was next determined at what MCC surface representation produces optimal 
transfection efficiency. Literature indicated that 2-5% of a particular targeting moiety is 
sufficient to produce optimal transfection in vitro and in vivo [160]. Liposomes containing 2-
16% SLC UnP-Gal (mole/mole) were generated and lipoplexed at a ratio of 6 parts liposome 
to 1 one part psi-Check2.2 (w/w). Transfection of the Huh7 cell line (Figure 2.2.3A) indicated 
that the presence of 2% SLC UnP-Gal produced the best transfection efficiency, whereas 
16% SLC UnP-Gal only slightly increased transfection efficiency. Liposomes containing 4-12% 
SLC UnP-Gal result in decreased transfection efficiency compared to liposomes without 
galactose (DC Chol alone). Transfection of HEK293 cells resulted in decreased transfection 
efficiency as the concentration of SLC UnP-Gal increased (Figure 2.2.3B). Interestingly the 
transfection efficiency from 12-16% SLC UnP-Gal in both Huh7 and HEK293 cell lines 
recovered in efficiency. Liposomes containing 3-5% PEG-2000 diminished transfection 
completely in Huh7 and HEK293 cells (Figure 2.2.3). It is well documented [161] that 
PEGylation of liposomes abrogates transfection of cultured cells, despite the surface 
representation of PEG only being 3-5% (mole/mole). 
 
A B 
A B 
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Figure 2.2.3: Luciferase assay to evaluate the transfection efficiency of liposomes with varying surface representation of SLC UnP-Gal in Huh7 (A) and HEK293 (B) cells. 
Liposomes were generated containing 0-16% SLC UnP-Gal or 3-5% SLC UnP-Gal and 3-5% PEG, lipoplexed with psi-Check2.2 at a DNA to lipid ratio of 1:6. Transfection 
efficiency was compared to liposomes without galactose moieties (DC Chol). Luciferase activity is used as a measure of reporter plasmid delivery. Statistical analyses were 
performed using a student t-test, n=3, SEM. *, P  <  0.05. 
 
 
 
 
A B 
A B 
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2.2.5 Comparison of SLC P-Gal and Lipofectamine2000 transfection efficiency.  
The presence of galactose on the surface of liposomes provided an advantage in 
liposomal delivery of pDNA facilitated by the interaction with the ASGPr on liver cells. It was 
assessed whether this transfection enhancement was comparable to Lipofectamine2000, a 
popular commercially available transfection reagent. Varying amounts of psi-Check2.2 were 
transfected into Huh7 cells using 2% SLC UnP-Gal containing liposomes at lipid to DNA ratio 
of 6:1 (w/w) or Lipofectamine2000, at a ratio of 1:1 (v/w). It was found that regardless of 
the amount of DNA transfected into Huh7 cells, using Lipofectamine2000 resulted in higher 
luciferase activity (Figure 2.2.4). 
 
 
                   
Figure 2.2.4: Luciferase based assay to compare transfection efficiency between Lipofectamine2000 and 2% 
SLC, UnP-Gal containing liposomes in Huh7 cells. Lipoplexing was carried out at a lipid to DNA ratio of 6:1 
(w/w) using SLC UnP-Gal and 1:1 (v/w) using Lipofectamine2000. Plasmid DNA was transfected in varying 
amounts, ranging from 50-900 ng. Luciferase activity is an indication of liposomal based delivery of psi-
Check2.2 Statistical analyses done by student t-test, n=3, SEM.   
 
2.2.6 In vivo delivery of anti-HBV siRNAs using hepatotropic liposomes 
The liposomes containing galactose ligands were assessed for hepatotropic behaviour in 
vivo [155]. In a previous study it was determined that CL19 from a library of cationic lipids 
demonstrated the best transfection efficiency. Liposomes were formulated using SLC P-Gal, 
DOPE and CL19 in a mole ratio of 8:20:11, respectively. The formulated liposomes were 
combined with ANA-siRNAs at a mass ratio of 17:1, respectively. Lipoplexed siRNAs were 
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administered to groups of eight HBV transgenic mice [162] at 1 mg/kg weekly, over a course 
of 37 days. Blood samples were collected from mice using retro-orbital puncture on days -2 
(baseline), 0, 9, 21 and 37 (Illustrated in Figure 2.2.5).  
 
Figure 2.2.5: Illustration of the experimental program conducted on transgenic HBV mice. Groups consisted of 
eight mice, injected weekly over four weeks in a period of 37 days. Some groups received a single injection on 
day 0. Retro-orbital bleeding was used to collect blood samples on days -2, 0, 9, 21 and 37. Levels of circulating 
VPEs and HBsAg were assessed from each blood sample; hepatotoxicity was assessed using samples collected 
on day 21. 
 
Circulating viral particle equivalents (VPEs) were determined using quantitative real time 
PCR (qPCR) (Figure 2.2.6A + 2.2.7A). Animals that received the anti-HBV siRNAs 
demonstrated a significant decrease in viral replication (Students unpaired t-test p < 0.05). 
Animals injected with a non-targeting siRNA (LacZ) also displayed viral knockdown, however 
knockdown was attributed to the off-target effects of the LacZ siRNA. Treatment with saline 
resulted in a decrease in circulating VPEs, potentially as an effect of the administration on 
viral replication within the liver. This observation has been made previously using transgenic 
HBV mice, despite no toxicity associated with saline. Systemic delivery of naked siRNAs did 
not result in VPE knockdown. It has been noted that the transgenic HBV mice display 
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increased liver sensitivity, perhaps as a consequence of constitutive viral production. This 
sensitivity may impact the degree of knockdown achieved using anti-HBV and control 
siRNAs. The alternative marker for HBV replication and knockdown is the surface antigen 
HBsAg. It would appear that the knockdown of HBsAg is less marked than the circulating 
VPEs (Figure 2.2.6B and 2.2.7B). As the HBsAg is expressed at high levels in transgenic mice, 
the impact on its knockdown may be less profound in comparison to circulating VPEs. 
Nonetheless, knockdown of the surface antigen corroborates the knockdown demonstrated 
for circulating VPEs. 
 Serum activities of aspartate transaminase (AST), alanine aminotransferase (ALT) and 
lactate dehydrogenase (LDH) were assessed. These enzymes are released as a consequence 
of hepatocyte injury, making them useful markers of hepatotoxicity. It was found that the 
uncomplexed liposomes and siRNA-liposome complexes result in slightly elevated liver 
enzyme marker levels (Figure 2.2.8). Marker levels of AST and ALT were below 100 IU/L and 
LDH below 1000 IU/L, which suggested liver inflammation to be minimal. 
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Figure 2.2.6: HBV knockdown with antiHBV siRNAs, assessed by circulating levels of viral particle equivalents (A) and viral surface anitgen (B). siRNAs were administered to 
mice complexed within liposomes (L) or naked (N). Each bar from left to right represents a particular time point at 0, 2, 9, 23 and 37 days after injection. Serum VPEs (A) 
were assesed by qPCR, and surface antigen levels by ELISA. Statistical analyses done by student t-test, n=3, SEM. 
B 
A 
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Figure 2.2.7: In vivo lipoplex efficiency against HBV measured by VPEs knockdown (A) and HBsAg knockdown 
(B). Transgenic mice constitutively expressing HBV were injected weekly with lipoplexed anti-HBV siRNAs at 1 
mg per 1kg of mouse weight. Blood samples were collected by retro-orbital puncture. Statistical analyses done 
by student t-test, n=3, SEM.   
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Figure 2.2.8: Assessment of hepatotoxicity by the measurement of serum liver-enzyme levels. Weekly administration of saline, liposomes, liposome-complexed ANA-
siRNAs and liposome-complexed siRNAs did not increase LDH levels above 1000 IU/L and AST/ALT levels above 100 IU/L. Lipoplexed samples indicated by (L), naked 
(uncomplexed) siRNAs by (N). Statistical analyses done by student t-test, n=3, SEM. 
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2.3. Discussion 
Liposome vectorology requires several considerations to produce an effective, robust 
and responsive nucleic acid vehicle. Every rate limiting step has to be overcome such that 
the DNA cargo is not cleared from circulation or within an intracellular environment. In 
contrast, viral based delivery systems have benefited from the effects of evolution, 
optimised for infection and gene transfer. Currently viral vectorology lends itself to a more 
efficient reliable means of therapeutic gene transfer. Despite the difficulties, the 
rationalised approach toward non-viral vector design and the understanding of liposome-
cell interaction and trafficking will ideally produce a successful delivery candidate(s). Initially 
the enhancement of liposome-DNA binding could be addressed, highlighted by the stark 
difference between DNA binding capacity of Lipofectamine2000 and 2% SLC UnP-Gal 
liposomes. DC Chol is a well-established cationic lipid, however since its inception there 
have been more effective DNA binding lipids produced. One such example is bis-
guanidinium-trencholesterol (BGTC), a highly cationic, compact cholesterol derivative [163]. 
The DNA binding capacity of liposomes must be balanced with sufficient release capacity, as 
DNA-bound to cationic lipid is suggested to inhibit/hinder transcription.  
The data indicated that linker length of the targeting galactose ligand played an 
important role in DNA binding and transfection efficiency. The linker may shield the 
liposome surface from interaction with pDNA, thus an increasing amount of lipid was 
required to completely sequester pDNA. PEG polymers are known to undergo various 
conformations, determined by their molecular weight and concentration on the liposome 
surface [164, 165]. It is speculated that PEG concentrations will also affect the galactose 
conformation and interaction with the ASGPr, by promoting liposome surface exposure or 
burying it within the PEG chains (particular for LLC). It was suggested to use a short link 
between galactose and cholesterol (no linker as such), as it produces the most efficient 
transfection results in Huh7 cells (Prof. Mario Ariatti, personal communication). The 
inclusion of acid-labile PEG in such liposomes would improve functionality in vivo, however 
it would have to be included as a separate entity from the galactose moiety.  
Transfection of HEK293 cells with MCC indicated that the presence of galactose moieties 
had the potential to enhance transfection efficiency. However, later studies revealed 
inconsistency in liposome preparation, particularly of the control liposome, DC Chol. It was 
noted that certain liposome preparations remained opaque after sonication. Generally the 
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sonication process converts the opaque lipid emulsion into a clear solution of liposomes. It 
was found that sonicated solutions that remained partially or slightly opaque did not 
transfect efficiently. These opaque solutions may not have undergone adequate sonication, 
resulting in a combination of liposomes and lipid emulsion. It was confirmed that the 
presence of galactose does indeed decrease transfection efficiency in HEK293 cells, and is 
not as marked as initially established in Huh7 cells (Figures 2.2.2 and 2.2.3). 
The use of cell culture models to infer in vivo transfection efficacy of liposomal-based 
delivery systems is not ideal. Major contributing factors are the condition and composition 
of plasma that differ vastly to culture medium. This has an impact on the design of the 
liposome, as factors/ligands that provide function in vivo may hinder functionality in vitro. 
SLC UnP-Gal containing liposomes transfection efficiency is better than liposomes without 
galactose, however neither are as effective as Lipofectamine2000 in culture. As such, a 
typical in vitro to in vivo translational hurdle is highlighted. Lipofectamine2000 is known to 
be a poor in vivo transfection reagent, which does not necessarily equate to the same 
outcome for SLC UnP-Gal liposomes. 
The field of liposome in vivo vectorology requires considerable improvements prior to its 
application being realised within a clinical setting. Nonetheless, recent research appears to 
have made headway in realising in vivo liposome-based delivery to the liver [166]. As 
highlighted by Wooddell et al, lipoplexes are able to deliver RNA to cells, a feature absent 
from viral-based vectors. It was demonstrated that the liposomes comprising DOPE, SLC P-
Gal and the novel cationic lipid CL19 were capable of delivering siRNAs to the liver of 
transgenic mice. Encouragingly, lipoplex administration did not result in hepatotoxicity or 
immune activation despite dosage being 100-fold higher than in other studies [167]. Future 
improvements to the cationic head group and inclusion of the unprotected galactose ligand 
may result in increased RNA binding capacity of the liposomes as well as enhanced 
hepatotropism.  
Non-viral vectors are in their infancy in development, as several cellular uptake and 
trafficking pathways are not completely understood. Since liposomal vector development is 
dependent on the elucidation of such pathways, emphasis on research of these pathways is 
paramount. Liposomes present with many advantages in their use as vectors for gene 
therapy, and will hopefully develop to a point comparable with viral vectors. The MCC 
compounds within liposomes show potential in increasing the transfection efficiency with 
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Huh7 cells compared to liposomes without. Other than liposomes, it may be possible to 
introduce these ligand moieties to alternative delivery particles. Virus-like particles also 
display potential as a nucleic acid delivery system, and could be enhanced with hepatotropic 
properties by including MCC compounds on their surface. Work described in chapter 3 
explores the potential to modify the surface of HBV capsids (a virus-like particle) to facilitate 
the inclusion of MCC-like compounds on their surface. These viral structures are highly 
ordered and self-assemble within bacterial expression systems, making them a candidate for 
gene therapy vectorology.  
  
2.4. Materials and methods 
2.4.1 Formulation and lipoplexing 
Lipid compounds were dissolved in chloroform as 10 mg/ml stocks and stored at -20 oC. 
DC Chol and all MCC compounds were synthesised by the Department of Chemistry, 
University of the Witwatersrand (Synthesis of compounds was performed by Dr. Rafique 
Islam, Prof. Charles de Koning and Prof. Willem van Otterlo). Liposomal formulations 
comprised 6 parts cholesterol based species and 4 parts DOPE (Avanti Polar Lipids, AL, USA) 
based species. Thus despite the inclusion of monosaccharide-conjugated cholesterol or 
DOPE-PEG, this 6 to 4 ratio remained constant. Lipids were combined to a total of 2 mol 
(1.2 mol cholesterol species : 0.8 mol DOPE species) in a final volume of 1 ml chloroform, 
after which lipid films were produced in a round bottomed flask under vacuum by rotary 
evaporation. Lipid films were resuspended and rehydrated overnight at 4 oC in saline. Vortex 
mixing the subsequent morning resulted in an opaque lipid emulsion. Liposomes were 
generated by sonication; 50 l of lipid emulsion was sonicated at 35 kHz for 30 minutes in a 
Bandolin Sonorex sonicating bath. Liposomes were used on the day generated and not 
stored. Plasmid DNA (refer to Appendix 3 for plasmid preparation) was lipoplexed with 
liposomes as a mass ratio. One microgram of plasmid DNA was incubated in 15 l distilled 
water and the required amount of liposome in 15 l saline for 10 minutes at room 
temperature. Both suspensions were combined and further incubated at room temperature 
for 20 minutes. 
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2.4.2 Mobility Shift Assay 
One microgram of DNA was lipoplexed with increasing amounts of liposome and loaded 
into a 1% agarose gel containing 0.02% (w/v) ethidium bromide. Electrophoresis at 80 V in 
Tris-Acetate-EDTA (1 X TAE) buffer (Appendix 2) resulted in the migration of non-lipoplexed 
plasmids into the agarose gel. Migrated DNA was viewed using short wave ultraviolet in the 
G:Box gel docking system (Syngene, Cambridge, UK). A DNA to lipid ratio was determined by 
the complete sequestration of plasmid DNA by the liposomes. 
2.4.3 Transfections and Luciferase Assays 
DNA transfections were performed in the human-derived liver cell line, Huh7, and a 
human embryonic kidney cell line HEK293 (See Appendix 3 for culturing methods). Cells 
were seeded at 50% confluency in a 24 well culture dish one day prior to transfection in 10% 
foetal calf serum (FCS) (v/v) Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Life 
Technologies, CA, USA). The following morning each well received lipoplexed 100 ng pCI-
eGFP [168] and 50 ng psi-Check2.2 (Promega, WI, USA) DNA in a total of 50 l unless 
specified otherwise. Lipoplexing DNA to lipid ratios for transfection were determined by 
mobility shift assays. Lipofectamine-2000 (Invitrogen, Life Technologies, CA, USA) was used 
according to the manufacturer’s instruction. Cells were harvested 24 hours after 
transfection and luciferase luminescence induced using the Dual-Luciferase Reporter Assay 
System (Promega, WI, USA) according to the manufacturer’s instructions. Luminescence was 
measured in the Veritas Microplate Luminometer (Turner Biosystems, CA, USA). 
2.4.4 In vivo assessment of hepatotropic delivery of liposomes in transgenic 
mice 
All animal experimentation protocols were approved by the University of the Witwatersrand 
Animal Ethics Screening committee (Ethics certificate numbers 2010/10/04 and 08/24/03). 
Liposomes were formulated by combining SLC P-Gal, DOPE and cationic lipid 19 in a mole 
ratio of 8:20:11, respectively. Liposomes were generated as described in Chapter 2.4.1. 
Liposomes were combined with siRNAs at a mass ratio of 17:1. siRNAs were administered at 
a constant dose of 1 mg/kg to transgenic mice, with the volume of injectate ranging from 
0.1-0.2 ml. Blood samples were collected by retro-orbital puncture. VPEs and HBsAg levels 
were determined by methods described previously [169].  
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2.4.5 Statistical analysis 
All data is expressed as the mean with standard error of the mean. Statistical difference 
was considered significant when p < 0.05, determined by students two tailed unpaired t-test 
using the GraphPad Prism software package (GraphPad Software Inc., CA, USA). 
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Chapter 3: Amino acid substitutions to the immunodominant loop of 
the HBV capsid to generate ligand conjugation sites as a means of 
improving vector-like properties. 
 
3.1. Introduction 
Virus-like particles (VLPs) have shown potential as new biomaterials in fields spanning 
from gene therapy to metallo-organic chemistry. Appropriately, these viruses and VLPs are 
often termed “reactive molecular containers” within the realms of bionanotechnology. 
Several virus scaffolds have been developed within the field of biotechnology, derived from 
plant, animal, human and bacterial viruses. Included in these is a scaffold derived from the 
hepatitis B virus. There are several features which make the HBV capsid, VLPs and protein 
scaffolds attractive as catalysts and containers:  
 Viruses and VLPs generally form capsid structures that are consistent in size and 
shape.   
 Capsids can undergo engineered pleomorphism, however require chemical 
modification or change in amino acid composition.  
 Capsids are generally amenable to amino acid modifications. Insertions and 
substitutions range from single amino acids up to whole protein sequences. Both the 
inner and outer capsid surfaces can be modified according to application.  
 Certain capsids have shown stability at various environmental pHs (3-10). Recently 
identified thermophilic viruses have shown stability at 80 oC and pH 1. These 
extremophile viruses are yet to find their niche within biotechnology, however it is 
only a matter of time until it happens [170, 171]. 
 Capsids generally comprise a single/few protein species, providing a means for 
simple, recombinant and scalable production.  
 Capsid interiors are charged to accommodate passenger nucleic acid. These cationic 
surfaces have also been used as catalytic metallo-nucleation sites.  
The HBV capsid is associated with several of the aforementioned properties, which 
facilitates their generation of enhanced vector-like properties for gene therapy.    
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VLP applications are considerably varied; and in addition to gene therapy they vectors 
have been used in several interesting biochemical and biomedical applications. Protein 
scaffolds and VLPs present in a variety of nano-scaled shapes and sizes; icosahedron ranging 
from the 12 nm diameter ferritin [172] or heat shock protein cage [173, 174], to the 
Paramecium bursaria Chlorella virus type-1 of 190 nm diameter [175]. Rod-shaped virus 
scaffolds include the 300 nm tobacco mosaic virus (TMV) [176] and the 900 nm 
bacteriophage M13 [177]. Some of the virus, VLPs and protein scaffolds in development for 
bionanotechnology are illustrated in Figure 3.1.1. Protein scaffolds and VLPs are generally 
amenable to amino acid substitutions which facilitate the binding/inclusion of a large variety 
of molecules, such as drugs [178], antigens for vaccines [179], bioimaging markers such as 
nanogold or fluorophores [180, 181], immuno-evasive compounds such as PEG [45], and 
tropic ligands [182] (Figure 3.1.2).  In addition to the internal and external surfaces, the 
regions between capsids subunits (such as pores) can be altered and controlled. Speir and 
colleagues showed that by introducing divalent metal ions to the VLPs of cowpea chlorotic 
mottle virus (CCMV), they could control the pores opening and closing to the environment, 
exposing or isolating their inner contents [183, 184]. Viruses have been manipulated and 
altered in a variety of ways to produce agents ranging in function from therapeutic gene 
delivery to catalytic nucleation sites for inorganic reactions.  
This chapter focuses on the manipulation and analysis of the HBV capsid, in which 
particular amino acids found on the capsid surface were substituted with lysine or cysteine 
residues. The introduction of the new amino acid residues facilitated the attachment of 
functional ligands (Described in later chapters). There are several amino acid residues which 
have been used for ligand conjugation reactions, however this thesis focused on using lysine 
or cysteine as the site of functional ligand conjugation. Both lysine and cysteine are popular 
residues for the conjugation of functional ligands to protein surfaces. Both undergo 
conjugation with a reactive ligand under mild conditions, favouring protein stability. As a 
result of the general abundance of lysine residues within proteins, this species is often 
associated with multiple but random conjugation events to the protein surface. Conversely, 
cysteine residues occur infrequently on protein surfaces, thus are often required to be 
engineered in to introduce a conjugation site. In doing so a specific conjugation site is 
generated. Both conjugation techniques have benefits and drawbacks, discussed in detail in 
Chapter 4. The following sections aim to explore the functional unit of the HBV capsid, 
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known as the core protein or core antigen, and the potential to manipulate particular 
domains of the core protein in order to enhance the vector-like properties for gene therapy.  
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Figure 3.1.1: Structural predictions of virus/VLP/protein scaffolds with potential application in bionanotechnology. (A) Paramecium bursaria Chlorella virus type-1, 190 nm 
diameter [185]. (B) Adenovirus, 95 nm diameter [186]. (C) Sulfolobus turreted icosahedral virus, 74 nm diameter [171]. (D) Murine polyomavirus, 45 nm diameter [187]. (E) 
Hepatitis B virus capsid, 30 nm diameter [188]. (F) Cowpea mosaic virus, 28 nm diameter [189]. (G) Adeno-associated virus, 20 nm diameter [190] (H) Ferritin, 12 nm 
diameter [191] (I) Tobacco mosaic virus, 300 nm length 18 nm diameter [192]. (J) Bacteriophage M13, up to 900 nm length 7 nm diameter [177]. Figure adapted from 
[193].  
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Figure 3.1.2: A schematic depiction of the VLP surfaces used for nanoplatforms and biomedicine. A) Exterior 
surfaces are often used for conjugation of a variety of moieties, such as peptides, polyethylene glycol or 
nanogold particles. B) Inter-capsid subunits form function-specific pore-like structures, which can be regulated 
by the presence of metal ions. C) VLP interiors have been used as molecular containers to i) transport nucleic 
acids ii) facilitate polyoxometalate crystal formation iii) produce isolated environments to observe enzyme 
reaction kinetics. Figure adapted from [193]. 
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3.1.1 Composition of the hepatitis B virus capsid and applicability as a vector 
for gene therapy. 
The HBV capsid has seen little development in the field of bionanotechnology as a gene 
therapy vector, and is perhaps better known for its use in developmental vaccines [194] and 
establishment of icosahedron capsid assembly kinetics [195-197]. Nonetheless, the HBV 
capsid does display several of the aforementioned VLP properties and also includes useful 
features such as:  
 Simplicity of expression and construction - E. coli expressed recombinant core 
proteins auto-assemble into capsids.  
 The “display” region (immunodominant loop) of the capsid is situated on the tip of 
tetra--helix bundles protruding from the capsid surface, which tolerate amino acid 
substitutions and insertions well. This highly exposed region is an ideal position for 
antigenic proteins in vaccine development and conjugation based reactions for the 
addition of immuno-evasive and tissue-tropic ligands.  
 The capsid interior is highly cationic, however recombinant capsid formation is not 
dependent on the presence of these C-terminal protamine motifs. 
The HBV capsid is formed by a single species of protein, hepatitis B core antigen (HBcAg). 
The core antigen comprises 183 amino acids, has a molecular weight of approximately 
21kDa and is composed of 55-60% -helices [198]. This was an unusual discovery, as the 
majority previously elucidated viral core proteins predominantly contained eight-stranded 
-barrels [199]. This uncommon -helix structure was supported by other researchers, and 
later confirmed by Wynne and colleagues through the analysis of the crystal structure of 
HBcAg/core particles [200, 201]. The various predicted and determined secondary structure 
distributions within the HBcAg are illustrated in Figure 3.1.3.  The HBcAg is predicted to 
contain five major -helices, in which helix 3 and 4 fold at a hairpin loop and form a 
spike-like structure, illustrated in Figure 3.1.4 [201]. Much of the HBcAg is stabilised by 
hydrophobic interactions. The core of the HBcAg is stabilised by highly conserved 
hydrophobic residue interaction between 1, the 1-2 connecting loop, 4b and 5 [201].  
Similarly, the interaction between 3 and 4 is stabilised by interhelical hydrophobic forces. 
The hairpin loop region formed between 3 and 4 contains a non-helical 
immunodominant loop (IL), which forms the distinct conformational HBcAg epitope (also 
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known as e1) located between residues 78-83 [202, 203]. The IL is well exposed at the 
capsid surface and is amenable to amino acid (aa) insertions and substitutions [202, 203] 
(described in detail in later sections).  
The HBcAg is divided into three main domains, comprising the core (aa 1-140), linker (aa 
141-149) and protamine domains (aa 150-183). The core domain forms the bulk of the 
HBcAg and capsid structure. It is capable of assembly into homodimers and the complete 
capsid without presence of the linker and protamine domains [93]. The linker domain has no 
apparent defined structure and is responsible for connecting the core and protamine 
domain, providing flexibility to the protamine domain within the capsid interior. The 
protamine domain contains four arginine-repeat motifs, two of which comprise three 
arginine residues, the other four arginine residues, resulting in a highly basic domain 
necessary for binding of viral DNA and RNA. Furthermore, three of the four repeat motifs 
comprise the sequence SPRRR, in which the serine residues are an important site for 
phosphorylation. It is generally accepted that the protamine domain is unstructured, and 
supported by the secondary structure prediction algorithm, Phyre2 [204]. Core proteins 
without the arginine domain (c149) were assembled into capsids and used in several 
pioneering studies to observe icosahedral capsid assembly kinetics and mechanisms. The 
c149 capsids were morphologically similar to the wild type counterparts (which contain full 
length core protein, c183), however did not bind and encapsidate RNA, an additional factor 
which may have complicated the kinetic observations and calculations [196, 205, 206]. 
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Figure 3.1.3: The predicted and determined primary and secondary structure of the hepatitis B virus core protein. The core domain (aa 1-140) forms of the bulk of the 
structured protein. The immunodominant loop is present from the amino acid residues 78-83 (yellow). The linker domain (aa 141-149) is highlighted in green and 
protamine (aa 150-183) domain in orange. Secondary structural distribution determined by crystallography by Wynne et al.  (1) [201] and Swiss PDB entry (3) [201]. 
Predicted secondary structure by Bringas et al.  (2) [200] and by the Phyre
2
 algorithm (4) [204]. The -helices from residues 140-183 determined by Phyre
2
 were predicted 
to have a high probability of disorder. Figure adapted from [207]. 
Page | 47  
 
                                        
Figure 3.1.4: The predicted structure of HBV core protein. Five -helices are present within the core protein, of 
which 3 and 4 associate to form a spike-like structure (yellow helices). Helices 1, 2 and 5 are involved in 
capsid stabilisation and inter-dimer interactions. The immuno-dominant loop (IL) is highlighted in red. Green 
lines represent connecting unstructured regions within the protein. Protein structure modelled in Swiss-PDB 
Viewer [214] using data from Wynne et al [201].  
Core proteins naturally associate to form homodimers, and rarely exist as individual 
units. The homodimer is stabilised by the hydrophobic interaction of the two helical 
hairpins, 3 and 4, forming a four-helix bundle. Wynne and colleagues have reported that 
the helical hairpins are highly amphipathic, and as much as 63% of their surface is buried in 
a hydrophobic interaction within the four helix bundle [201]. The four-helix bundle contains 
a single disulphide bridge, created by the Cys61 residue from each monomer [208]. The 
dimer has almost two-fold symmetry, illustrated in Figure 3.1.5. 
Capsids assemble from HBcAg into icosahedral particles of approximately 30 nm in 
diameter, with the four-helix bundles protruding 2.5 nm from the surface [201]. The capsids 
assemble into two conformations with triangulation numbers of T=3 and T=4. Both have 
been expressed in vitro and isolated from patients [209]. This is unusual as most viruses 
have a single unique T number that remains conserved amongst even distantly related 
viruses [210]. Initial studies indicated that c149 and c183 assemble into both T=3 and T=4 
conformations [209], however it was later established that c183s have a propensity to form 
T=4 capsids [211]. In a T=3 conformation a capsid comprises 90 dimers (180 HBcAg), 
whereas in T=4 conformation 120 dimers (240 HBcAg) make up the capsid. Dimers pack 
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predominantly in a quasiequivalent manner around both two-fold and five-fold axes, as 
illustrated in Figure 3.1.6 [212, 213]. 
 
Figure 3.1.5: Homodimer of the truncated HBV core protein (c149). A single disulphide bridge is created by the 
Cys61 residue from each monomer indicated by the white arrow. The colour-scheme is similar to that of Figure 
3.1.2. Protein structure was modelled in Swiss-PDB Viewer [214] using data from Wynne et al [201].  
Figure 3.1.6: Schematic representation of the icosahedral symmetry of the HBV capsid in T=3 and T=4 
conformation. Each independent subunit of a dimer is indicated as either A, B, C or D. Subunits are identical 
and associate as dimers, AB, CD or CC, depending on capsid conformation. Colour scheme of dimers indicates 
icosahedral faces or pentamer units on the capsid surface. One icosahedral face is represented by the dotted 
triangle, containing the two-, three- and five-fold symmetrical axes. Capsid pores are contained within these 
axes. The T=4 capsid contains 120 subunits, comprising 60 AB and 60 CD units. The T=3 capsid contains 90 
subunits, comprising 60 AB and 30 CC units. Both capsid conformations have been illustrated in a two 
dimensional plane. When displayed in a three dimensional space (i.e. spherical), the spacing between subunits 
decrease significantly while pores retain their size. Figure adapted from [201, 215].  
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Dimer-dimer interactions mainly occur between the two- and five-fold axes of symmetry 
of the capsid [201]. As with the four-helix bundle, these interactions are mostly stabilised by 
weak hydrophobic interactions [197]. Residues from helix 5, aa 128-136 and aa 137-142/3 
primarily stabilise inter-dimer interactions. The residue Tyr132 plays a crucial role in capsid 
formation, burying itself within a pocket formed by Pro20, Asp22, Phe23, Phe122, Trp125, 
Ala137, Pro138, Ile139, and Leu140 of an adjacent subunit [216]. In doing so, Tyr132 is 
locked into place by an adjacent dimer pocket. This arrangement occurs throughout the 
capsid, contributing to the stability of the structure.    
The capsid contains pores around the icosahedral two-, three- and five-fold axes with 
diameters ranging from 12 to 15 Å [201]. The three-fold and quasi three-fold pores comprise 
the polar residues D2, K7, R39, E40 and E43 [201] (Figure 3.1.6). It is suggested that these 
pores allow for the shuttling of components required for reverse-transcription during virion 
maturation as well as the release of degraded RNA template monomers. Several researchers 
have established that the internalised protamine domain is able to protrude on the capsid 
surface via the pores. Residues from Glu145 to Cys183 have been identified to be exposed 
on the capsid surface [217]. This exposure is thought to promote phosphorylation of the C-
terminus domain serine residues by cellular kinases, which play a role in nuclear uptake of 
the capsid and aid in dissociation from the viral nucleic acid sequence [218].  
Curiously it would appear that the most exposed region of the capsid, the IL, plays no 
direct role in the interaction with HBV envelope surface proteins. Studies conducted in 
which the IL was bound by protein aptamers resulted in poor virion formation. Thus it was 
suggested that the IL is involved in surface protein (preS2) interaction [219]. However 
Koschel and colleagues report that this is a consequence of steric hindrance between 
surface and core proteins over direct inhibition of interaction. [220]. They suggest rather the 
residues between capsid spikes involving the residues A11-V13, R133-P155 and L140-S141 
are responsible for interacting with the surface protein domain. Typically the surface protein 
domain is exposed at the endoplasmic reticulum, the initial site for HBcAg and surface 
protein interaction.  
The HBcAg has been identified to contain two major epitope sites. These epitopes are 
shared with a structurally similar protein, hepatitis B e-antigen (HBeAg). The HBeAg open 
reading frame overlaps with the HBcAg, however the N-terminus contains an additional 10 
starting amino acids. Consequently the HBeAg is unable to form capsid-like structures. The 
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first shared epitope of the two proteins is the IL on the tip of the protruding dimer spike (aa 
78-83 – e1) which is highly exposed on both the HBcAg and HBeAg. The second antigen is 
within a non-helical region (aa 128-133 – e2) that becomes buried upon capsid formation, 
however remains exposed with HBeAg [202, 203, 221]. Several other epitopes have been 
mapped, of which the majority are in the region of the IL, the remainder straddle the 
interface of adjacent dimers [222-224]. Capitalising on the immunogenic properties, 
researchers in the early 1980s identified the HBV capsid as a candidate for fusion-protein-
based immunostimulation. The HBcAg tolerated the insertion of peptides and exogenous 
proteins at the N- and C-termini, while allowing for the formation of stable core particles. It 
is suggested that the polymeric nature and strong immunogenic response of the capsids 
enhanced the immunising effect of fused/conjugated exogenous peptides/proteins [225, 
226]. It was later shown that HBV capsids bind directly to naive B cells, promoting a profuse 
production of anti-core antibodies [227]. The capsids carrying the fusion peptide/protein 
sequence induced the formation of antibodies against the capsid and fusion sequence [228, 
229]. Interestingly it was found that the terminal positioning of the antigens did not 
stimulate an immune response as prolific as the one against the core particle itself. With 
insertion of the peptide antigen into the predominant core epitope, e1 (within the IL), 
Brown and colleagues established a tenfold increase in immunogenic response when 
compared to terminal fusion species [225]. Subsequently, a large number of studies have 
incorporated  a wide variety of antigens into the IL, well reviewed by Pumpens and Grens 
[230].  
Ultimately, the display of a whole antigenic protein would produce the most 
comprehensive vaccine. Insertion was only possible with the elucidation of the HBV core 
protein structure, after which several whole proteins were inserted into the IL. Pioneering 
work by Kratz and colleagues indicated that whole protein insertion into the IL was 
tolerated by capsid formation, provided the core protein and core dimer structure were not 
disrupted [179]. With the inclusion of short linker sequences between the IL region and the 
termini of eGFP, it was possible to express capsids with functional eGFP displayed on the 
surface. Inclusion of whole proteins within the IL was applied to the outer surface of 
lipoprotein A (OspA) of Borrelia burgdorferi, the agent responsible for Lyme disease [231]. 
Recombinant particles containing OspA were produced ineffectively as a result of the poor 
core protein formation. The OspA protein is oblong in shape, with the N- and C-termini 
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located on opposite ends of the structure, preventing correct association between core 
helices 3 and 4. This obstruction was overcome by the introduction of a protease 
cleavage site near the IL region, in which cleavage removed any strain associated with 
HBcAg formation [232]. Alternatively, the core protein has also been expressed as two 
halves, either the N- or C-termini “half” (or both) with an exposed exogenous protein in 
place of the IL [233]. Both the IL cleavage and Splitcore systems assemble correctly, which in 
turn allows for correct dimer association and ultimately capsid formation. Common 
modifications to the core protein IL are illustrated in Figure 3.1.7. 
       
Figure 3.1.7: Schematic illustration of methods used to introduce bulky whole antigens/ligands to the spike 
apex (IL) of the HBV core protein. (i) Conformation of wt 3 and 4, linked by the IL.  (ii) Insertion of an amino 
acid residue into the IL facilitating the conjugation of ligands such as PEG. (iii) Insertion of eGFP into the IL, 
facilitated by linker sequences [179]. (iv) Insertion of whole antigens with remote termini, facilitated by site 
directed protease cleavage [232]. (v,  vi + viii) N and C termini expressed separately still form stable core 
proteins. Whole antigens can be included with the N- or C-terminal region, or both [233]. (vii) N and C termini 
of core protein expressed separately, each with an attached portion of protein domain. Formation of whole 
core protein allows for the reconstitution of attached antigen. Figure adapted from [233]. 
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Aside from vaccine development, HBV recombinant capsids have also been used as 
vectors for gene therapy. Choi and colleagues developed a modified capsid vector with a 
RGD motif targeting integrin within the IL and replaced the cationic binding domain with 
p19 binding protein [98]. Despite establishing siRNA delivery to cultured B16F10 cells, Choi 
did not determine whether the capsid uptake was specific or indiscriminate. Furthermore, 
capsid uptake resulted in trafficking to the lysosome for degradation. Paradoxically, by 
replacing the protamine domain with a RNA binding domain, capsids lost their nuclear 
localisation signal [234, 235]. Despite bound siRNAs being predestined for cytoplasmic 
activity, avoidance of lysosomal clearance would optimise the efficacy of this modified 
vector.  In a follow up study, Choi and colleagues tested the in vivo tumour targeting 
capacity of capsids containing the RGD motif [236]. Capsids were still significantly taken up 
by the liver without apparent explanation. Further investigation is required to determine 
the capsid uptake, intracellular fate, and effects of modification on the capsid surface with 
regards to cellular processing, trafficking and capsid content release. According to Cooper 
and Shaul, HBV capsids are indiscriminately taken up by a variety of cell lines [99]. Cellular 
uptake of capsids has been described to occur by various mechanisms. Cooper and Shaul 
found the Rab5 GTPase clathrin-mediated pathway to be responsible [237], whereas Choi 
and colleagues later identified clathrin-, caveolae- and macropinocytosis-mediated 
pathways involved in capsid uptake [98].  
The HBV capsid requires tissue tropic properties to become a useful agent for nucleic 
acid delivery. Apart from the motif insertions done within the IL, single amino acids may also 
be substituted to facilitate site specific ligand conjugation. Two amino acid residues have 
played important roles in the conjugation of ligands, namely lysine and cysteine. Both lysine 
and cysteine residues have successfully been used to conjugate ligands to cowpea mosaic 
virus and adenovirus in in vitro [94, 238] and in vivo applications [45, 239]. This chapter 
compared the effects of residue substitution into the IL of HBcAg on the formation of 
capsids and their physicochemical properties. The IL sequence, DPASRD, displays an overall 
negative electrostatic charge in physiological conditions. The following work describes that 
disruption of the wild type IL charge with cationic residues can have an impact on capsid 
yield. Amino acid substitutions to the IL which had little or no impact on the electrostatic 
potential did not disrupt capsid formation and expressed similarly to wild type variants.
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3.2. Results  
3.2.1. Generation of HBV capsid library with modifications to the protamine 
domain. 
The HBV capsid is able to withstand modifications to the protamine domain without 
having an impact on assembly. Two major variants are well described in the literature, c149 
and c183 (wild type). c149 comprises the core domain and the linker region, and has the 
entire protamine domain removed. It was described that the removal of the linker region is 
also possible, resulting in c140 which still assembles into capsids. In addition to the 
aforementioned variants, this study generated two additional mutants, in which the length 
of the protamine domain was varied. c160 contains the first eleven amino acids of the 
protamine domain, in which two arginine rich motifs are present. c170 contains a further 
ten amino acids and an additional arginine rich motif. The various protamine domain clones 
are schematically described in Figure 3.2.1. 
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Figure 3.2.1: Protamine domain of HBV capsid variants c140, c149, c160, c170 and c183. c140 does not contain a linker or protamine domain, whereas c149 contains a 
linker domain. The clones c160 and c170 contain two and three arginine rich motifs, respectively (red). c183 is the full length of wild type HBV core protein.
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3.2.2. Capsid yield is impacted by the position of lysine residue substitutions 
within the immunodominant loop  
Two HBcAg IL variants were initially generated, a 15 amino acid Gly-Lys substitution, the 
other containing two lysine substitutions – D78K S81K, illustrated in Figure 3.2.2. The 
cloning procedure to generate these mutants was challenging, and several difficulties were 
encountered in the planning and generation of mutant clones. The first mutant, termed 
LinkedLys, substituted P79A80 with the amino acid sequence GGGGKGKGKGKGGGG, in 
which four lysine residues would be exposed at the IL tethered by flexible glycine residue 
linkers. Immunodominant loop flexibility provided by the glycine residues was thought to be 
required as the repulsive electrostatic forces brought about by the excess lysine residues 
may have impacted on monomer folding and dimerisation. PCR amplification to generate 
clonal variants produced single DNA fragments of anticipated size during agarose 
electrophoresis (data not shown). However, through sequence analysis of LinkedLys clones, 
deleterious mutations in the IL region were revealed, illustrated in Figure 3.2.3. It is possible 
that the repetitive nature of the LinkedLys insert (5’-GGAGGAGGAGGAAAGGGAAAGGGAAA 
GGGAAAGGGAGGAGGAGGAGGA-3’) compromised the fidelity of the polymerase during the 
PCR or within host E. coli. Further investigation of the LinkedLys clones was not pursued. It 
was reasoned that varying the 15 amino acid sequence with additional or less glycine and 
lysine residues or interchanging their various triplet codons would be time consuming, and 
would not guarantee improved cloning outcomes.  
Several protocols describe the purification of recombinantly expressed HBV capsids. 
Comparison of the protocols revealed duration and complexity had a direct effect on capsid 
yield. Shorter protocols were often more crude, however yielded higher levels of capsid, 
whereas increased stages of capsid refinement removed bacterial contaminants but also 
decreased overall yield. The large capsid size (±4 MDa) in comparison to other bacterial 
components allowed for many of the purification steps to rely on size-based exclusion. One 
of the first attempted protocols relied on the separation of the capsids from other bacterial 
contaminants using sucrose-based density centrifugation. This was the crudest attempted 
method, as it only utilised a single purification step after bacterial lysis. The end step capsid 
product often contained several additional contaminants, which would considerably 
complicate downstream analyses if not removed. Thus a second purification protocol was 
attempted (Protocol 2), which excluded the sucrose gradient however included ammonium 
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sulphate precipitation of the capsids followed by size exclusion-based chromatography 
(SEC). This protocol resulted in removal of majority of the bacterial contaminants however 
their levels were high enough to necessitate further investigation of alternative purification 
methods. The last purification protocol (Protocol 3), relied on pelleting of the capsids by 
centrifugation overnight, followed by two SEC steps. The final polishing step involved 
sucrose gradient based centrifugation of the capsids. This final protocol had the longest 
preparation time, however capsid purity was much improved when compared to the 
previous protocols described. The first protocol however, is not without use and was often 
employed to assess expression levels of newly cloned recombinant capsids. Capsid purity 
was often assessed using agarose gel and denaturing polyacrylamide gel electrophoresis. As 
a result of the non-denaturing environment of the agarose gel, DNA ladder markers were 
used to indicate the migratory position of intact capsids (up to 4 MDa). This is purely a 
means to reference relative migratory position as both capsid size and charge influence its 
electrophoretic mobility. 
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Figure 3.2.2: Amino acid sequence of (A) wild type, (B) D78K S81K core mutant and (C) LinkedLys core mutant IL. Red and blue boxes are associated with negative and 
positive residue charges at physiological pH, respectively. 
 
 
Figure 3.2.3: Sequencing results of various LinkedLys clones (A-E).  All clones contained mutations to the IL region in comparison to the anticipated sequence (F). 
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Recombinant protein expression of a successfully cloned pET-c149 D78K S81K yielded 
undetectable amounts of capsid. Expressed capsids were separated from the majority of 
cellular debris by sucrose gradient centrifugation. Gradient fractionation and analysis by 
agarose gel electrophoresis and SDS-PAGE revealed no detectable expression of c149 D78K 
S81K protein (Figure 3.2.4 and 3.2.5). This was found to be true for all the clonal variants 
(pET-c149 - pET-c183) of D78K S81K. Several attempts were made to re-clone the mutant 
capsids, however all resulted in poor core protein expression. Introduction of basic residues 
into the IL may have resulted in a variety of new undetermined protein-protein interactions, 
perhaps resulting in core protein sequestration, degradation or precipitation. It was thus 
reasoned that any further substitutions into the IL should cause as little disruption as 
possible, without any major changes in electrostatic potential. Generation of the lysine 
recombinant HBcAg species was time consuming and laborious, thus to avoid future 
difficulties a simpler means to generate mutations within the IL was developed. 
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Figure 3.2.4: Preparative core protein distribution within a 10-60% sucrose gradient separated by 1% agarose 
gel-based electrophoresis. Sucrose gradient fractions (1 to 10) were loaded from lowest (±0%) to highest 
concentration (±45%). A) Ethidium bromide staining of passenger mRNA within c149 revealed capsid within 
fractions 3-5, just below the 3000 bp point (black arrow). No capsids appear present for the c149 D78K S81K 
preparation. B) Capsids stained with Coomassie Brilliant Blue-R250 similarly appear in fractions 3-5 for the 
c149 preparation (black arrow), however are absent from the c149 D78K S81K preparation. 
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Figure 3.2.5: Core protein distribution within a 10-60% sucrose gradient assessed by 15% SDS-PAGE. Fractions 
(1 – 9) were loaded from lowest (±0%) to highest (±42%) sucrose concentration. Coomassie Brilliant Blue R-250 
stained core proteins migrate near 17 kDa, indicated by the arrow. The c149 preparation contains core protein 
in fractions 3-6, whereas c149 D78K S81K contains undetectable levels of the mutant core protein. 
3.2.3 Development of the core ‘Snap-in’ system as a means to simplify cloning 
into the IL region. 
Specific mutations to the IL have proven difficult to engineer using canonical cloning 
methodologies. The IL region contains little to no conventional restriction sites, complicating 
the process of fragment (double stranded oligonucleotide or PCR product) insertion and 
ligation. Consequently an alternative, simple and universal cloning method was developed 
to insert any desired DNA fragment into the IL encoding region.  
The cloning system relied on the use of directional non-palindromic type IIS restriction 
enzymes [240]. The cleavage process ensured complete removal of the type IIS restriction 
enzyme recognition site and generated unique overhangs facilitating fragment insertion in 
the correct orientation. The overall process to generate the ‘Snap-in’ cloning system is 
explained diagrammatically in Figure 3.2.6. The recognition site for the type IIS restriction 
enzyme BbsI (5’-GAAGAC-3’) was introduced in two sites, each within the IL region. A single 
treatment with BbsI would cause cleavage at sites flanking the region encoding the IL, thus 
result in a backbone with unique sticky overhangs which could accommodate virtually any 
insert. In doing so a simple and effective system to alter the region encoding the IL was 
generated. Type IIS restriction enzymes have been used in other studies (intron cloning 
[241] and TALEN generation [242]) however is the first time it has found practical use in the 
generation of whole HBV capsid variants. This system is applicable beyond single amino acid 
substitutions, and could be applied for whole antigens. 
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Figure 3.2.6: Schematic representation of the generation and application of the HBV core ‘Snap-in’ system. (A) The core ORF was amplified by PCR into part A and Part B 
using core specific primers in two separate reactions. Primers that directly flanked the IL encoded two additional restriction enzyme sites, BbsI and NheI (i). (B) The NheI 
site common to both fragments was cleaved with NheI, the remaining sticky ends used to reconstitute the core “Snap In” system. (C) The ‘Snap-in’ cloning system 
contained a central reconstituted NheI binding site, flanked by two BbsI binding sites. Treatment with the BbsI restriction enzyme resulted in directional cleavage, which 
generated a unique 4 nucleotide 5’ non-complementary overhang (ii and iii). (D) Any remnants of the BbsI and NheI region are completely excised, and can be replaced 
with a double stranded oligonucleotide of approximately 40 nucleotides in length that reconstitutes the IL (which provides any required insertions/substitutions) (iii). (E) 
Region encodes modified IL. 
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 3.2.4. Introduction of lysine and cysteine residues into the IL with minimal 
impact on electrostatic potential  
Previous substitution of charged amino acids within the IL appeared to have an impact 
on capsid yield after expression. As such, follow up substitutions were designed to have 
minimal impact on capsid charge, morphology and assembly. As opposed to the 
cumbersome cloning methodology previously employed, the novel ‘Snap-in’ system allowed 
for quick and simplified generation of each substitutional variant of recombinant clones 
c149 to c183.  Lysine residues were inserted into position R82 or A80 and R82, resulting in 
clones R82K and A80K R82K respectively. Similarly, cysteine residues were substituted into 
positions S81 or L76 and S81, which generated clones S81C and L76C S81C, respectively. The 
substitutions within the IL region are schematically represented in Figure 3.2.7. The lysine 
and cysteine residue substitutions into the IL did not appear to significantly impact on core 
protein expression. Crude extracts of bacterial lysates were subjected to sucrose-gradient 
based centrifugation and analysed by SDS-PAGE. A large proportion of the proteins in the 
lower fractions (5-8) were predominantly HBV core (Figure 3.2.8 and 3.2.9). All fractions 
contain capsid however the later fractions contain less bacterial protein contaminants. 
 
Figure 3.2.7: Illustration of the amino acid sequence of the IL region containing engineered lysine and cysteine 
substitutions. (A) Wild type IL amino acid sequence. (B, C) Substitution of lysine residues into positions R82 or 
A80 and R82. The second lysine substitution replaced a neutral with a basic residue. (D, E) Cysteine residues 
are substituted into positions S81 and L76 S81. Acidic residues are indicated in red, basic in blue and sulfhydryl 
in yellow.  
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Figure 3.2.8: Core protein distribution within fractions of a 10-60% sucrose gradient. Fractions (3-10) were 
loaded from lowest (±14%) to highest (±46%) sucrose concentration, subjected to SDS-PAGE and stained with 
Coomassie Brilliant Blue R250. Crude preparation of protein contains a high expression level of both R82K and 
A80K R82K in c149 (black arrow). HBcAg dimers are also present in the preparation (white arrow).    
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Figure 3.2.9: Core protein distribution within fractions of a 10-60% sucrose gradient. Fractions (4-12) were 
loaded from lowest (±18%) to highest (±55%) sucrose concentration. SDS-PAGE and Coomassie Brilliant 
BlueR250 staining was used to analysis protein content of each fraction. Core proteins (c149 S81C and L76C 
S81C (black arrow)) were the major protein species in the lower fractions. 
Analysis of the electrostatic properties of the IL revealed that the substitution, R82K, had 
negligible effects on charge at physiological pH. Both pKa3 values for arginine and lysine are 
well above physiological pH, indicating both residues remain positively charged in the IL. 
Anionic HBV capsids, like DNA, migrate within an agarose gel matrix by electrophoresis. 
Consequently, disruption of capsid charge (and size) will have a direct effect on 
electrophoretic mobility. Analysis of expressed recombinant anionic capsid migration by 
electrophoresis within an agarose gel revealed that the single lysine substitution (R82K) had 
Page | 65  
 
little to no effect on capsid electrophoretic mobility. This is indicative that the electrostatic 
potential of R82K mutants remains largely unchanged in comparison to wild type (Figure 
3.2.10A). The addition of two lysine residues (A80K R82K) caused a positive shift in 
electrostatic potential, which resulted in these capsids migrating slower within the gel 
matrix, as compared to wild type and the R82K mutant (Figure 3.2.10A). Substitution of the 
lysine into position A80 caused an increase in overall positive electrostatic potential, thus 
shifting the anionic capsid charge to that of a more neutral state. The uniform nature of 
expressed recombinant HBV capsids (T=4) indicates that the electrophoretic shift occurred 
as a result of a change in charge and not size. As anticipated, cysteine insertions into the IL 
did not affect the electrophoretic nature of the capsid, and both S81C and L76C S81C 
mutants migrate similarly to wild type capsid (Figure 3.2.10B).   
           
Figure 3.2.10: Effects of IL amino acid substitutions on capsid electrophoretic mobility in agarose gels. Crude 
preparations of T=4 mutant capsids were stained with Coomassie brilliant blue R250 after electrophoresis.  A) 
Mutant R82K and wild type capsid migrate to the position of the black arrow, whereas A80K R82K migrate to 
the position of the white arrow. B) Cysteine substitution (S81C and L76C S81C) capsids migrate to a similar 
position as wild type (black arrow). 
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The electrostatic potential of the IL was modelled, which corroborated the mobility shift 
data. The electrostatic fields of the IL region were mapped using Swiss PDB Viewer [214], 
under the following parameters: protein and solvent dielectric constants, 4 and 80, 
respectively; 162 mM ionic strength (further details can be found in the materials and 
methods section). Comparison of the wild type and R82K mutant suggested negligible 
charge changes occur (Figure 3.2.11B + C). Introduction of the second lysine introduces an 
additional positive electrostatic region, however does not appear to influence effects of the 
acidic residues significantly (Figure 3.2.11A + B). The prediction software did not take into 
account the formation of salt bridges between acidic and basic residues, in which the 
formation of these bonds may impact on the extent of charged areas. Despite the exclusion 
of salt bridges, the predicted data of the lysine substitutions show no diminished anionic 
regions, rather just the introduction of a cationic region.  
Similarly, the electrostatic potential of the cysteine-containing IL was predicted (Figure 
3.2.12A – C). As anticipated, negligible changes in charge occur at the IL. The exchanged 
residues are considered to carry uncharged side chains, thus do not affect the local pKa of 
the IL significantly. Of interest was the change in charge of the IL of the original lysine 
mutant, D78K S81K (Figure 3.2.13). The predicted electrostatic potential reveals that these 
substitutions have a significant impact on IL charge. The replacement of an acidic with a 
basic residue and the introduction of an additional basic in place of the uncharged residue 
would appear to cause an equal distribution of both positive and negative charge at the IL. 
This does not imply that the IL charge became neutralised, however it may suggest that a 
significant change in charged residues may alter capsid behaviour within the bacteria, which 
caused poor yield after expression. 
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Figure 3.2.11: Electrostatic potential predictions of the monomer IL region of c149 (wild type), c149 R82K and 
c149 A80K R82K mutants. The apex of the hairpin is rotated 90
o
 horizontally to provide additional perspective. 
The side chain at position K80 and K82 are included in the illustration. Red areas map negative charge and blue 
represents positive charge. Protein backbone annotated as in Figure 3.1.4. Electrostatic predictions are based 
on Swiss-PDB Viewer of model [201]. 
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Figure 3.2.12: Electrostatic potential predictions of the monomer IL region of c149, c149 S81C and c149 L76C 
S81C mutants. Side chains of the cysteine residues at position S76 and S81 are included in the illustration. Red 
areas map negative charge and blue represents positive charge. Protein backbone annotated as in Figure 3.1.4. 
Electrostatic predictions are based on Swiss-PDB Viewer of model [201]. 
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Figure 3.2.13: Electrostatic potential prediction of the monomer IL region of c149 and c149 D78K S81K mutant. 
The region of both monomers is shown at different perspectives. Substituted amino acid side chains of the 
D78K S81K mutant are included in the illustration. Red areas map negative charge and blue represents positive 
charge. Protein backbone annotated as in Figure 3.1.4. Electrostatic predictions are based on Swiss-PDB 
Viewer of model [201].  
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3.3. Discussion 
Virus-like particles are attractive candidates for gene therapy vectors as their amenable 
nature allows for manipulation to introduce desired/required properties. A variety of 
modifications are discussed in the literature, encompassing nanowire formation to 
corrective-gene delivery. The HBV capsid is a suitable candidate for development, as it 
displays several of the required hallmark features for VLP vectorology. Previous work by 
other authors has demonstrated that the IL of the HBV capsid  is amenable to insertions and 
substitutions, provided these changes do not interfere with monomer and dimer formation 
[179, 233]. As such, it was possible to introduce amino acid residues into the IL to provide a 
site for the conjugation of functional ligands. This novel study incorporated two of the more 
commonly used residues for conjugation chemistry, lysine and cysteine. The HBV capsid 
contains one exposed lysine and no exposed cysteine residues, thus substitution into the IL 
formed ideal specific conjugation sites. 
The initial substitutions to the IL were made not taking physicochemical properties of 
the capsid into account. Consequently, the mutant D78K S81K displayed a significant change 
to the IL electrostatic potential. Further investigation regarding the poor expression of the 
core mutant was not pursued. It was reasoned that the drastic change in IL charge may have 
accounted for the almost absent yield of D78K S81K mutants, potentially as a result of 
capsid-protein interaction, which led to the sequestration and/or clearing of capsids during 
the preparation process. These data suggest that the IL is less robust than indicated in the 
literature, and consideration of its electrostatic nature needs to be assessed if insertions or 
substitutions are made. 
The LinkedLys motif was planned to contain four lysine residues separated by glycine 
residues, and tethered to the spike tip by two linkers comprising four glycine residues. This 
was encoded by highly repetitive AG sequence, which is known to cause polymerase 
slippage and poor replication [243]. Glycine and lysine codons comprise mainly of adenine 
and guanine, making use of the repetitive AG sequence unavoidable. It was later 
demonstrated that a minimum of one target residue is sufficient in the conjugation process, 
consequently further development of the quadruple lysine LinkedLys-like clones were not 
pursued.  
Modification to the region encoding the IL was found to be onerous, thus the 
development of a simplified cloning system was addressed. Insertion of type IIS restriction 
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sites flanking the region encoding the IL facilitated a convenient means to insert 
oligonucleotides with substituted amino acid triplet codons. This allowed for the cloning of 
sixteen recombinant HBV capsid clones in a short space of time. The ‘Snap-in’ system 
provides a means of cloning applicable to any VLP, simplifying generation of novel VLPs in 
the field of bionanotechnology and vectorology.  
Walker and colleagues provided an interesting solution to the purification of capsids that 
may experience conformational constraints or difficulties during synthesis [233].The 
Splitcore technique has been demonstrated to overcome conformational constraints at the 
IL site when exogenous peptides were inserted. This was of particular relevance when whole 
or protein fragments were introduced into the immunodominant loop. The Splitcore 
approach may have aided in the production of mutants such as LinkedLys and D78K S81K. 
Division of the IL where each section contains a desired mutation may have allowed for 
formation and isolation of recombinant capsids, despite not containing an intact IL. It is not 
known what effect a dissociation-reassociation step used for therapeutic nucleotide 
incorporation into capsids would have on the Splitcore species during a capsid loading step. 
The ‘Snap-in’ system allowed for the generation of whole HBcAg, and simple insertion or 
substitution of amino acid residues into the IL. Whole HBcAg would presumably assemble 
more efficiently after therapeutic sequence incorporation than species that comprise two 
halves. Both techniques, Splitcore and ‘Snap-In’, provide different advantages of cloning into 
the HBcAg. 
A lysine substitution into position R82 did not affect the overall capsid electrostatic 
potential, as very little change in residue charge occurred. The substitution of the second 
lysine at position A80 was done to further increase the chance of ligand conjugation to the 
IL. The amino acid position 80 was considered suitable for substitution as a change in the 
acidic residues (D78 or D83) was undesirable. Furthermore a change to the proline at 
position 79 was avoided, as proline residues are often involved in turning points within 
protein structures. Removal of the proline species may place additional conformational 
constraint within the IL (by creating a less flexible IL), hindering efficient HBcAg formation. 
As demonstrated in both mobility shift and electrostatic predictions, A80K R82K does 
decrease the overall capsid negative electrostatic potential, however did not significantly 
impact on capsid expression or purification. Substitution of cysteine at position S81 and L76 
S81 had no observable impact on capsid expression, purification or electrostatic potential. 
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The second cysteine was placed in a region flanking the IL to avoid the potential cystine 
bridges forming within and between ILs. Double lysine and cysteine mutants were 
generated with the aims to potentially improve conjugation reactions. Overall the 
introduced substitutions that did not significantly alter the IL charge, thus capsid charge, 
were well tolerated by the recombinant HBV capsid. 
Introduction of the lysine and cysteine residues within the IL provide a specific site for 
ligand conjugation. These functional ligands provide attributes such as hepatotropism and 
immuno-evasion. Unlike liposomes which require less than 10% surface ligand 
representation, the surface of the capsid required extensive decoration such that 
indiscriminate cellular uptake was avoided. This may require > 80% ligand conjugation to the 
capsid surface. The following chapter describes the conjugation of various ligands to the 
capsids surface, some of which were described in Chapter 2, with the aims to generate a 
hepatotropic vector. Furthermore, the effects of capsid envelopment within liposomes 
which also provide immuno-evasive and potentially hepatotropic properties were explored. 
3.4. Materials and methods 
3.4.1. Cloning of recombinant c140, c149, c160, c170 and c183 cassette 
constructs 
3.4.1.1. Polymerase Chain Reaction (PCR) 
The template for wild type (wt) core protein and its variants was the greater-than 
genome length HBV encoding plasmid pCH3091 [244]. Primers shown in Appendix 1 were 
used to generate the core protein cassettes and variations thereof (generic core forward, 
core reverse 149-183). The PCR mix consisted of the following components 1.25 U High 
Fidelity PCR Enzyme Mix, 5 l 10x High Fidelity PCR Buffer (75 mM Tris-HCl (pH 8.8 at 25 °C), 20 
mM (NH4)2SO4, 0.1% (v/v) Tween 20, 1.5 mM MgCl2), 10 nmol forward and reverse primer, 1 l 
of 10 nM dNTPs, 1 l of 10 nM pCH3091 up to 50 l with H2O (PCR reagents obtained from 
Fermentas, Burlington, Canada and primers obtained from IDT, IA, USA). The PCR 
amplification cycle was as follows: 5 minutes at 95 oC, followed by 35 cycles of 95 oC for 30 
seconds 55 oC for 1 minute and 72 oC for 1 minute. The final elongation step was for 10 
minutes at 72 oC.   
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3.4.1.2. PCR fragment isolation and purification 
The completed PCR was mixed with 10 l 6x DNA Loading Dye (Fermentas, Burlington, 
Canada) and loaded into a 1% (w/v) agarose gel containing 0.02% (w/v) ethidium bromide. 
Electrophoresis proceeded at 80 V in 1 X TAE buffer. DNA fragments were visualised using 
short wave ultraviolet and excised from the gel. The DNA fragments were extracted and 
purified using a standard phenol-chloroform protocol (Appendix 3). Briefly DNA fragments 
were excised then removed from the gel by centrifugation at 16000 × g for 10 minutes. 
Eluate was combined with an equal part of chloroform and salt-saturated phenol. Samples 
were thoroughly mixed and centrifuged at max speed (>8000 × g) for 90 seconds. The upper 
phase was retained and equal volume of chloroform added. Samples were thoroughly mixed 
and centrifuged at max speed (>8000 × g) for 90 seconds. This chloroform wash step was 
repeated. The upper phase was retained and an equal volume of chilled isopropanol added, 
to this 10% of the total volume 3 M sodium acetate was added. Samples were incubated on 
ice for 30 minutes and then centrifuged (>8000 × g) for 30 minutes at 4 oC. Supernatant was 
removed and DNA pellet washed with 70% ethanol. Supernatant was removed and DNA 
pellet dried at room temperature. The dried DNA pellet was resuspended in an appropriate 
volume of distilled water. DNA concentrations were determined by UV spectrometry using a 
Nanodrop ND-1000 (Thermo Fisher, Massachusetts, USA). 
3.4.1.3. Cloning into the bacterial vector pTZ57R 
All bacterial growth media was obtained from Oxoid (Thermo Scientific, MA USA). 
Purified PCR fragments were ligated into the T/A cloning vector pTZ57R (pTZ57R/T) 
according to manufacturer’s instructions (Fermentas, Burlington, Canada). The completed 
ligation reaction was added to 100 l of chemically competent DH5 E. coli bacteria 
(Appendix 3) and incubated on ice for 20 minutes, followed by heat shock at 42 oC for 90 
seconds after which bacteria were placed back on ice for 5 minutes. Lysogeny broth (LB) 
agar plates containing 0.01% ampicillin (Sigma, MO, USA) and 800 g isopropyl -D-1-
thiogalactopyranoside (IPTG) (Sigma), 800 g 5-bromo-4-chloro-indolyl-galactopyranoside 
(X-gal) (Sigma) on the surface of the agar were used in the blue-white screening process. 
Transformed DH5 E. coli were plated onto IPTG-X-gal-ampicillin-enriched LB agar plates 
and incubated over night at 37 oC. White colonies were indicative of fragment insertion, and 
were selected for by two rounds of screening. The first screen was colony PCR, using 
primers M13 forward and M13 reverse (Appendix 1). A small portion of a positive bacterial 
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colony was picked and resuspended in the PCR mix. The PCR consisted of the following 
components 0.25 U GoTaq® DNA polymerase (Promega, WI, USA), 3 l 5x PCR Buffer 
(GoTaq® Reaction Buffer (proprietary, pH 8.5)) 1.5 mM MgCl2, 5 nmol forward and reverse 
primer, 0.5 l of 10 nM dNTPs, up to 15 l with H2O. The PCR amplification conditions were 
as follows: 10 minutes at 95 oC, followed by 25 cycles of 95 oC for 15 seconds 55 oC for 15 
seconds and 72 oC for 30 seconds. The PCR products were separated and visualised using 
agarose gel electrophoresis, as described in section 3.4.1.2. Selected clones were considered 
positive if a PCR product of 624 bp (149 core), 657 bp (160 core), 687 bp (170 core) and 726 
bp (183 core) was present. The second screen was performed using restriction digestion. 
Positive colonies were selected and individually seeded into 5 ml LB supplemented with 
0.01% ampicillin, grown overnight at 37 oC. Plasmids were extracted from DH5 using the 
protocol described in Appendix 3. Extracted plasmid was digested with XhoI and NcoI using 
the following conditions: 1 g plasmid DNA, 10 l Buffer Tango (66 mM Tris-acetate (pH 7.9 
at 37 °C), 20 mM magnesium acetate, 132 mM potassium acetate, 0.2 mg/ml BSA - 
Fermentas), 0.5 U restriction enzyme, H2O up to 50 l, 37 
oC for 60 minutes. Digested 
products were visualised using agarose gel electrophoresis, as described in section 3.4.1.2. A 
positive clone produced a digested product of 456 bp (core 149), 489 bp (core 160), 519 bp 
(core 170), 558 bp (core 183). Sequencing with the M13 forward primer was used to check 
insert sequence integrity (Inqaba Biotec, ZA).  
3.4.1.4. Cloning into the bacterial expression vector pet15b 
Core sequences of the species c140-c183 were excised from pTZ57R vectors using NcoI 
and XhoI (as per section 3.4.1.3.). The bacterial protein expression vector, pet15b, was 
similarly treated however 1 U Antarctic phosphatase (Fermentas) was included within the 
reaction. DNA fragments were isolated using agarose gel electrophoresis and phenol-
chloroform extraction as described in section 3.4.1.2. Insert (core fragment) and backbone 
(pet15b fragment) were combined as a mole ratio of 5:1 respectively, in a ligation reaction 
using T4 DNA ligase (Fermentas) according to manufacturer’s instructions. Chemically 
competent Rosetta II E. coli were transformed with the ligated insert and backbone 
(eukaryotic protein E. coli expression strain Rosetta II (EMD Millipore, Darmstadt, Germany)) 
as described in section 3.4.1.3.  Transformed Rosetta II bacteria were distributed over 
chloramphenicol (0.0034% w/v) -ampicillin (0.01% w/v) - enriched LB agar plates and 
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incubated overnight at 37 oC. The following day a colony was isolated and cultured for 
protein expression studies. 
3.4.2 Cloning of core D78K S81K mutant and core LinkedLys mutants 
The aim of this cloning procedure was to introduce mutations within the IL region which 
substitute wild type for lysine codons. Core species 149-183 encoded within the respective 
pet15b backbone (Section 3.4.1.4) were used as templates in a PCR-based procedure which 
generated two halves of the core ORF: part A and part B. This methodology was used to 
generate both D78K S81K and LinkedLys clones.  
Part A of the LinkedLys clone was generated using the primers Generic core forward and 
LinkedLys Int reverse (Appendix 1). The second half of LinkedLys was generated using a two-
step PCR, in which LinkedLys Int forward 1 and respective reverse primer pertaining to core 
clone size (c149-c183) produced an amplicon template for the second reaction. Purified 
amplicon (described in Section 3.4.1.2.) was subjected to a second round of PCR using the 
primers LinkedLys Int forward 2 and a reverse primer pertaining to core clone size. The 
protocol for the above PCRs was described in Section 3.4.1.1. The cloning procedure is 
schematically described in Figure 3.4.1. 
Part A of D78K S81K was generated using the generic core forward and Lys sub Int 
reverse primers. Part B of D78K S81K was generated using Lys sub Int forward and Core 
reverse 149 (See Appendix 1). The PCR protocol for these two reactions is described in 
Section 3.4.1.1). The cloning strategy for LinkedLys and mutant core D78K S81K is 
diagrammatically described in Figure 3.4.1.  
Part A and part B amplicons were cloned into the bacterial vector, pTZ-57R, as according 
to the manufacturer’s instruction (Fermentas). The screen for positive clones is described in 
Section 3.4.1.3. An unanticipated common restriction site was present in pTZ – D78K S81K 
part B of clones c160, c170 and c183. This resulted in an adaption in the standard cloning 
procedure and is addressed at the end of this section. Positive clones were cultured and 
plasmids isolated as described in Section 3.4.1.3. To reconstitute the IL of the mutant core 
clones, part A and B clones were subjected to restriction digestion and respective fragments 
ligated together. pTZ-c149 LinkedLys part A was treated with the restriction enzymes ScaI 
and StuI; pTZ-c149 LinkedLys part B restriction enzymes DraI and ScaI (the part B LinkedLys 
clones of c160, c170 and c183 clones were treated similarly); pTZ-c149 D78K S81K part A 
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with ScaI and Ecl136II; and pTZ-c149 D78K S81K part B with NlaIV and ScaI. All restriction 
digests were carried out according to manufacturer’s instruction (Fermentas). Restriction 
digestion fragments were isolated as described in section 3.4.1.2. Part A and part B of each 
respective clone (which also contained a half of the pTZ57R plasmid) were ligated using T4 
DNA ligase (Fermentas) according to the manufacturer’s instruction. The cloning process is 
illustrated in Figure 3.4.1. 
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Figure 3.4.1: Schematic illustration of the cloning strategy used to generate the pTZ-LinkedLys and pTZ-c149 D78K S81K. (I) The LinkedLys species (c149-c183) 
were generated as two halves by PCR. The first half (Part A) was cloned directly into the cloning vector pTZ-57R, the second half (Part B) underwent a second PCR 
step and then cloned into pTZ-57R. Positive clones of both A and B were combined after restriction digestion and ligation, producing the recombinant pTZ-
LinkedLys (for clones c149-c183). (II) The clone pTZ-c149 D78K S81K was generated in a similar manner, in that two halves of the construct were initially 
generated by PCR. Part A and Part B were cloned separately into pTZ-57R, screened, and a positive clone of each was treated with restriction endonucleases and 
ligated together, reconstituting pTZ-c149 D78K S81K. 
I II I
I 
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3.4.2.1 Cloning of D78K S81K into the core species c160, c170 and c183 
The part B pTZ-D78K S81K c160, c170 and c183 clones contained the blunt cutting NlaIV 
restriction site in two locations, which prevented the reconstitution of the sequence 
encoding core protein when digested with NlaIV. Thus a four-way ligation approach was 
used (summarised in Figure 3.4.2) which cloned directly in pET15b, circumventing the 
pTZ57R cloning step. Screening of colonies and plasmid preparation have been described in 
Sections 3.4.1.2 and 3.4.1.3. pTZ-c149 D78K S81K Part A treated with restriction enzymes 
NcoI and Ecl136II; pTZ-c149 D78K S81K Part B with NlaIV and BspEI; pTZ-c160 (or c170/c183) 
treated with BspEI and XhoI; lastly the bacterial expression vector pET-15b with XhoI and 
NcoI. The restriction digests were performed according to the manufacturer’s instruction 
(Fermentas). DNA fragments were isolated as previously described (Section 3.4.1.2) and 
ligated together in equal mole ratios with T4 ligase (Fermentas) according to the 
manufacturer’s instruction. 
 
Figure 3.4.2: Schematic representation of the four-way cloning strategy used to generate the mutant clones 
D78K S81K directly in the bacterial expression vector pET-15b. (A) pTZ-c149 D78K S81K Part A was used to 
generate the first half of the cassette. The remainder of the cassette was reconstituted as follows: a fragment 
of pTZ-c149 D78 S81K Part B, which completes the mutated IL region; a fragment from c160, 170 or c183 to 
generate the various clonal sizes of core protein. (B) All fragments were generated by restriction digestion and 
ligated into the pET-15b backbone. 
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3.4.3 Generation of the IL ‘Snap-in’ system in pTZ57R. 
A simple method for substituting triplet codons was required, as the flanking sequences 
to the IL contained very few useful restriction sites. A method was developed in which the IL 
encoding region could be excised out using type IIS restriction enzymes and replaced with a 
42 bp ds oligonucleotide. The core cassette was divided in two halves using PCR: primers 
Generic forward core and Part A RE2 ‘Snap-in’ reverse for Part A; Part B RE2 ‘Snap-in’ 
forward with respective reverse primer pertaining to core clone size (c149-c183) for Part B 
(Appendix 1). PCR conditions and fragment purification were described in section 3.4.1.1 
and 3.4.1.2. The expected amplicon sizes for Part A were 253 bp; 227 bp for Part B c149; 260 
bp for Part B c160; 290 bp for Part B c170; and 329 bp for Part B c183. Fragments were 
cloned into pTZ57R/T according to manufacturer’s instruction (Fermentas), which generated 
the clones pTZ-core ‘Snap-in’ part A and pTZ-core ‘Snap-in’ part B c149 (or c160-c183). Clone 
screening was as described in Section 3.4.1.2. The ‘Snap-in’ system was assembled by 
matching a Part A with a respective Part B. pTZ-core ‘Snap-in’ part A and pTZ-core ‘Snap-in’ 
part B were cleaved with enzymes ScaI and NheI (Fermentas) as follows: 1 g plasmid DNA, 
5 l ScaI Buffer (10 mM bis-Tris Propane-HCl (pH 6.5 at 37 °C), 10 mM MgCl2, 100 mM KCl, 
0.1 mg/ml BSA - Fermentas), 0.5 U restriction enzyme, H2O up to 50 l for 2 hours at 37 
oC. 
The restriction digest yielded fragments of 1332 bp for part A; 2032 bp for Part B c149; 2065 
bp Part B c160; 2095 bp Part B c170; and 2125 bp c183, which were isolated as previously 
described in Section 3.4.1.2. Part A and Part B fragments were ligated together using T4 
ligase according to manufacturer’s instructions (Fermentas). Chemically competent E. coli 
strain DH5was transformed with ligated productas described in Section 3.4.1.3. Selection 
of positive clones was described in Section 3.4.1.3. Figure 4.4.3 and schematically describes 
the above mentioned procedure. 
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Figure 3.4.3: Summary of the ‘Snap-in’ cloning procedures. A PCR was used to generate 2 sequences flanking 
the region encoding the IL region (A-B). Amplicons were ligated into pTZ57R (C). Each respective plasmid was 
digested with NheI and ScaI and fragments ligated to reconstitute pTZ57R and generate a ‘Snap-in’ core 
cassette. The highlighted region contains the type IIS restriction enzyme, BbsI (D and E). 
3.4.3.1 Cloning into the ‘Snap-in’ system followed by insertion into the bacterial 
expression vector pet15b 
pTZ-Snap-in clones treated with BbsI generated an insertion site for an oligonucleotide 
encoding a modified IL region (modified sites include R82K, A80K R82K, S81C and L76C S81C 
– Appendix 1). The restriction digest proceeded overnight at 37 oC using 1 g plasmid, 1 U 
BbsI, 1 U Antarctic phosphatase, 5 l Buffer G (10 mM Tris-HCl (pH 7.5 at 37 °C), 10 mM 
MgCl2, 50 mM NaCl, 0.1 mg/ml BSA -  Fermentas) up to 50 l H2O. DNA was purified as 
described in Section 3.4.1.2. One hundred picomol of insert oligonucleotide was treated 
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with T4 polynucleotide kinase (Promega), according to manufacturer’s instructions. 
Phosphorylated oligonucleotides were purified by the phenol:chloroform extraction method 
(Appendix 3). Phosphorylated insert and dephosphorylated backbone were ligated as a 5:1 
mole ratio respectively using T4 ligase, according to manufacturer’s instructions 
(Fermentas). Chemically competent DH5were transformed with the ligated productas 
described in section 3.4.1.3 Positive clones were selected as described in Section 3.4.1.3. 
The ‘Snap-in’ core clones (c149-c183) were inserted into the pET15b plasmid as described in 
Section 3.4.1.4. The above methodology is illustrated in Figure 3.4.4 and 3.2.5. 
                        
Figure 3.4.4: Schematic representation of the ‘Snap-in’ cloning system to generate a modified IL construct 
within the bacterial expression vector pET15b. pTZ-core ‘Snap-in’ (c149-c183) were cleaved with BbsI to 
remove the interconnecting NheI region (A-B). A phosphorylated oligonucleotide encoding mutations to the IL 
was inserted (C-D).The IL-modified core cassette (c149-c183) was cleaved from pTZ backbone with NcoI and 
XhoI and inserted into the bacterial expression vector pET15b (E). 
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3.4.3. Core protein expression in Rosetta II bacteria 
Three purification protocols were attempted, all varying in duration and complexity. It 
was found that the purification required two size exclusion steps to purify capsids to a 
satisfactory level. Bacterial expression broth recipe can be found in Appendix 2.  
3.4.3.1. Protocol 1 – sucrose gradient-based purification. 
Fifty millilitres of lysogeny broth supplemented with chloramphenicol (0.0034% w/v)-
ampicillin (0.01% w/v) was inoculated with a core protein-expressing colony or bacterial 
glycerol stock and grown at 37 oC overnight with shaking. The following day 300 ml of 
protein expression broth (Appendix 2) was inoculated with 1-10 ml of seed culture grown 
the previous night. Variation in inoculation volume was based on culture growth rate. It was 
found that the cysteine modified capsids grew slower than the unmodified species. Cultures 
were incubated at 37 oC with vigorous shaking until the optical density of the culture had 
reached 0.5 at 600 nm, at which point were supplemented with IPTG to a final 
concentration of 1 mM (0.0238% w/v). Protein induction continued at 37 oC with vigorous 
shaking for 2 hours. Bacterial cells were harvested by centrifugation (5 minutes at 5000 × g) 
and resuspended in 10 ml Tris-NaCl buffer (Appendix 2) supplemented with 2 mg/ml 
lysozyme (Sigma) and frozen overnight at -20 oC. The following day sonication (20 seconds 
with 80% cycling and 80% power - performed in quadruplicate) was used to rupture the 
remaining bacterial cells. Lysates were stored overnight at 4 oC, following which 
centrifugation at 8000 × g for 1 hour pelleted cellular debris. Capsids within the lysate 
supernatant were purified on a 10-60% sucrose gradient by centrifugation at 250 000 × g for 
2 hours at 20 oC. Distinct opaque bands formed within the sucrose gradient, most of which 
were bacterial contaminants. Fractions of 1 ml were taken from the gradients and analysed 
by SDS-PAGE for capsid content (Appendix 3). Fractions containing core protein were pooled 
and dialysed against TN buffer overnight, with initial buffer changes after one and two 
hours. Capsids were concentrated by centrifugation-based ultrafiltration with Amicon 
Ultracel 10k (Millipore, MA, USA). Samples were concentrated to 0.5-2 mg/ml and stored at 
-80 oC. 
3.4.3.2 Protocol 2 - Expression and purification “Zlotnick protocol”  
A second protocol was used to purify recombinant HBV capsids, based on the method 
described by Zlotnick et al.  [213]. Recombinant core expressing E. coli was initially cultured 
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as described in Section 3.4.3.1, however 500 ml protein expression broth was seeded with 
1-15 ml starter culture. Once cultures had reached an OD of 0.5 at 600 nm, IPTG was added 
to a final concentration of 2 mM (0.0475% w/v) and shaken vigorously for 3 hours at 37 oC. 
Bacteria were harvested by centrifugation and the pellet resuspended in 10 ml resuspension 
buffer A supplemented with 2 mg/ml lysozyme (Appendix 2). The bacterial suspension was 
frozen overnight at -20 oC. The following day the remaining bacterial cells were ruptured by 
sonication (20 seconds with 80% cycling and 80% power - performed in quadruplicate). 
Cellular debris was removed by centrifugation at 26 000 × g for 1 hour. Solid sucrose was 
added to the lysate supernatant to a final concentration of 0.15 M and further centrifuged 
at 100 000 × g for 1 hour. Solid (NH4)2SO4 was slowly added to the supernatant to avoid 
permanent protein precipitation, after which the solution was gently agitated at 4 oC for 1 
hour. Precipitated protein was collected by centrifugation at 26 000 × g for 1 hour. Protein 
pellets were resuspended in 5 ml column buffer A and loaded onto a pre-equilibrated 
Sepharose CL-6B column (GE Healthcare, NJ, USA) (22 mm x 300 mm). Majority of the 
capsids were eluted in the void volume using a column flow rate of 700 l/min. Fractions 
containing core protein were pooled according to SDS-PAGE analysis. Capsids were 
concentrated to 0.5-2 mg/ml by centrifugation-based ultrafiltration using Amicon Ultracel 
10k (Millipore) and stored at -80 oC. 
3.4.3.3 Protocol 3 - Expression and purification “Porterfield protocol”   
The final protocol used to isolate recombinant capsids was derived from Porterfield et 
al.   [245]. Recombinant E. coli was cultured as described in Section 3.4.3.1, however 750 ml 
protein expression broth was seeded with 1-15 ml starter culture. Cultures were incubated 
at 37 oC with vigorous shaking until the optical density had reached 0.5 at 600 nm. Cultures 
were then supplemented with 0.238 g of IPTG (2 mM final concentration) and protein 
induction continued at 37 oC with vigorous shaking for 5 hours. Bacterial cells were 
harvested by centrifugation. The bacterial pellet was resuspended in 12 ml resuspension 
buffer (Appendix 2) supplemented with 2 mg/ml lysozyme (Sigma) and frozen at -20 oC 
overnight. Bacterial suspensions were allowed to thaw at room temperature, after which 
sonication (20 seconds with 80% cycling and 80% power - performed in quadruplicate) was 
used to disrupt the remaining intact bacteria and shred RNA and DNA. Lysate debris was 
collected by centrifugation at 8000 × g for 1 hour at 4 oC and discarded. The remaining 
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supernatant was subjected to further centrifugation at 120000 × g for 14 hours to pellet 
capsids. Capsid pellets were resuspended in 6 ml column buffer B (Appendix 2) and loaded 
onto a CL6B Sepharose (GE Healthcare) column (22 mm x 300 mm), equilibrated with 
column buffer B. Column flow rate was set to 500 l/min. Fractions containing capsids were 
identified using SDS-PAGE analysis, pooled, and loaded onto a Blue Sepharose (GE 
Healthcare) column (16mm x 300mm) equilibrated with column buffer B. Column flow rate 
was 300 l/min. Capsid-containing fractions were identified by SDS-PAGE analysis, pooled 
and loaded onto a 50 mM PBS-buffered 2 mM TCEP (pH 7.5) 40-60% sucrose gradient. 
Gradients were subjected to centrifugation at 120000 × g for 4 hours. Fractions containing 
capsids (determined by SDS-PAGE analysis) were pooled and dialysed overnight against 
column buffer B. Capsids were concentrated to 0.5-2 mg/ml with Amicon Ultracel 10k 
(Millipore, MA, USA) by centrifugation-based ultrafiltration and stored at -80 oC. 
3.4.4 Agarose gel and polyacrylamide gel analysis and staining 
3.4.5 Electrostatic modelling. 
Modelling was done using the Swiss protein data base viewer (DeepView) [214] using 
the following parameters:  
 Poisson-Boltzmann computation – A more sensitive and accurate analysis over 
Coulomb computation.  
 Protein dielectric constant – 4. Determination of protein dielectric constant remains 
controversial [246], thus the software suggested value was used.  
 Solvent dielectric constant – 80. This is the standard dielectric constant for water at 
20 oC, the solvent used to resuspend the capsids in. 
Ionic strength – 162 mM. This was the ionic strength of the PBS solution [247]. 
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Chapter 4: Modification of recombinant HBV capsids using functional 
moiety-IL conjugation or liposome encapsulation. 
4.1 Introduction 
In Chapter 3 it was described how lysine or cysteine residues were introduced into the IL 
of the HBV capsid. These particular residues are frequently used for conjugation-based 
reactions, to facilitate the attachment of a variety of functional ligands to the protein 
surfaces. The ligands in turn provide the capsid with functionality suited towards gene 
therapy vectorology. As naked capsids are highly immunogenic and are indiscriminately 
taken up by a wide variety of cell types, adequate decoration of their surface with these 
functional ligands is useful to improve targeting and uptake efficiency. There are a few 
specific natural amino acids associated with ligand conjugation reactions, however 
unnatural amino acids have also been used for the ligand attachment. Lysine and cysteine 
residues are a popular choice for conjugation-based reactions; the less utilised residues 
include glutamic acid, aspartic acid and tyrosine. Of late, the azide-alkyne cycloaddition 
reaction with unnatural amino acids has seen increased use for the conjugation of ligands to 
protein surfaces. There are several factors which influence the choice of residue selected for 
the conjugation process:  
 Stability of the formed conjugate, as certain conjugates (such as the ester-based 
reaction products) tend to be less stable.  
 The prevalence of the target amino acid residue on the protein surface, as excessive 
surface decoration is associated with significant disadvantages such as ligand and 
protein inactivation.  
 Location of the amino acid residue(s) on the protein surface, as ligand conjugation 
may influence protein stability or activity.  
 Accessibility to the amino acid residue(s) by reactive ligand moieties.  
 Selection of the conjugation site according to local environment. Neighbouring 
residues can alter the local environmental pKa, which influences the success of 
residue-ligand conjugation.  
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It has been shown possible to insert residues required for conjugation into the HBV 
capsid IL without affecting structural assembly or preparation yield (Chapter 3). The first 
substitutions to the IL of the HBV capsid utilised lysine. The lysine residue contains a primary 
amine which reacts with compounds containing N-hydroxysuccinimidyl esters (NHS-esters). 
This method of moiety to protein conjugation has successfully been employed in a 
multitude of studies, including the covalent linkage of polymers [248], fluorophores [249], 
transferrins [250], small molecules [251], PEG [252] and epitopes [253]. The presence of 
lysine on the protein surface offers several benefits when conjugating with functional 
ligands. The residue is hydrophilic in nature, which often allows for protein surface 
exposure. Of the 20 natural amino acids, lysine makes up 6.3% of amino acids in proteins 
[254], which usually makes  it a readily available conjugation target. The potentially high 
surface representation of lysine residues can however present difficulties, as excessive 
decoration with ligands may result in protein or VLP instability, precipitation or ligand 
inactivation. The ester linkage within the ligand is also prone to hydrolysis (< 5 hour half-
life), which has been shown to increase in environments above pH 7 [255]. Despite these 
disadvantages, NHS-esters are a popular choice for ligand conjugation, as reaction 
conditions are mild and a variety of ligands are commercially available. 
Cysteine residues were also incorporated into the IL, facilitating an alternative 
conjugation reaction. A common group used to react with exposed cysteine is maleimide, 
however other reactive species are available [256]. Maleimide-based conjugation, like the 
NHS-esters, has been used in a wide variety of reactions including covalent linkage of 
peptides [253], small molecules [257], polymers [258] and fluorophores [259, 260]. 
Typically,  cysteine residues represent ±1.1% of the 20 amino acid residues within proteins 
[254]. Consequently, externally located cysteine residues are sparse, and for conjugation 
purposes often require to be engineered into the target protein. It follows that cysteine 
residues provide site specific conjugation, preventing potential moiety conjugation to active 
or receptor-interacting sites. Exposed cysteine residues do pose several shortcomings, the 
most significant being the formation of cystine bridges with other proteins under oxidising 
conditions. Disulphide bond formation is also associated with protein misfolding after 
translation [261].  In an attempt to overcome cystine bridge formation, researchers have 
engineered cysteine residues within protein pockets, or within the interior of VLPs [261, 
262]. A concern of generating VLPs with exposed cysteine residues was the potential 
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formation of cystine bridges, resulting in aggregation during the preparation or storage 
process. Interestingly Chapter 3 described the substitution of cysteine residues into the IL of 
the HBV capsid that were highly exposed to the environment. These VLPs did not aggregate 
significantly and were stable during storage. As with the NHS-ester reactions, maleimide 
reacts with cysteine under mild conditions, facilitating simple conjugation with a wide range 
of available (or synthesisable) ligands. 
The alternative conjugation methods available are not as popular as linking to lysine or 
cysteine. Both aspartic and glutamic acid can be used as sites for conjugation, employing the 
use of carbodiimide and a primary amine-containing ligand [263]. The carbodiimide forms a 
reactive intermediate with the carboxylic acid group of glutamic or aspartic acid, allowing 
for interaction with the primary amine. This is a potential limitation, as it facilitates the 
conjugation of lysine residues to carboxylic acids between intra- and inter-protein residues. 
Tyrosine residues are also available as conjugation sites, and may provide for discreet 
linkage as they are represented 3.3% of the natural amino acids within proteins [254]. The 
conjugation reaction often involves the use of benzenediazonium to conjugate functional 
moieties to tyrosine residues on the protein surface [264]. Unfortunately conjugation to 
tyrosine residues require oxidising reagents which may cause undesired side reactions with 
the target protein [265]. 
Unnatural amino acids for ligand conjugation provide an alternative to naturally 
occurring amino acids. There are over 70 unnatural amino acids available [266], and 
techniques such as global-replacement that is residue specific (GRRS) or site specific 
incorporation (SSI) have been used to introduce artificial amino acids into proteins [267-
269]. GGRS relies on the replacement of a natural amino acid with an analogous artificial 
variety during translation, and SSI utilises a stop codon as a tRNA encoding site for the 
unnatural amino acid. These techniques have allowed for the introduction of alkyne 
residues, facilitating the reaction with azide groups (Reviewed in [270, 271]). This process is 
known as azide alkyne cycloaddition (“click” chemistry), and is gaining popularity as a 
protein conjugation technique. A concern associated with the azide alkyne cycloaddition 
reaction is the presence of residual copper ions after the reaction and sample degradation 
by reactive oxygen species. The aforementioned conjugation techniques are illustrated in 
Figure 4.1.1. 
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Figure 4.1.1: Illustration of various chemistries used to conjugate ligands to proteins and nanoparticles. (A) 
Lysine-NHS chemistry is a popular conjugation method as lysine residues are generally well represented on 
protein surfaces.  (B) Cysteine-maleimide chemistry is another useful method, generally employed for site-
specific conjugation. (C) The reaction between carboxylic acids and amines is facilitated by carbodiimide. 
Activated carboxylic acids may react with lysine residues. (D) Tyrosine based conjugation with diazonium. The 
reaction requires a strong oxidiser which may react with other protein residues. (E) Azide alkyne cycloaddition 
can occur at low reagent conditions in mild reaction conditions. It is noted that the triazole moiety may cause 
protein/VLP instability. 
Several factors impact on the choice of reaction and ligand type for conjugation:  
1) Prevalence and location of targeted residues affect protein stability and activity.  
2) The reaction environment should not impact on protein/VLP stability or structure.  
3) Availability of ligand may also influence the type of conjugation employed.  
As a result of the mild and simple nature of their conjugation chemistries, as well as their 
infrequent occurrence on the capsid surface, both lysine and cysteine make ideal candidates 
for ligand conjugation. As a proof of principle starting point, initial conjugation reactions 
with lysine and cysteine were performed with the readily available succinimidyl carbonate 
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PEG5000 (scPEG) as the NHS-ester or maleimide PEG5000 (malPEG). Successful conjugation 
to these residues would prompt further analyses with synthesised galactose-, glucose-, 
polygalactose- and fluorescein-based ligands. As described in Chapter 2, the galactose ligand 
provides hepatotropism to the nanoparticle by interacting with the ASGPr on liver cells 
[132]. The glucose moiety was included as an uptake control, as hepatocytes have a far 
greater affinity for galactose. It was also assessed whether cellular uptake was increased 
when using polygalactose ligands. Decoration of the capsid surface with galactose would 
ideally also prevent the indiscriminate uptake of capsids by a variety of cell types. With 
adequate decoration using the galactose moieties, the HBV capsid may also gain immuno-
evasive properties. It is anticipated that the positioning of the conjugation site and the bulky 
nature of the galactose compound may shield capsid surfaces which are prone to immuno-
detection (such as the IL). Thus the galactose compounds may function similarly to an 
attached PEG molecule. The ligands conjugated to the HBV capsid surface in this study are 
illustrated in Figure 4.1.2. 
 
Figure 4.1.2: Diagrammatic representation of ligand moieties used to conjugate to the HBV capsid surface. 
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Alternative means are available to introduce functional moieties and ligands to the 
capsid surface. This may be required as the newly introduced residues and/or ligands 
change the capsid physicochemical properties in such a manner that capsids become 
unstable. It has been noted that excessive PEGylation to the adenovirus surface leads to VLP 
instability [272]. An alternative is to avoid covalent linkage to the capsid surface, thus 
decrease chances of capsid destabilisation. Moreover, these covalent-free methods avoid 
inclusion of reactive residues (such as cysteine). It has been demonstrated by a variety of 
researchers that it is possible to envelop VLPs in a liposomal formulation. The liposome 
exposes functional moieties anchored within its bilayer, avoiding the requirement of direct 
ligand attachment to the capsid surface. Like VLPs, liposomes have been shown to deliver a 
wide variety of cargoes. Innovative development has generated liposomes which are 
capable of drug and metal compound delivery, vaccine capacity, diagnostic imaging and 
delivery of proteins and peptides (reviewed in [273]). Early studies that attempted to 
envelop and deliver picornavirus demonstrated that cellular uptake was slow and passive 
[274]. The slow uptake mechanism is attributed the overall anionic charge of the 
picornavirus capsid, liposome membrane and cellular membrane, which reduces their 
association and interaction. Several years later Faller and Baltimore attempted to overcome 
retrovirus superinfection using anionic liposome virus-encapsulation [275]. Despite showing 
an improvement in superinfection with anionic liposomes, notable re-infection results were 
only generated once (poly)cations, such as polybrene, were included in transfections and 
infections [276, 277]. Similarly, the inclusion of cationic species on the liposome surface 
translates to significantly improved liposome-based DNA transfection over anionic 
liposomes [76]. The cations present on the surface of the liposomes facilitated the 
interaction with the anionic DNA phosphate-backbone, not only allowing for envelopment 
but also enhanced interaction with cellular membranes. Anionic capsids of retroviruses 
were also shown to interact with cationic liposomes, resulting in their envelopment and 
successful uptake by superinfected cells [278-282]. The cationic liposome based-
envelopment principle should be applicable to any anionic VLP, including the HBV capsid. 
Liposome envelopment of VLPs provides a means to display functional ligands, improve 
vector stability and increase immuno-evasion [278]. This is of particular importance as 
immune recognition of therapeutic VLPs remains a major hurdle within the field. The 
introduction of tissue-tropic ligands to the surface of liposomes may offer an alternative to 
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generating a variety of expressed motifs or conjugation-based ligands on the capsid surface. 
This may become necessary if the capsid preparation yields too many capsid aggregates as a 
result of introduced residues. 
This chapter explores the optimal ligand concentration and incubation time to optimise 
VLP decoration with functional moieties. It was found that maleimide-cysteine based 
conjugation produced the most decorated capsids. The recombinant capsids of c149, c160 
and c170 containing cysteine substitutions were able to undergo various degrees of 
conjugation. It was also assessed whether the HBV capsid can undergo envelopment using 
DC-Chol-DOPE-based liposomes [158]. Furthermore, it was demonstrated that liposome 
envelopment of HBV capsids may be possible, using cationic liposomes embedded with PEG. 
Both forms of modification resulted in potential improvement of the naked HBV capsid as a 
vector for gene therapy. It was found that the HBV capsid may be permissible to liposome 
envelopment, however required the presence of PEG to stabilise the new VLP structures.  
4.2 Results 
4.2.1 Assessment of lysine-N-hydroxysuccinimide-based conjugation of 
scPEG to capsids containing R82K and A80K R82K 
Wild type core protein contains two lysine residues, K7 and K96 (Figure 4.2.1). Lysine 7 is 
located within the three-fold and quasi three-fold axes pore [201]. This location may have 
limited accessibility to bulky compounds such as PEG, preventing conjugation with scPEG at 
this site. Conversely K96 is located on the 4 helix, which is readily exposed to the 
environment and may undergo lysine-NHS based reactions. The lack of readily exposed 
lysine residues has made the HBV capsid an ideal protein to be modified with NHS-based 
chemistry as it favoured site-directed conjugation to the IL. A mutation such as K96R could 
further facilitate site-directed conjugation to the IL without impacting on capsid stability, 
formation and physicochemical properties. 
The lysine-NHS reaction was assessed using c149 A80K R82K at a mole ratio of 1 scPEG 
to 1 IL lysine residue over a time course of 24 hours. In addition, a reaction consisting of the 
mole ratio 10 scPEG to 1 IL lysine was incubated for 8 hours at room temperature. These 
initial reaction conditions were assessed as the literature varied in reported ligand 
concentration and incubation times. SDS-PAGE analysis revealed that no significant 
conjugation occurred over the time course of 24 hours (Figure 4.2.2).  
Page | 92  
 
A series of additional reaction conditions were assessed, varying the reaction buffer, 
protein and ligand concentration, pH, salt concentration, incubation time and temperature. 
All of the varied reaction conditions did not yield a conjugate (data not included). Control 
proteins with significant lysine content were also assessed for conjugation to scPEG. Bovine 
serum album (BSA) and creatine phosphokinase (rabbit muscle) (CK) contain 59 and 33 
lysine residues (Figure 4.2.1.3B), respectively, of which a large proportion are exposed to 
the protein surface. Similarly to reactions with c149 A80K R82K, the control proteins did not 
undergo scPEG conjugation (Figure 4.2.3A).  
Lack of conjugation to the protein surface suggested that the reactive succinimidyl 
carbonate moiety may have undergone hydrolysis or oxidised with atmospheric oxygen. Dry 
stocks of scPEG were maintained within a desiccation chamber, thus decreasing the chances 
of hydrolysis. Nonetheless, chemical assessment of scPEG reactivity may reveal why the 
conjugation reaction to c149 A80K R82K failed. As a wide variety of reaction variables were 
assessed in attempting to conjugate lysine and scPEG, it was decided to investigate the 
alternative cysteine-maleimide reaction. Similarly to scPEG, initial reactions with maleimide-
PEG were performed to determine moiety to target ratio and reaction incubation times.   
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Figure 4.2.1: Distribution of lysine residues within c149, c149 R82K and c149 A80K R82K. The wild type c149 
contains 2 lysine residues at position 7 and 96. The K7 residue is located within the three-fold axis pore (Figure 
3.1.6) and K96 within helix 4.  c149 R82K contains an additional lysine residue at position 82, and c149 A80K 
R82K has two additional lysine residues at position 80 and 82. The colour-scheme used is similar to that of 
Figure 3.1.4. Protein structure was modelled in Swiss-PDB Viewer [214] using data from Wynne et al [201].  
   
Figure 4.2.2: SDS-PAGE analysis of c149 A80K R82K reaction with scPEG over 24 hours. c149 A80K R82K, 
stained with Coomassie Brilliant Blue-R250, is indicated by the black arrow.  The control sample (C) was 
treated with DMSO and contained no reactive succinimidyl groups.  Samples 2h -24h were incubated at room 
temperature at a ratio 2 scPEG5000 to 1 core protein. The sample 8h (10:1 scPEG5000) was incubated for 8 
hours with 20 scPEG5000 molecules per 1 core protein at room temperature. 
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Figure 4.2.3: SDS-PAGE analysis of CK PEGylation using scPEG over an eight hour period. (A) A total of 1 g of 
CK underwent a conjugation reaction, which contained 10 moles of scPEG for every 1 mole CK (black arrow). 
The untreated protein sample, was incubated with DMSO only. Proteins were stained with Coomassie Brilliant 
Blue-R250. (B) Predicted structure of CK (green), with surface exposed lysine residues highlighted (dotted 
regions) [283].  
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4.2.2 Maleimide-based ligand conjugation to inserted cysteine residues of 
S81C and L76C S81C 
Ligand linkage to a cysteine residue provides an alternative to lysine-NHS chemistry. 
Generally wild type proteins have little to none exposed cysteine, allowing for site directed 
conjugation of introduced residues. Creatine phosphokinase contains a single exposed 
cysteine residue at position 254, which was used to assess conjugation of malPEG to the 
protein surface. As with lysine-NHS, the literature reports varied incubation times required 
for cysteine-maleimide conjugation. An initial time course assay was performed to 
determine the required duration for observable PEG-CK conjugation (Figure 4.2.4). After one 
hour incubation with malPEG5000 (at a mole ratio of 10 maleimide-PEG to 1 CK), a 
characteristic shift of ±5 kDa was observed with ±60% of the CK population. The conjugation 
did not appear to increase with extended incubation time. A second time course assay 
revealed that incubation for as little as 15 minutes at room temperature was sufficient to 
reach conjugation end-point between malPEG5000 and CK (data not shown).  
With the aforementioned parameters in mind, the single and double cysteine mutants of 
c149, c160 and c170 were assessed for conjugation with malPEG5000 (Figure 4.2.5). 
Recombinant c183 S81C and c183 L76C S81C did not purify to accepted levels, despite a 
variety of preparation protocols attempted. Thus, c183 S81C and c183 L76C S81C were 
initially omitted from the conjugation assessment. Approximately 60% of both c149 S81C 
and c149 L76C S81C showed a migration-shift during SDS-PAGE analysis. Interestingly a 
second dominant band appeared in samples c149 S81C and c149 L76C S81C nearing 35 kDa 
in size. Protein in this band may have been the product of conjugation between malPEG and 
a dimerised core protein (±33.4 kDa). Curiously a predominant 5 kDa shift of dimer 
occurred, as opposed to a potential 10 kDa shift of a double PEGylated dimer. The initial 
conjugation of bulky PEG compounds may have significantly reduced access to the IL region 
of the four-helix bundle, preventing the second conjugation event. The control protein, wild 
type c149, did not undergo any observable migratory shift.  This data suggests that the 
inserted cysteine residues underwent a conjugation-based reaction with malPEG, and the 
native cysteine residues (C48 and C61) did not interact with malPEG. No observable 
conjugation occurred between malPEG and the single and double cysteine substitutions of 
c160 and c170.  
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It is documented that the protamine domain is capable of protruding from capsid pores, 
extending outwards from residues 149-183 [217]. The cationic nature of the protamine 
domain has the potential to interact with the anionic IL, thus resulting in restricted access to 
the reactive cysteine residues. This was supported by the data in Figure 4.2.5, whereby 
capsid particles that contained a protamine domain (c160 and c170) displayed decreased 
efficiency in conjugation to ligands or moieties compared to capsid particles without 
protamine domains. It was reasoned that incubation periods beyond 1 hour may permit 
sporadic conjugation reactions to the IL, in which an observable change in protein size 
would occur. 
               
Figure 4.2.4: SDS-PAGE analysis of the conjugation reaction between CK and malPEG5000, over an 8 hour 
period. (A) MalPEG was combined with 1 g CK (black arrow) at a mole ratio of 10 moles to one mole, 
respectively. In the presence of malPEG, an additional protein species forms (white arrow). The control 
sample, “untreated”, did not receive malPEG treatment. (B) The predicted structure of CK, highlighting the 
single exposed cysteine residue (white and yellow region) [283]. 
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Figure 4.2.5: SDS-PAGE analysis of malPEG conjugation with core clones with/out cysteine substitutions within 
the IL, stained using Coomassie Brilliant Blue-R250. Preparations of c149, c160, c170 and their respective S81C 
or L76C S81C mutants were incubated with malPEG for 30 minutes at room temperature. One microgram of 
core protein was analysed, in which 10 moles malPEG molecules were present for every 1 cysteine residue at 
the IL. One microgram of wild type protein (control) was combined with malPEG such that 10 moles of malPEG 
were present for every 1 mole of core protein. The c149 S81C and c149 L76C S81C form additional distinct 
bands after incubation (black and white arrows). These additional bands are not present in the wild type c149, 
or any of the c160 and c170 clones. 
4.2.3 Increased incubation time results in malPEG conjugation to c160 L76C 
S81C and c170 L76C S81C. 
It was undetermined whether potential intermittent association of the protamine 
domain to the IL prevented the maleimide-cysteine conjugation reaction. However, the 
structurally-plastic nature of the protamine domain [218] may allow for flexibility at the IL. 
Without a fixed association, dissociation of the protamine domain from the IL may allow for 
occasional malPEG conjugation events. Subsequently c160 L76C S81C and c170 L76C S81C 
were incubated with malPEG5000 over a 24 hour period at room temperature (Figure 4.2.6 
A and B). PEGylation of both core proteins became evident after two hours, and continued 
to increase up until 8 hours. Protein levels appeared to decrease after 12 hours, in which 
aggregation, destabilisation or degradation of core proteins may have occurred. Similarly 
destabilisation of CK is observed after 24 hours (Figure 4.2.6 C), in which the additional 
protein bands may have resulted from the PEGylation of internal cysteine residues. 
PEGylation of c149 capsids was considerably more efficient than the c160 and c170 species, 
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however the increased incubation period allowed for feasible amounts of ligand to be 
conjugated to their capsid surface. Having established malPEG conjugation to the capsid 
surface, alternative maleimide-ligands were assessed for their potential conjugation to c149 
L76C S81C and c160 L76C S81C. 
             
Figure 4.2.6: SDS-PAGE analysis of c160 L76C S81C and c170 L76C S81C incubation with malPEG5000 over 24 
hours.  (A) c160 L76C S81C (black arrow) incubation with malPEG5000 for 2 hours or longer at room 
temperature resulted in an additional protein band (white arrow). Similar results were found for c170 L76C 
S81C (B). The control protein CK also resulted in an additional band present after incubation with malPEG5000 
for 24 hours (C).  
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4.2.4 Cysteine-maleimide conjugation of functional ligands to c149 L76C S81C 
and c160 L76C S81C 
Capsids are indiscriminately taken up by a variety of cultured cells and decoration of the 
capsid surface with specific ligands may provide much required tissue-tropism [98, 99, 236]. 
Three maleimide-monosaccharide ligands, malPEG or F5M were independently conjugated 
to the surface of c149 L76C S81C. Ligand and capsid were incubated for 6 hours at room 
temperature at a mole ratio of 10 maleimide-ligands to 1 cysteine residue. The conjugation 
events resulted in an electrophoretic mobility shift, effected by the new overall charge and 
molecular weight (Figure 4.2.7). It was anticipated that not all core protein units will 
undergo conjugation (Figure 4.2.6), which would result in a heterogeneous capsid 
population with varying degrees of modification. Ethidium bromide incorporation revealed 
the position of the T=4 capsids at approximately 3000 bp, and less so the T=3 capsid near 
1500 bp (band visibility may also be as a result of protein auto-fluorescence).  Surprisingly 
the modified capsids showed uniform conjugation, represented by the capsid conformation 
T=3, which migrated as a distinct band, indicated in Figure 4.2.7. The T=4 capsid band 
contains large amounts of capsid, in which it was difficult to differentiate varying states of 
modification (indicated by the black arrow). As such, it would appear that these regions 
contain a variety of heterogeneous ligand-conjugated capsids. Both galactose-maleimide 
and glucose-maleimide conjugation decreased the electrophoretic mobility of c149 L76C 
S81C. As galactose and glucose are 4-C epimers of each other, modified capsid migratory 
patterns were similar. These two monosaccharide moieties appear to increase the 
‘bulkiness’ over altering the electrostatic potential of the capsid. As expected the compound 
galactose4-maleimide further decreased capsid electrophoretic mobility. Galactose4-
maleimide displays similar physicochemical properties to the monosaccharide species, 
however is approximately four times larger, thus further decreasing the mobility of capsid 
conjugates in the agarose gel. MalPEG is the largest and bulkiest of the moieties and had the 
greatest effect on decreased electrophoretic mobility. Interestingly, F5M increased 
electrophoretic mobility, despite the molecular weight being similar to galactose-maleimide 
or glucose-maleimide. F5M increased the overall anionic nature of c149 L76C S81C, which 
resulted in increased electrophoretic mobility.  
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Figure 4.2.7: Effect of c149 L76C S81C mobility with surface ligand conjugation, analysed by agarose gel electrophoresis. Capsid preparations were incubated with various 
maleimide-ligand moieties for 2 hours, which resulted in altered electrophoretic mobility compared to unmodified c149.  Ten moles of mal-ligand was combined with 1 
mole exposed IL cysteine residue, in a reaction total of 1 g core protein. Capsids produced weak auto-fluorescence, made visible under shortwave UV light (A). Two capsid 
conformations were present, the major T=4 conformation (black arrow) and the minor T=3 conformation (white arrow) (B). The shift in capsid electrophoretic mobility is 
more easily noticed when comparing T=3 over T=4 capsids indicated by the white asterisk (Untreated c149 L76C S81C), yellow asterisk (monosaccharide conjugate), red 
asterisk (polysaccharide conjugate) and blue asterisk (FITC conjugate). 
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Modified c149 L76C S81C was subjected to SDS-PAGE to determine the mobility shift of 
individual core proteins as a result of ligand conjugation. Overall the conjugation effect on 
mobility was difficult to distinguish from unmodified core protein, except for the sample 
conjugated with malPEG (Figure 4.2.8). The capsids conjugated with malPEG showed the 
anticipated ±5 kDa shift. The conjugation of galactose-maleimide, glucose-maleimide and 
F5M does not result in an obvious shift in core size (of approximately 0.5 kDa). This may be 
attributed to modified and unmodified bands being poorly distinguishable from each other. 
It was noted that a slight shift of mobility occurred for each of the monosaccharide-modified 
core proteins. Lastly, capsids modified with galactose4-maleimide resulted in a faint 
additional band ±2 kDa above the unmodified core protein. This shift correlates to the 
anticipated size of galactose4-maleimide (2240 Da). The additional band suggested that the 
sample contained both modified and unmodified core protein, and indicated that the 
conjugation did not occur on each protein. Once conjugated, these bulky ligands may 
spatially interfere with the second conjugation event to the dimer, explaining the presence 
of both modified and unmodified core proteins. 
           
Figure 4.2.8: SDS-PAGE analysis of functional-ligand conjugation to c149 L76C S81C.  One microgram of core 
protein was reacted with its respective ligand such that 1 mole of core protein was combined with 20 moles of 
mal-ligand. Conjugation with galactose-maleimide, glucose-maleimide or F5M resulted in a shift of protein 
migration. Two protein bands become visible after conjugation with galactose4-maleimide. A predominant 
core species near 25 kDa becomes visible after incubation with malPEG5000.  
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The c149 L76C S81C recombinant protein provided a proof of concept platform in which 
the effects of ligand surface-conjugation were assessed. It is required of the HBV capsids to 
deliver a therapeutic payload to a specific cell type. As such the c149 core protein is 
inadequate as a nucleic acid vector as it does not contain a protamine domain which is 
involved in DNA/RNA binding. Both c160 L76C S81C and c170 L76C S81C contain protamine 
domains; and were amenable to maleimide-based ligand conjugation with increased 
incubation time. As a result of higher yields after induced expression in E. coli, c160 L76C 
S81C was selected for ligand conjugation analysis. Previously described ligands were 
independently incubated with c160 L76C S81C for 6 hours at room temperature, following 
which conjugates were analysed by agarose gel electrophoresis and SDS-PAGE (Figure 4.2.9 
and Figure 4.2.10, respectively). A mole ratio of 10 ligand to 1 cysteine was used during the 
conjugation reaction. In stark contrast to the c149 L76C S81C ligand conjugation reactions, 
c160 L76C S81C displayed exceptional efficiency in ligand conjugation. It was observed that 
each of the modified capsids displayed a distinct electrophoretic mobility in comparison to 
the unmodified core protein. Capsids modified with galactose-maleimide and glucose-
maleimide display decreased co-migration to similar positions (±4.5 kb position), while 
galactose4-maleimide exhibited a further decreased electrophoretic mobility (±10 kb 
position). As previously stated this decrease in electrophoretic mobility is most likely on 
account of increased capsid bulk, as opposed to change in capsid electrostatic nature. 
Conjugation of malPEG to the capsid surface resulted in majority of the capsids aggregating 
near the loading well. This aggregation may be attributed to the sheer bulky nature of 
PEGylated capsids or precipitation of the capsids in the presence of PEG, however no 
flocculates were observed in solution prior to sample loading into the agarose gel. As 
previously described for the T=4 capsids of c149 (and cysteine variants thereof), c160 L76 
S81C without ligands migrates near 3 kb. SDS-PAGE analysis demonstrated a slight migratory 
shift to the majority of c160 L76C S81C conjugated with galactose-maleimide or glucose-
maleimide compared to unmodified (Figure 4.2.10). Conjugation of galactose4-maleimide 
was less efficient than the monosaccharide ligand, but a clear shift in migratory behaviour is 
seen. MalPEG5000 shifts the modified core protein migration to just less than 25 kDa, and is 
also not as efficient as the mono-sugar ligands. Curiously, it would appear that a single 
conjugation event occurs per protein, despite the presence of 2 cysteine residues. These 
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results confirm that HBV capsids are amenable to surface modification, which enable 
properties such as tissue-tropism and immuno-evasion to be conferred.  
As described in Chapter 3, capsid integrity/viability was compromised by the exchange 
or addition of various amino acid residues. Furthermore, other than the ‘Snap-in’ cloning 
system, changes made to the IL can be laborious and challenging during cloning. All of these 
factors prompted the investigation into alternative methods of displaying functional 
moieties on the capsid surface without any covalent linkage. An interesting, but less utilised 
approach to capsid decoration with ligands is the envelopment of capsids with liposomes. 
As opposed to direct conjugation to the capsid surface, tissue-tropic and immuno-evasive 
ligands are embedded within the lipid bilayer. It may prove as an advantage to envelop 
capsids as the highly immunogenic IL becomes hidden within the liposomal complex, further 
enhancing the vector-like properties of this VLP.  The following section addresses the 
possibility of HBV capsid-liposome envelopment. 
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Figure 4.2.9: Effect of c160 L76C S81C electrophoretic mobility with surface moiety conjugation, analysed by agarose gel electrophoresis. Capsid preparations were 
incubated with various maleimide-ligands for 6 hours. One microgram of recombinant core protein was reacted with its respective mal-ligand, such that 1 mole of core 
protein was combined with 10 moles of mal-ligand. RNA loaded capsids incorporated EtBr, and were visible near 3000 bp (C1 and C2), 4500 bp (galactose-maleimide and 
glucose-maleimide) and 10 000 bp (Galactose4-maleimide) under short wave UV light. Conjugation with malPEG5000 resulted in capsids not migrating from the well. 
Coomassie Brilliant Blue R250 staining revealed identical migratory behaviour as seen with EtBr incorporation. Control protein C1 contains a fluorescently labelled 
oligonucleotide, whereas C2 does not. 
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Figure 4.2.10: SDS-PAGE analysis of c160 L76C S81C conjugated with various functional ligands. One 
microgram of core protein was reacted with its respective ligand for 6 hours such that 1 mole of core protein 
was combined with 20 moles of mal-ligand. A distinct shift in core size occurs after conjugation with galactose-
maleimide and glucose-maleimide. Two core protein species were evident after conjugation with galactose4-
maleimide. Conjugation with malPEG introduced a second protein band. Control proteins C1 and C2 do not 
contain any modifications to their surface.  
4.2.5. Assessment of VLP liposome envelopment using mobility shift assay 
analysis 
The anionic surface of capsids is a useful feature for electrophoresis, as capsids migrate 
based on size and charge through the agarose gel matrix. Capsid envelopment by liposomes 
nullifies the native charge and consequent electrophoretic migration was assessed by 
mobility shift assay in agarose gel, shown in Figure 4.2.11. Liposomes were generated by 
combining up to three of four lipid variants, cholesterol or DC Chol and DOPE or 5-10% 
DOPE-PEG. Liposomes comprising 60% cholesterol moiety and 40% DOPE moiety 
(mole/mole) were used as previously described [155]. In doing so four liposome varieties 
were generated: cholesterol with DOPE; cholesterol with DOPE and 5-10% DOPE-PEG; DC-
Chol with DOPE; DC Chol with DOPE and 5-10% DOPE-PEG. Liposome and capsid were 
combined at various concentrations (0.25, 0.1 and 0.05 g/l) as to assess the effects of 
complex concentration on precipitation [284]. Capsid envelopment was most successful in 
the presence of liposomes that contained DC Chol and DOPE-PEG. Densitometric analysis 
revealed that in the presence of DC Chol and PEG (5 and 10%), capsids were sequestered 
60% more efficiently than liposomes without either lipid species. Liposomes with an overall 
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anionic surface charge (DOPE-cholesterol) did not significantly sequester capsid. 
Interestingly DOPE-DC Chol liposomes did not sequester capsids either, despite the 
potential for liposome-capsid electrostatic interaction. PEGylated DOPE-cholesterol 
liposomes interacted poorly with the capsids suggesting that an anionic surface charge, 
despite improved liposome stability provided by PEG, is insufficient for capsid sequestration. 
These data suggest that the combination of DOPE-PEG and DC Chol in liposomes is required 
for the interaction, binding and sequestration of anionic HBV capsids. 
 
 
Figure 4.2.11: Assessment of capsid envelopment by agarose-based mobility shift assay with ethidium bromide 
and Coomassie Brilliant Blue-R250 staining. Liposomes comprised 60% cholesterol (cholesterol or DC Chol) and 
40% DOPE (DOPE and/or DOPE-PEG2000) moiety (mole/mole). Liposome and capsids were combined in equal 
amounts (w/w), at 0.25, 0.1 or 0.05 g/l and incubated overnight at 4 
o
C.  Non-enveloped capsid migrated 
into the agarose gel by electrophoresis. The capsid control lane does not contain liposomes, Lane L is DNA 
ladder. The arrow indicates the position of capsid stained either with ethidium bromide (ES) or Coomassie 
Brilliant Blue R250 (CS). 
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4.2.6. Particle size analysis of capsids, liposomes and enveloped virus-like 
particles 
To further assess HBV capsid and liposome interaction, capsids, liposomes and potential 
enveloped particles were analysed by particle sizing as shown in Figure 4.2.12. Liposomes 
comprising DC Chol and 10% DOPE-PEG were used for envelopment of capsids. Prior to 
complexing, 95.6% of the liposomal population were particles 153 ± 1.5 nm in diameter. The 
remainder of this population comprised 1.67% 22.8 nm and 2.73% 4822 nm diameter 
particles. These liposome sizes have consistently been generated previously (data not 
shown). Capsid particles were also distributed in three distinct sized populations. 
Interestingly the largest capsid-sample population was represented by 91.2% of 220.4 nm 
diameter particles. The smaller population (5.33%) were 29.9 ± 2.8 nm in diameter, which 
corroborate published capsid sizes [76, 198]. A small remainder of the capsid population 
presented as a large aggregation.  Incubation of liposome with capsid yield two distinct 
populations, 90.6% as particles with a diameter of 740 nm and 9.4% with a 46 ± 9.2 nm 
diameter. The smaller unidentified particles correlate to known sizes of an enveloped HBV 
particle [285]. It was found that liposomes comprising DOPE and DC Chol (without DOPE-
PEG) in saline appeared to form visible flocculates when incubated overnight at 4 oC. This 
had a direct impact on particle sizes, in that aggregates were > 5000 nm in diameter (data 
not shown). Consequently liposomes without PEG were excluded from sizing analysis.  
These data show that the addition of liposomes to the capsid preparation containing ±30 
nm particles results in particles 46 ± 9.2 nm in diameter. Both of these small particles 
correlate to published sizes of the HBV capsid and wild type virus.  
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Figure 4.2.12: Particle sizing and size distribution analysis of liposomes, HBV capsids and liposomes combined 
with capsids.  Liposomes were formulated as mole ratio of 6 parts DC Chol, 3 DOPE and 1 DOPE-PEG. Equal 
amounts (w/w) of capsid and liposome at 50 g/ml were co-incubated overnight at 4 
o
C. DC Chol PEG 
liposomes () were predominantly represented by 153 nm diameter particles, HBV capsid (×) by 220.4 nm 
diameter particles and liposomes combined with capsid () by 740.5 nm diameter particles. X-axis plotted as 
logarithmic scale. Statistical analyses done by student t-test, n=3, SEM. 
4.2.7. Particle analysis by electron microscopy 
Capsid and capsids combined with liposomes were analysed by transmission electron 
microscopy, shown in Figure 4.2.13. Negatively stained capsid particles presented as 
individual units, small clusters of 2-5 particles or as large aggregates. Analysis of capsid-only 
preparations revealed the majority of particles had ± 30 nm diameter. These sizes were 
consistent whether the capsids were individual units or grouped in clusters. Incubation of 
liposomes with capsids produced two varieties of observable particles – those with and 
without a predominant lighter “halo”. Particles without predominant halos were found to 
be ± 30 nm in diameter. Particles with predominant “halos” were larger (up to 46 nm in 
diameter) however were only present in aggregates. It was noted that the halo-like 
structures only occurred in association with capsids. These data do not prove capsid 
envelopment, however suggests that the capsids may associate with lipids, which 
predominantly form large capsid-liposome aggregates. 
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Figure 4.2.13: Electron micrograph depicting HBV capsids before and after liposome envelopment. Capsids were combined with liposomes (comprising of 60% DC Chol, 
30% DOPE and 10% DOPE-PEG2000) and incubated overnight at 4 
o
C. Particles adhered to formvar coated grids and negatively stained with 5% uranyl acetate. Solid arrows 
indicate to individual capsids, hollow arrows to capsid aggregates. 
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4.3. Discussion 
Novel delivery systems, such as VLPs, are crucial to the development of safe and 
effective gene therapy vectors. The manipulable nature of VLPs has seen their development 
in vectorology as well as chemistry and engineering. This chapter described that the HBV 
capsid, containing cysteine residues within the IL, was capable of conjugating with variety of 
functional moieties. These ligands in turn provide function to the capsid, in the form of 
immuno-evasion, hepatotropism, or fluorescence. Furthermore, decorating the capsid with 
ligands would ideally ablate the indiscriminate cellular uptake, a feature of several capsids 
[94, 286]. 
Two PEG moieties were initially assessed for conjugation to the capsid surface. The NHS-
ester species did not react with IL-embedded lysine residues, while the maleimide species 
displayed a significant degree of conjugation to introduced cysteine residues. Generally the 
NHS-ester reaction is robust, and it was not established why the reaction was unsuccessful. 
Reagent quality was a concern, however the conjugation process had indeed been 
successful for PEGylating adenovirus [45]. It is feasible for the reagent to have undergone 
hydrolysis during storage, however this seems unlikely as several scPEG products were 
assessed. It was known that NHS-esters react with any anime group, thus care was taken to 
avoid buffers that contained tris(hydroxymethyl) aminomethane (Tris). Alternatively, the 
conjugation reaction may have been impacted by the potential formation of salt bridges 
between lysine and neighbouring acidic residues [287]. The IL contains two acidic residues, 
Glu77 and Asp83, both in close proximity of the inserted lysine residues. Despite potential 
disruption of the conjugation process, salt bridges would not completely inhibit the 
reaction, thus a slight degree of PEGylation would have been observed. Testing of ester 
viability within reactants may provide further insight to the failed lysine conjugation.   
Maleimide-based conjugation was shown to occur successfully on both recombinant 
clones S81C and L76C S81C. The L76C S81C variety did not show an increased level of 
PEGylation, and may be explained by the effects of stearic hindrance. Once conjugated, the 
bulky nature of the PEG molecule may have prevented additional PEG molecules from 
accessing the IL, significantly decreasing conjugation opportunity. An alternative explanation 
for equivalent conjugation may be as a result of the helical nature of 3, which may have 
caused C76 to be buried by the helix or four-helix bundle, making it poorly accessible to 
bulky ligands.  
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PEGylation of the c160 and c170 cysteine recombinants required an increased 
incubation time as opposed to the c149 variant. It is established that the capsid pores allow 
for the exposure of the protamine to the surface of the capsid. Functionally this is required 
by infective virus, as it directs nuclear localisation, as well as phosphorylation of the 
protamine domain, which is important for capsid disassembly. It is feasible for the cationic 
protamine domain to reach and interact with the anionic IL. In doing so, the cysteine at 
position C81 may be sheltered from incoming ligands, increasing the overall reaction time 
required. As a result of the transient protamine domain and IL interaction, conjugation at all 
sites is eventually possible. It is possible that the IL-protamine domain interaction of c183 
may have resulted in a disulphide bridge formation between the cysteine residue at position 
183 (C183) and C76 or C81, which may account for the poor capsid yield of the c183 S81C 
and c183 L76C S81C species.  
Ligand conjugation to the capsid surface changes the capsid physicochemical properties. 
This was observed by capsid and core protein electrophoresis. Capsids decorated with 
galactose and glucose on their surface displayed a decrease in electrophoretic mobility, as a 
result of the bulky neutral monosacharrides and perhaps an increase in electrostatic 
potential from the secondary amines within the linker chains. As to be expected, the 
electrophoretic mobility decreased with the addition of the galactose polymer. Fluorescein 
increased the electrophoretic mobility of the capsids, as both the phenolic and carboxylic 
groups are deprotonated at neutral pH [288].  
Maleimide-based conjugation to the c160 recombinant capsids was significantly more 
efficient than to the c149 variety. This may be as a result of several factors, including: The 
initial lysis step of the bacteria uses a buffer containing dithiothreitol (DTT) to prevent 
potential disulphide bridge formation, and protein aggregation. This component was 
removed during the c160 cysteine-containing recombinants preparation and replaced with 
TCEP, as the thiols present in DTT react with maleimide. Despite two SEC steps and dialysis, 
it was possible that the DTT was not sufficiently diluted in the c149 recombinant 
preparation. Quality of capsid preparation will also play a role in the outcomes of 
conjugation. The c149 cysteine capsids were prepared several months prior to the c160 
variety. With time, refinement of the purification technique occurred, perhaps producing 
higher quality preparations. Nonetheless, the c149 cysteine capsids served their purpose as 
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a proof of principle model, as further studies required capsids capable of transporting 
nucleic acids associated to the protamine domain. 
Liposome envelopment of retroviral particles has shown to be an effective measure to 
superinfect cultured cells [275-277]. Viral and VLP envelopment does not appear to have 
made any major impact in the field of gene therapy, perhaps a result of technical challenges 
associated with both viral production and the envelopment process, particularly in the 
application to in vivo systems. Despite technical challenges, liposome envelopment may 
offer several benefits to viruses and VLPs used in gene therapy. Envelopment ensures viral 
particles are concealed from the immune system, increasing the half-life of circulating 
particles. The addition of PEG to liposome surfaces further ensures immuno-evasion and 
increases particle stability. Liposome envelopment may also offer a means to alter VLP 
tropism by including ligands on the liposome surface.  
This study has shown that hepatitis B virus capsids were sequestered by liposomes 
provided two criteria were met. Liposomes require a cationic surface charge, which may 
facilitate the electrostatic based interaction with the anionic capsids. Anionic/neutral 
liposomes showed poor/limited interaction with capsids, a result of poor electrostatic based 
interaction or unstable liposome particles which switch to inverted hexagonal morphology 
(described in chapter 2) [113]. Consequently the capsid binding capacity of inverted 
hexagonal liposomes is greatly diminished, resulting in liposome/complex precipitation. The 
second criterion is for the addition of PEG to liposomes, as this is known to stabilise 
micellar/lamellar structure by decreasing inter-membrane interaction and the potential of 
phase conversion. 
As demonstrated by particle sizing and electron microscopy, the capsids were prone to 
aggregate in small clusters or large masses. The preparative methodology employed to 
isolate capsids was fairly crude, in which additional contaminating cellular material was 
present amongst the capsids (Protocol 1, Chapter 3). Protein contaminants were indeed 
shown to be present by SDS-PAGE analysis (data not shown) and is thought to have caused 
capsid and liposome aggregation. The aggregation of the capsids could potentially be 
overcome by further purification of the HBV capsids, as described in Protocol 3, Chapter 3.    
The three experiments strongly suggest that PEGylated cationic liposomes interact with 
HB capsids, which may form enveloped VLPs. Agarose gel electrophoresis confirmed 
PEGylated cationic liposomes are required to interact with and sequester capsids. Particle 
Page | 113  
 
sizing indicated particles 30 nm in diameter, with which the addition of liposomes to the 
preparation resulted particles with ±42 nm diameters. Both of these particles correlate to 
wild type capsids and HBV sizes. Analysis by electron microscopy confirmed that capsid 
preparations contained uniform 30 nm diameter particles, many of which were part of 
aggregations. Addition of liposomes to capsid preparations resulted in majority of the capsid 
particles to aggregate, each particle surrounded by a predominant halo-like structure. It is 
enticing to suggest the envelopment has occurred, however can only be confirmed with a 
more pure version of capsid preparation. 
In conclusion, it has been demonstrated for the first time that the HBV capsid can be 
decorated with ligands attached by specific amino acids. These chemical species and ligands 
have shown functionality in other nanoparticles [45, 125, 128, 147], thus have the potential 
to provide the HBV capsid with much needed immuno-evasive and tissue tropic qualities. 
These findings suggest that the HBV capsid is a potential candidate for gene therapy 
vectorology, provided it can be loaded with a payload. Chapter 5 explores the potential to 
introduce foreign nucleic acids to purified HBV capsids and the potential to deliver these 
decorated recombinant HBV capsids in cell culture. 
 
4.4 Materials and methods 
4.4.1 Recombinant capsid preparation 
Recombinant capsids involved in conjugation-based reactions were prepared using the 
‘Porterfield protocol’ (Protocol 3 described in Section 3.4.3.3) [245]. Recombinant capsids 
used for liposome envelopment studies were prepared using protocol 1, described in 
section 3.4.3.1. 
4.4.2 Conjugation of ligands to capsid surface 
Prior to all conjugation reactions, protein concentration was determined by the 
bicinchoninic acid (BCA) assay according to manufacturer’s instructions (Thermo Fischer, 
MA, USA). The number of IL exposed lysine or cysteine residues were subsequently 
calculated, using the Mw of the various recombinant clones (c149 – 16.7 kDa; c160 – 18.2 
kDa; c170 – 19.8 kDa; c183 – 21.4 kDa). Reactive ligands were dissolved as stock solutions in 
DMSO (Sigma, Germany) at 10 mg/ml. The reactive PEG moiety was an exception and 
dissolved at 100 mg/ml then stored at -20 oC.  
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4.4.2.1 NHS-based conjugation 
Recombinant capsids at 1 g/l were combined with the scPEG ligand stock at an 
appropriate mole ratio. Overall reaction volumes were typically 100 l, the reaction buffer 
composed of PBS (core protein stocks contain PBS). An example calculation to determine 
lysine:ligand mole ratio can be found in Appendix 4. All conjugation reactions were 
performed at room temperature unless specified otherwise.  Reactions with the capsid 
surface were quenched by the addition of excess L-Lysine (Sigma, Germany). Conjugated 
capsids were stored at -80 oC. 
4.4.2.2 Maleimide-based conjugation 
Recombinant capsids containing cysteine substitutions at 1 g/l were incubated at 
room temperature with a reactive ligand at the appropriate mole ratio. Reaction volumes 
were typically 100 l, in PBS. As previously mentioned, an example calculation to determine 
cysteine:ligand mole ratio is within Appendix 4. Reactions were quenched by overnight 
dialysis against PBS or by the addition of 2x protein loading dye (Appendix 2). Conjugated 
capsids were stored at -80 oC 
4.4.3 Molecular modelling  
All proteins species were modelled using Swiss protein data base viewer (DeepView) 
[214] with parameters as described in Section 3.4.4. 
4.4.4 Complexing of virus-like particles with liposomes 
Generation of liposomes has been described in Chapter 2. Equal amounts (w/w) of VLP 
and liposome were incubated in 50 l at 4 oC overnight. 
4.4.5 Particle sizing  
Particles were prepared at 0.25 g/l in PBS and size determined using a Zetasizer Nano 
ZS (Malvern, Worcestershire, UK) at 25 oC. Sizing was carried out in accordance to 
manufacturer’s instruction. 
4.4.5 Mobility shift assays 
Complexed VLPs were loaded into a 1% agarose (w/v) 0.02% ethidium bromide (w/v) gel 
and subjected to electrophoresis at 80 V. Uncomplexed capsid particles migrated into the 
gel matrix and their RNA content was visible under short wave UV illumination. The capsids 
were made visible by soaking the agarose gel in Coomassie Brilliant Blue R250 stain for 1 
hour, followed by destaining. 
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4.4.6 Electron Microscopy  
Capsids and/or liposomes were applied to formvar-coated copper grids for 1 minute, any 
remaining solution was blotted from the grid surface. Capsids were negatively stained using 
5% uranyl acetate solution for 1 minute, and excess stain was blotted off. Capsids were 
observed using a JEM-1400 transmission electron microscope (JEOL, Tokyo, Japan) under 
high vacuum at 100 kV. 
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Chapter 5: Assessment of the decorated and loaded capsid 
hepatotropic properties with cultured cells 
5.1 Introduction 
The previous chapter described the successful decoration of the recombinant capsid 
surface with a variety of functional moieties such as PEG or galactose. As naked capsids are 
indiscriminately taken up by cells [99], it was required to conjugate functional moieties to 
provide hepatotropism and immuno-evasion. To assess whether the newly decorated 
capsids exhibit tropism, the capsid cavity was loaded with reporter oligonucleotides. 
However, recombinantly expressed capsids contain bacterially-derived mRNA which 
required removal prior to the introduction of the reporter cargo [93]. In a natural infection, 
HBV core proteins associate with pregenomic RNA (pgRNA) and viral polymerase to 
assemble into capsids [289]. The viral polymerase recognises the  loop signal on the 5’ end 
of the pgRNA, and together with the core protein facilitate capsid formation [244, 290]. It is 
not known how these three components interact to ensure the encapsidation event, 
however it is suggested that the pgRNA interacts with the viral polymerase initially, followed 
by interaction with core proteins [289]. Importantly, the nucleic acid binding domain 
(protamine domain) of the core protein requires phosphorylation to package pgRNA [291, 
292]. Three serine residues within the protamine domain (S155, S162 and S170) are thought 
to be involved in phosphorylation, which not only ensures specific pgRNA packaging but are 
also associated with reverse transcription of pgRNA and cellular trafficking of matured HBV 
capsids [234, 291-293]. Recombinant expression of the HBV capsid within E. coli does not 
result in the phosphorylation of the three serine residues within the protamine domain. 
Subsequently, the HBV capsids indiscriminately package nucleic acids during their 
formation. Typically packaged nucleic acids consist of those near the site of translation, such 
as the core protein mRNA and bacterial tRNAs [93]. This is to the advantage of this study, as 
it allows for removal of bacterially-associated RNA and introduction of therapeutic/reporter 
nucleic acids. The reporter oligonucleotides are introduced after capsid denaturation, an 
established process primarily accomplished by chemical denaturation [197, 245, 294].  
Hepatitis B virus capsid dissociation was previously performed to model icosahedral 
capsid assembly kinetics [197, 206, 295]. These pioneering studies were performed using 
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the c149 capsid variety as it comprises a single protein species and no nucleic acid cargo. 
These factors helped ensure that the kinetic assembly analyses remained simple, 
uninfluenced by the presence of complicating factors such as protamine domain – RNA 
interaction. The addition of the protamine domain, generates a more stable variation of the 
capsid in comparison to c149, as a result of core protein - core protein interaction and core 
protein - RNA interaction [197, 198]. The combined effects of these interactions ensure 
capsid stability at both high and low ionic strength environments. It is possible however, to 
disrupt the loaded capsid structure with well-known protein denaturing agents. Porterfield 
and colleagues demonstrated that low concentrations of guanidinium hydrochloride were 
capable of dissociating capsids, and the addition of lithium chloride assisted in the 
precipitation of packaged RNA [245].  
The single or double stranded nature of the packaged nucleic acid plays a major role in 
the efficiency of capsid formation or reassociation of disassembled capsid [245, 294]. 
Certain bacteriophage capsids that incorporate double stranded DNA are initially 
preassembled prior to packaging and require active DNA pumping into the capsid interior 
[296]. These capsids are robust, able to withstand the significant internal forces created by 
coiling double stranded DNA [297, 298]. Conversely, capsids that package single stranded 
DNA or RNA are typically stabilised by weak inter-core protein interactions. Following 
association with DNA or RNA, the capsid becomes predominately stabilised by protein-
nucleic acid interaction [299, 300]. The HBV capsid initially packages single stranded pgRNA, 
a highly flexible substrate, which is later converted to double stranded DNA/RNA hybrid 
within the capsid by encapsidated viral polymerase. This conversion may have a significant 
impact on capsid stability, and may help drive the capsid disassembly after entering the host 
nucleus.  
Nucleic acids in their single and double stranded formations have a particular degree of 
flexibility in solution, where nucleic acid length and distance between 5’ and 3’ ends 
describe the minimal length at which a polymer becomes inflexible (persistence length) 
[301]. The persistence length of double stranded DNA is approximately 50 nm (150 base 
pairs) [294]. This means double stranded DNA considerably larger than 50 nm does not 
require energy to bend, whereas strands shorter than 50 nm exhibit rod-like behaviour and 
require energy to bend (thus requires active pumping of DNA into viral capsids). 
Consequently, double stranded DNA at its persistence length will not be packaged into the 
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HBV capsid as a result of structural constraint. It was demonstrated that double stranded 
DNA of 600, 1600 and 2700 base pairs in length did not package into HBV capsids, and 
rather formed aberrant structures during the capsid reassembly process [294]. Conversely, 
single stranded DNA or RNA has a low persistence number, and allows for a strand 
approximately 3 kb to be packaged within HBV capsids (persistence length ±1-2 nm) [302]. 
Short single stranded oligonucleotides (25-mer) exhibit very low persistence length (similar 
to single stranded RNA) and were suitable as 32P or fluorescein labelled reporter molecules 
to load into the HBV capsid.  
It has previously been described that c183 can be loaded with short reporter 
oligonucleotides, followed by cellular uptake in cultured cells [99]. Naked capsids containing 
a fluorescently-labelled reporter oligonucleotide were indiscriminately taken up by a variety 
of cell lines. In an attempt to provide tropism to the HBV capsid, Choi and colleagues 
inserted the integrin-targeting RGD motif into the immunodominant loop [98, 236]. 
Unfortunately, RGD-targeting was not specific in vitro and in vivo, as modified capsids were 
taken up by a variety of cell types. Following these studies, HBV capsid uptake was 
suggested to occur by several mechanisms including clathrin-mediated endocytosis, 
macropinocytosis and claveolae-mediated endocytosis [98, 99, 237, 303]. It is a curious 
phenomenon that the HBV capsid can utilise various pathways and may suggest why 
indiscriminate cellular uptake occurs. Naturally, hepatotropism is conferred to the HBV by 
preS2 proteins embedded within the viral membrane, which interact with the sodium 
taurocholate co-transporting polypeptide of hepatocytes [304]. Viral binding to the 
hepatocyte surface allows for receptor mediated endocytosis, after which the virus escapes 
from the endosomal pathway without endosome vesicle acidification [305]. Interestingly it 
has been demonstrated that an infectious HBV capsid enveloped within a synthetic lipid 
membrane mimics wild type infection efficacy in cultured cells [306]. Despite the synthetic 
membrane utilising an alternative cellular uptake pathway, the viral capsid was still able to 
escape from the endosomal pathway. Once the HBV capsid has escaped from the 
endosomal vesicle, it is trafficked within the cytoplasm to the nucleus using the microtubule 
intracellular transport system [306]. Nuclear import of the capsid is an interesting process, 
as it requires the dissociation and reassociation while travelling from cytoplasm to nucleus. 
The HBV capsid docks within the nuclear pore, localised within the nuclear basket after 
genome maturation [307, 308]. Core proteins interact with host nucleoporin 153, and capsid 
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disassembly ensues. Capsids have the capacity to reassemble within the nucleus in an RNA-
dependent manner once its components have passed through the nuclear pore. Viral 
genomic material is then released and virus production ensues. Bionanotechnology studies 
utilising naked HBV capsids as delivery vehicles demonstrated that their contents were 
released into the nucleus and cytoplasm. Cooper and colleagues demonstrated delivery of a 
reporter oligonucleotide to the nucleus [99], whereas Choi et al.  showed siRNA delivery to 
the cytoplasm [98]. Lack of nuclear delivery may be as a consequence of replacing the 
protamine domain with the p19 RNA binding protein. Unfortunately it was not assessed 
whether the p19-modified capsids make use of the cellular trafficking machinery. Both 
studies did also not determine how many capsid particles were cleared through the 
endosomal pathway. This is an important factor for determining the efficacy of the 
recombinant HBV capsid as a delivery vehicle. 
To assess whether galactose decoration on the capsid surface provided hepatotropism, 
two cell lines were compared for their capsid uptake capabilities. The human hepatocellular 
carcinoma cell line, Huh7, displays the cell specific ASGPr which has a high affinity for 
galactose [132]. The second cell line was used as an uptake control, as human embryonic 
kidney cells (HEK293) do not display the ASGPr [132]. As described in Chapter 2, binding and 
uptake by the ASGPr occurs by receptor mediated endocytosis often resulting in lysosomal 
degradation [132]. Endosomal escape plays a major role in the efficacy of the gene therapy 
vector, as it has been demonstrated that a large proportion of the delivered product is 
recycled out of the cell or degraded within the endosomal processing pathway [107, 309]. It 
is not established how wild type capsids escape from the endosomal pathway, and unknown 
if any protein domains on the capsid surface are responsible during the escape process. 
Addition of functional moieties to the capsid surface may influence the ability of the capsid 
to escape from the endosomal pathway, an aspect poorly examined currently.  
It is described in this chapter that c183 capsids were successfully loaded with 25-mer 
oligonucleotides during re-association. Furthermore it was demonstrated that loaded 
capsids provided protection to their cargo against environmental nucleases. It was found 
that c160 L76C S81C also encapsidated FITC-labelled reporter oligonucleotides and 
underwent highly efficient surface decoration with a variety of maleimide-based 
compounds. In vitro assessment of cellular capsid-uptake revealed that decoration of the 
capsid surface resulted in poor uptake in both Huh7 and HEK293 cells. As previously noted 
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[99], naked capsids were taken up by both cell lines. It is proposed that the ligand structure 
is responsible for poor cellular uptake, and optimised ligands may well allow for discriminate 
cellular entry of loaded capsids. 
5.2 Results 
5.2.1 Encapsidation of radio-labelled oligonucleotides by c183 
HBV capsids were assessed for their loading with short single stranded oligonucleotides. 
As it has previously been demonstrated by Porterfield and colleagues, the HBV capsid 
readily disassembles and loads with single and double stranded nucleic acid fragments 
varying in length [245]. It was necessary to determine whether the recombinant cysteine 
capsid mutants were amenable to dissociation, loading combined with re-association and 
finally surface decoration with functional moieties. As a point of reference, purified c183 
particles were chemically dissociated in 1.5 M guanidinium chloride containing 0.5 M lithium 
chloride. Dissociated capsids were combined with 32P-labelled 25-mer oligonucleotides and 
allowed to re-associate. The persistence length of the 25-mer did not affect capsid loading, 
and any potential secondary structure length was far shorter than the capsid diameter. 
Capsids containing the reporter radio-labelled oligonucleotide were separated from free 
oligonucleotides by agarose gel electrophoresis. The agarose gel was dried onto Whatman 
filter paper and analysis was conducted using a phosphorimager (Figure 5.2.1). It was shown 
that radio-labelled oligonucleotides were successfully encapsidated after capsid dissociation 
and re-association. A minimum of four hour dialysis against the dissociation buffer was 
required for significant oligonucleotide encapsidation, suggesting that 4 hours of dialysis 
was required for adequate capsid dissociation. To rule out the arbitrary association of 
oligonucleotides with the outer surface of capsids, samples were treated with DNase. It was 
found that dialysis for 4-6 hours against dissociation buffer followed by re-association was 
adequate to provide protection to encapsidated oligonucleotides. Inadequate dissociation 
(0-2 hours) did not allow for oligonucleotide uptake, resulting in their degradation. Thus 
these data suggest that the radio-labelled oligonucleotides are indeed housed within intact 
capsids, and gained protection from environmental nucleases. The dissociation/re-
association process appeared to cause some of the oligonucleotides to become lodged 
within the agarose gel well. This was most-likely an effect of capsid aggregation between 
dimer-dimer units and/or potential bacterial protein contaminants. Coomassie brilliant blue 
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staining revealed no significant decrease in the migrated capsid concentration of dissociated 
and non-dissociated capsids (data not shown). 
 
Figure 5.2.1: Phosphorimage of c183 capsids loaded with 
32
P- labelled oligonucleotides, separated by agarose 
gel electrophoresis. c183 capsids were dialysed against a dissociation buffer for 0-6 hours. DNase was included 
after re-association to degrade free oligonucleotides. The black arrow indicates the position of c183 capsids, 
while the white arrow indicates labelled 25-mer oligonucleotide. 
5.2.2 In vitro cellular uptake assessment of decorated, loaded c160 L76C S81C 
Having established that recombinant capsids were amenable to surface modification 
(Chapter 4), their delivery efficacy was assessed in vitro. The recombinant c160 L76C S81C 
capsid was selected to be loaded, decorated and tested in cell culture. c160 L76C S81C was 
able to undergo efficient conjugation with a variety of maleimide-based moieties and 
contains a truncated protamine domain which was capable of binding cargo nucleic acids. 
For the purposes of microscopy, a fluorescein-labelled oligonucleotide was encapsidated as 
opposed to the radio-labelled variety. It was reasoned the fluorescence would indicate 
subcellular localisation of the cargo during microscopy. Similarly to the c183-oligonucleotide 
encapsidation, c160 L76C S81C was dissociated and loaded with the fluorescent reporter. 
Re-associated capsids were then decorated with functional moieties described in Chapter 
4.2.4. Degree of conjugation was assessed by agarose gel electrophoresis (Figure 5.2.2). 
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Capsids loaded with fluorescently-labelled oligonucleotides were difficult to distinguish from 
non-loaded, as the capsids display auto-fluorescence under short-wave UV. As successful 
loading was accomplished in c183, it was assumed that c160 L76C S81C contained enough 
reporter oligonucleotide to be visualised during microscopy. 
          
Figure 5.2.2: Loaded and decorated c160 L76C S81C analysis by agarose gel electrophoresis. Capsids were 
loaded with FITC-oligonucleotides followed by decoration with a functional moiety. Capsids and 
oligonucleotides were viewed using shortwave UV. Decorated c160 L76C S81C migrate to various positions 
within the gel (white arrows). Free oligonucleotides are indicated by the black arrow. Control 1 (C1) contains 
loaded but undecorated c160 L76C S81C capsid. Control 2 (C2) contains c160 L76C S81C without FITC 
oligonucleotides. 
Decorated and loaded c160 L76C S81C were assessed for hepatotropism in cell culture.  
Approximately 70 000 Huh7 or HEK293 cells were inoculated with 4 g of loaded capsids 
and incubated for 2 hours. This equated to a MOI of ±4 x106 which did not take into account 
the low levels of contaminating proteins as well as any malformed or capsid aggregates. 
Thus the amount of particles per cell is suggested to be lower than initial estimates. A ten-
fold decrease in the amount of core protein administered did not produce visible 
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fluorescence (data not shown). Cellular uptake of the decorated capsids presented as 
localised fluorescence within the cells, assessed by fluorescence microscopy. Decoration of 
the capsid surface with the galactose and glucose ligands significantly decreased the cellular 
uptake of the loaded capsids in both cell lines (Figure 5.2.3 and 5.2.4 A + B). A low degree of 
localised fluorescence was present in both cell lines inoculated with the poly-galactose 
decorated capsids (Figure 5.2.3 and 5.2.4 C). This most-likely occurred as a result of 
incomplete capsid decoration, allowing for exposed capsid surface to interact with and be 
taken up by cells. PEGylation of the capsid surface prevented cellular uptake of the capsids 
(Figure 5.2.3 and 5.2.4 D). As established by previous researchers [98, 99], naked capsids are 
indiscriminately taken up by both cell lines (Figure 5.2.3 and 5.2.4 E), evidenced by the 
presence of localised fluorescence. Addition of naked oligonucleotide or naked, unloaded 
capsid to either cell line produced no visible fluorescence (Figure 5.2.3 and 5.2.4 F + G). 
Increased magnification revealed that a large degree of the oligonucleotides were localised 
to discrete bodies within the cells (Figure 5.2.5). These bodies are typically situated near the 
perimeter of the cell and are suggested to be involved in the endosomal-trafficking 
pathway. Currently it is not established whether the decorated capsids would escape the 
endosome and traffic to the nucleus. 
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Figure 5.2.3: Cellular uptake of decorated loaded 
capsids in the Huh7 cell line assessed by 
fluorescence microscopy under 200x 
magnification. (A-D) various functional attached to 
capsid surface. (E-G) Naked loaded capsid, naked 
capsid and naked oligonucleotides assessed for 
cellular uptake. Huh7 cells were not readily visible 
under transmitted light, and certain cells have their 
perimeters highlighted in white. Cell nuclei 
visualised by DAPI staining. Where faint, 
fluorescein fluorescence has been indicated (white 
arrow). 
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Figure 5.2.4: Cellular uptake of decorated loaded 
capsids in the Hek293 cell line assessed by 
fluorescence microscopy under 200x magnification. 
(A-D) various functional attached to capsid surface. 
(E-G) Naked loaded capsid, naked capsid and naked 
oligonucleotides assessed for cellular uptake. Cell 
nuclei visualised by DAPI staining. Where faint, 
fluorescein fluorescence has been indicated (white 
arrow). 
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Figure 5.2.5: Visualisation of endosomal vesicles after loaded naked capsid uptake in the Hek293 cell line 
under 630x magnification. Endosomal vesicles indicated with a black arrow and additional extracellular vesicles 
indicated by the white arrow. Cell perimeter indicated with a white-lined border. Cell nuclei stained with DAPI. 
5.2.4 Comparison of ligand linker lengths suggests why poor delivery 
occurred in cultured cells 
Despite the presence of the galactose ligand on the surface of the capsid, no uptake in 
Huh7 cells was observed. Linker length of the ligand invariably plays an important role in 
determining ligand interaction with the ASGPr. A similar observation was described in 
Chapter 2, where linker length played an important role in transfection efficiency. 
Comparison of the linker length of the two galactose compounds used in the liposome and 
capsid decoration studies revealed that they are of similar nature (Figure 5.2.6). Including 
medium linker chain unprotected galactose (MLC UnP galactose) in liposomes resulted in a 
significant drop in transfection efficiency compared to naked and short chain equivalents 
(Figure 2.2.2). Both the MLC and galactose-maleimide have linker chains of comparable 
length, and the significant drop in cellular uptake of the decorated capsids in both cell lines 
may be attributed to the linker moieties behaving like PEG. 
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Figure 5.2.6: Comparison of the linker length of the compounds medium length chain unprotected galactose 
(MLC, UnP galactose) used in liposomal studies with the galactose-maleimide ligand for conjugation to capsids. 
 
5.3 Discussion 
VLPs have several attractive properties useful in the developing field of gene therapy 
vectorology. Generally these particles are stable, simple and easy to produce, amenable to 
modification and receptive to cargo loading. The work described here aimed to assess the 
vector-like qualities of the HBV capsid after surface modification. A general property of 
examined VLPs is similar cellular uptake behaviour, in that naked capsids are 
indiscriminately taken up by a variety of cell types [286]. Accordingly it was required for the 
naked HBV capsid to be decorated with moieties that would provide either tissue tropism or 
immuno-evasive properties. It was assessed whether HBV capsids were receptive to 
reporter oligonucleotide loading followed by surface decoration. These modifications would 
confer hepatotropic properties to the capsids, and potentially allow for delivery of reporter 
oligonucleotides to cultured cells. 
HBV capsids were initially loaded with a radio-labelled oligonucleotide to assess whether 
dissociation and capsid uptake were indeed occurring. The amount of oligonucleotide 
loaded into each capsid was not assessed, as a result of two factors. The starting 
concentration of radio-labelled oligonucleotide was not determined, as a safety 
consideration while using communal equipment. Secondly, the drying process of the 
agarose gel into the filter paper does not always occur uniformly, and concentrated regions 
of radiolabeled oligonucleotides were seen to form. Nonetheless, this initial loading 
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experiment demonstrated that c183 were able to encapsidate 25-mer oligonucleotides. 
Loaded capsid treatment with DNase I cleared non-encapsidated oligonucleotides and 
demonstrated that the capsids provided a protective function against nuclease degradation. 
Future studies may include the incubation of loaded (and decorated) capsids within serum 
to assess the effect of serum proteins on capsids stability and aggregation. Once a successful 
loading protocol was established, c160 L76C S81C capsids were dissociated and loaded with 
fluorescein-labelled oligonucleotides. Again, the degree of oligonucleotide uptake was not 
easy to assess, as fluorescence measurements were also influenced by the auto-
fluorescence of the capsids. Furthermore, ethidium bromide staining revealed that not all 
the RNA of bacterial origin was removed from the capsids, thus further hindering 
spectroscopic analysis. Capsids containing a protamine domain gain stabilisation from their 
nucleic acid cargo. Thus the complete removal of residual RNA may not be easily 
accomplished as capsids will bind nucleic acids during re-association. Perhaps if the RNA 
were first degraded within the capsids prior to dissociation, it may be possible to load the 
capsids with only therapeutic/reporter oligonucleotides. 
It was assumed that the c160 L76C S81C capsids loaded a proportion of the fluorescently 
labelled oligonucleotides, and were then decorated with various moieties on the surface. As 
described in Chapter 4, a high degree of conjugation to the core protein occurred using 
galactose-maleimide, glucose-maleimide and maleimide-PEG. This was evidenced by the 
almost complete shift of core particles during agarose gel electrophoresis. Galactose4-
maleimide did not conjugate as successfully as the monosaccharide ligand. It was speculated 
that the high degree of monosaccharide ligand conjugation to the capsid may afford the 
vector with additional immuno-evasive properties. A basic means to assess this may be 
accomplished by performing an ELISA with primary antibodies targeting the IL of the HBV 
capsid. As described by several researchers, the IL is a predominant epitope of the HBV 
capsid and should elicit a reaction in the ELISA if exposed. 
According to protein concentration calculations, a MOI of ±4 x 106 viral particles was 
added to cultured Huh7 and Hek293 cells. Realistically the MOI was considerably lower, as 
there was a low level of protein contaminants in the capsid preparations and the 
dissociation/reassociation process may result in capsid aggregates (Figure 5.2.1 and 5.2.2). 
Upon addition to cells, the capsid stock experienced a 50-fold dilution, and majority of the 
capsids would have remained in suspension during the 2 hour incubation process. This was a 
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further dilution of VLPs to cells, decreasing the MOI. Thus despite the calculated MOI of ±4 x 
106, protein contaminants, potential core aggregation and VLPs that do not come into 
contact with cells, the estimated amount of capsids interacting with cells was far lower.  
The ligand structure attached to the capsid surface may play a major role in determining 
cellular uptake. It was demonstrated in Chapter 2 that the linker length between the 
liposome surface and galactose moiety played an important role in transfection efficiency. 
The linker length of the moieties conjugated to the capsid surface was similar to the 
liposomal species MLC. It was demonstrated that the MLC species cause a significant drop in 
transfection compared to the shorter length linkers. The moiety conjugated to the capsid 
surface possibly behaves more PEG-like, not only preventing potential ASGPr interaction but 
also creating a large enough distance between the cell surface and capsid to prevent 
interaction and uptake. Despite the lack of cellular uptake, it is useful to know that complete 
capsid decoration at the IL did prevent indiscriminate uptake. This is of particular 
importance, considering the purpose of this research. It was indicated in Chapter 2 that 
shortening of the linker length of the galactose compounds increased the transfection 
efficiency. Thus, conjugating galactose to the capsid surface with a short as possible linker 
may provide hepatotropism and retain the discriminate uptake.  
The HBV capsid does display potential as a vector for gene therapy. Several aspects will 
have to be addressed should a new ligand provide hepatotropism. One of the more 
problematic areas of synthetic gene delivery is the endosomal recycling of delivered cargo 
[107]. It will be required to determine the level of capsid uptake, release and/or degradation 
in cultured cells. This can be accomplished by monitoring the localisation of the capsid cargo 
over several time points. Over a period of 30 minutes to 2 hours, the majority of the cargo 
should be localised within the endosome. After 8 hours a larger proportion of the 
endosomal contents should be cleared, and after 24 hours even a greater degree of cargo 
clearance should be expected. Differential fractionation of cellular contents and analysis 
thereof (for example qRT-PCR) over this time period will reveal the degree of cargo delivery, 
especially when compared to in situ cellular DNA/RNA. This means of study will also give an 
indication of capsid disassembly and release of contents. An additional measurement to 
compliment localisation and recycling is the assessment of target gene knockdown induced 
by capsid cargo. An important aspect that many studies have overlooked is the live-cell 
Page | 130  
 
analysis of capsid trafficking within the cell, as modification to the outer surface of the 
capsid and the protamine domain may have major implications for cellular trafficking.  
An aspect of HBV capsid vectorology not addressed by this study is nucleic acid cargo 
optimisation. It is required to optimise the type of cargo encapsidated, bearing in mind what 
function it is to perform, and also optimise how the new cargo is encapsidated. Studies by 
Choi and colleagues revealed the delivery of siRNAs to cells by replacing the protamine 
domain with the p19 protein. Despite achieving knockdown of their target, it was not 
assessed whether the capsid was trafficked to the cytoplasm or nucleus, as the protamine 
domain is believed to play an important role in cellular localisation. Modification of the 
protamine domain may play an important role in the optimisation of the HBV capsid as a 
vector. Aspects such as capsid cellular destination and cargo size will need to be taken into 
consideration prior to modifying the protamine domain. Large protamine domains, like that 
of the wild type virus may traffic to the nucleus effectively but not easily dissociate from the  
small nucleic acid strands, such as those used in this study. The type and structure of the 
cargo may also play an important role in the efficacy of the delivery system. Short 
oligonucleotides may be ineffective in generating a therapeutic effect, as RNA is susceptible 
to degradation and short DNA strands have not had any significant impact within the field of 
gene therapy. Perhaps the introduction of short stable nucleic acids such as locked nucleic 
acids (LNAs) would transport well within modified HBV capsids. Double stranded nucleic 
acids longer than 150 bp will not package into the HBV capsid as a result of persistence 
length. The introduction of nicks or gaps into the double-stranded sequence may provide 
flexibility required to load into the capsid. Alternatively, single but complementary strands 
could be loaded individually into capsids and administered simultaneously. However, this 
form of administration would require double the amount of capsids, which may impact the 
host response.   
In conclusion, this chapter describes that the recombinant HBV capsid has the potential 
to be loaded with 25-mer oligonucleotides and then efficiently decorated with a variety of 
functional moieties. Furthermore it was found that capsids with adequate decoration to the 
IL did not undergo cellular uptake. This is of importance, as several of the capsids described 
within the literature are indiscriminately taken up in vitro and in vivo. This certainly bodes 
well for VLPs, as it is a matter of optimising the ligand structure to ensure hepatotropism or 
other cellular tropisms.  
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5.4 Materials and methods 
5.4.1 Recombinant capsid preparation 
Recombinant capsids involved in conjugation- and dissociation-based reactions were 
prepared using the ‘Porterfield protocol’ (Protocol 3 described in Section 3.4.3.3) [245].  
5.4.2 Capsid dissociation and re-association  
Recombinant capsids were dissociated by dialysing against dissociation buffer for 6 
hours at 4 oC unless indicated otherwise. Dissociated capsids were subjected to 
centrifugation for 30 minutes at 20 000 × g, 4 oC to remove encapsidated RNA. After 
centrifugation the supernatant was gently collected and pellet discarded. Fluorescein-
labelled oligonucleotides (25-mer, Inqaba Biotec) were added to the capsids at 25.7 pmol 
per 1 g capsid, respectively (Calculation can be found in Appendix 4). Oligonucleotides 
were made up as 2x stocks to desired concentrations using dissociation buffer (Radio-
labelled oligonucleotide concentration was not determined). Capsids were allowed to re-
associate overnight by dialysing against PBS at 4 oC. The final capsid working stock 
concentration was 1 g/l. Capsids were stored at -20 oC between analyses. 
5.4.3 32P-labelling of oligonucleotides  
Twenty five-mer oligonucleotides were labelled with [-32P]ATP. The reaction comprised 
10 U T4 polynucleotide kinase (Fermentas), 5 l 10x T4 polynucleotide kinase buffer (500 
mM Tris-HCl pH 7.6, 100 mM MgCl2, 50 mM DTT, 1 mM spermidine), 20 µCi [γ-32P]ATP 
(3000 Ci/mmol) and 100 pmol DNA oligonucleotide in a total volume of 50 l, incubated at 
37 oC for 2 hours. Oligonucleotides were purified by passing them through a 1 ml Sephadex 
G-25 column. FITC-labelled oligonucleotides were purchased from Inqaba Biotec (Pretoria, 
ZA) 
5.4.4 Imaging with the Phosphorimager 
Radio-labelled oligonucleotides were loaded into c183 capsids and subjected to agarose 
gel electrophoresis. A total of 30 g of loaded capsid was loaded per well, and subjected to 
electrophoresis at 80 V. The agarose gel was placed on Whatman 3MM Chr paper and dried 
at 80 oC under vacuum. Dried gels were exposed to the BAS SR 2040 imaging plate (Fuji, 
Tokyo Japan) overnight, and the FLA-7000 Phosphorimager (Fuji) was used to detect signal 
on the imaging plate the following day. 
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5.4.5 Cell Culture and VLP inoculations 
The cell lines Huh7 and Hek293 were maintained in DMEM (Gibco, Life Technologies, CA, 
USA) 10% FCS (Life Technologies, CA, USA) within a humidified incubator at 37 oC. To split 
Hek293 cells, medium was removed and 1 ml TripLE Express (Life Technologies, CA, USA) 
was added to a confluent 25 cm2 flask and incubated at 37 oC for 1 minute. Cells were gently 
aspirated and added to an appropriate volume of DMEM 10% FBS. Hek293 cells were not 
washed during splitting as they tend to dislodge easily from the flask surface. Huh7 cells in a 
25 cm2 flask were initially washed with 10 ml saline 0.5 mM EDTA, fresh 10 ml saline 0.5 mM 
EDTA added and incubated at 37 oC for 5 minutes. Following the two wash steps saline was 
removed and cells incubated with 1 ml TripLE Express (Life Technologies, CA, USA) for 5 
minutes. Cells were gently aspirated and added to an appropriate volume of DMEM 10% 
FCS. For VLP inoculations, cell lines were seeded at 60% confluency in 8-well glass Millicell 
EZ slide (Millipore, MA, USA). The following day medium was removed and replaced with 
200 l OptiMEM (Gibco, Life Technologies, CA, USA) containing 4 g of capsid preparation. 
The oligonucleotide control well received 100 pmol of naked FITC-labelled 25-mer. Capsids 
and cells were incubated together for two hours at 37 oC in a humidified chamber. Following 
incubation, cells were fixed to the slide surface by gently removing the medium and 
immersing the glass slide in ice cold methanol for 5 minutes. Following this cells were 
immersed in PBS containing 14.3 mM DAPI for 3 minutes at room temperature. Slides were 
briefly air dried and fluorescence preserving agent, Fluorsave (Millipore, MA, USA), added 
prior to covering cells with a cover slip. 
5.4.6 Microscopy and imaging 
Microscopy was performed using the Axiovert 100M (Zeiss, Oberkochen, Germany) 
fitted with the Axiocam MRm camera (Zeiss). Three images were taken to capture bright 
field, FITC fluorescence and DAPI fluorescence images. Excitation filters for DAPI and FITC 
were 365/10 nm and 470/40 nm. Combined images were generated using the Axiovision 4.8 
software (Zeiss). 
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Chapter 6: Conclusion 
The field of gene therapy has made rapid progress over the past two decades in treating 
conditions ranging from viral infections to autosomal diseases. Typically, in vivo treatment 
utilises a recombinant viral vector to deliver the corrective therapeutic. Success has been 
demonstrated using this approach in treating several diseases such as adenosine deaminase 
deficiency severe combined immunodeficiency (ADA-SCID) and has even shown potential 
against Parkinson’s disease [10, 310]. Despite the efficacy of the treatment itself, 
inefficiency of vectors remains major obstacle. Difficulties have been experienced using viral 
vectors, primarily involving stimulation of the immune response and a lack of immuno-
evasion, toxicity, cost and scaling up of production. A variety of alternative delivery vectors 
are under continuous development which attempt to simplify production, decrease cost and 
improve biocompatibility. However, synthetic vectors often demonstrate decreased in vivo 
efficacy compared to viral vectors. In an effort to improve on the application of synthetic 
vectors (which may also comprise hybrid organic-synthetic vectors, such as the decorated 
HBV capsid), several researchers have included VLPs in the development of gene therapy 
vectors. One of the more developed VLPs with regard to bionanotechnology is the cowpea 
mosaic virus (CPMV), which has seen modifications done to its structure to enhance the 
delivery capacity of the particle [94, 286]. Both the HBV and CPMV capsids offer similar 
vector capacity; however it is felt that the HBV capsid can be more efficiently produced as it 
does not require a plant host for synthesis.  
This study aimed to enhance the HBV capsid for delivery of a potential therapeutic 
cargo. The HBV capsid, like other VLPs, demonstrates indiscriminate cellular uptake in vitro 
and in vivo. Thus the introduction of a suitable chemical moiety to the capsid surface was 
required to prevent indiscriminate uptake and provide tissue tropism. Surface decoration 
was assessed by two means; conjugation of functional ligands to the capsids surface or 
envelopment of the capsids with liposomes. Maleimide-based conjugation of functional 
ligands to the capsid surface was accomplished by the introduction of cysteine residues into 
the IL of the capsid. It was shown in this study that the cysteine-maleimide reaction 
occurred very efficiently, attaching a functional moiety to almost all capsid proteins. In 
doing so, indiscriminate cellular uptake was prevented which may also function to decrease 
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initial immuno-stimulation in vivo. The HBV capsid will require tropism if it is to find use in in 
vivo application via systemic administration. This requires the development of alternative 
capsid ligands to provide the HBV capsid, and perhaps other VLPs, with cellular tropism. 
This study generated a useful and unique form of modifying the HBV capsid at the amino 
acid level. The ‘Snap-in’ method was able to overcome difficult cloning procedures 
associated with introducing foreign residues or peptides into the IL. The ‘Snap-in’ system 
allowed for the generation of several cysteine and lysine substitution mutants in a short 
space of time. This technology has the potential to be applied to various other VLPs that 
may require alterations to their capsid proteins. The SplitCore approach is another means of 
simplifying the cloning into the IL. This approach may also provide a means to stabilise bulky 
peptide sequences that would otherwise destabilise the core protein. Both approaches have 
their merits, however the defining feature of each system is an intact core protein 
generated by ‘Snap-in’ versus the halved core components produced by Splitcore. 
An aspect that will require further analysis is the type of cargo loaded into the 
recombinant capsid. Single stranded pgRNA (persistence length = 1-2 nm) is naturally 
encapsidated by the HBV capsid. Double stranded nucleic acids conversely have a fairly rigid 
structure (persistence length = ±50 nm), and a sequence of ±90 base pairs (30 nm) would 
not easily be encapsidated, nor contain viable therapeutic sequences. It is suggested that 
the material loaded into the capsid remains single stranded, such that both short and long 
sequences can be incorporated. It may be possible to administer a positive and negative 
strand individually, and ideally the complementary strands would combine within the cell 
nucleus. It may also be possible to introduce fragmented or nicked sequences, relying on 
the host repair machinery to reconstitute the therapeutic sequence. 
With the suggested improvements to the HBV capsid, it may become feasible to deliver 
a therapeutic cargo (these cargo may not necessarily be nucleic acids). The delivery may not 
be as efficient as the current virus-based delivery vectors, however may be considerably 
cheaper in production. This has particular importance in resource constrained countries 
such as Africa, where it is vital to address the various epidemics throughout the continent. 
VLPs, like liposomes, may one day be a feasible form of therapy, available for simple, 
inexpensive production in any country. 
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Appendix 1 
Primer sequences 
Generic core forward 
5’- GAT CCC ATG GAT GGA CAT CGA CCC TTA TAA -3’ 
Core reverse 140 
5’- GAT CCT CGA GCT ATA AGA TAG GGG CAT TTG -3’ 
 
Core reverse 149 
5’- GAT CCT CGA GCT AAA CAA CAG TAG TTT CCG -3’ 
 
Core reverse 160 
5’- GAT CCT CGA GCT AAG TTC TTC TTC TAG GGG -3’ 
 
Core reverse 170 
5’- GAT CCT CGA GCT ACG ATT GAG ACC TTC GTC -3’ 
 
Core reverse 183 
5’- GAT CCT CGA GCT AAC ATT GAG ATT CCC GAG -3’ 
 
M13F 
5’- GTA AAA CGA CGG CCA G -3’ 
 
M13R 
5’- CAG GAA ACA GCT ATG AC -3’ 
 
Lys sub int R 
5’- GAT CGA GCT CTC TTC GCT GGC TTT TCC AAA TTA ACA CCC ACC CAG G -3’ 
 
Lys sub int F 
5’- GAT CGG TAC CTA GTA GTC AGT TAT GTC AAC AC -3’ 
 
LinkedLys Int F1 
5’- GAT CGA TCT TTA AAG GGA AAG GGA AAG GGA AAG GGA GGA GGA GGA TCT A -3’ 
 
LinkedLys Int F2 
5’- GGG AAA GGG AGG AGG AGG ATC TAG AGA CCT AGT AGT -3’ 
 
LinkedLys Int R 
5’- GAT CAG GCC TCC TCC TCC ATC TTC CAA ATT AAC ACC CAC CCA GG -3’ 
 
Part A RE2 ‘Snap-in’ rev (43 bases) 
5’- CTA GCG ATC GCT AGC TAG GAA GAC GTT AAC ACC CAC CCA GGT A -3’ 
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Part B RE2 ‘Snap-in’ fwd (45 bases) 
5’- GAT CGC TAG CGA TCG ATC GAA GAC GTC AGT TAT GTC AAC ACT AAT -3’ 
 
Oligonucleotides  
Fwd single Lys R82K (38 bases) 
5’- GTT AAT TTG GAA GAT CCA GCG TCT AAG GAC CTA GTA GT -3’ 
 
Rev single Lys R82K (38 bases) 
5’- ACT GAC TAC TAG GTC CTT AGA CGC TGG ATC TTC CAA AT -3’ 
 
Fwd double A80K R82K (38 bases) 
5’- GTT AAT TTG GAA GAT CCA AAG TCT AAG GAC CTA GTA GT -3’ 
 
Rev double A80K R82K (38 bases) 
5’- ACT GAC TAC TAG GTC CTT AGA CTT TGG ATC TTC CAA AT -3’ 
 
Fwd single Cys S81C (38 bases) 
5’- GTT AAT TTG GAA GAT CCA GCG TCT AGA GAC CTA GTA GT -3’ 
 
Rev single Cys S81C (38 bases) 
5’- ACT GAC TAC TAG GTC TCT AGA CGC TGG ATC TTC CAA AT -3’ 
 
Fwd double L76C S81C (38 bases) 
5’- GTT AAT TGT GAA GAT CCA GCG TCT AGA GAC CTA GTA GT -3’ 
 
Rev double L76C S81C (38 bases) 
5’- ACT GAC TAC TAG GTC TCT ACA CGC TGG ATC TTC ACA AT -3’ 
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Appendix 2 
Reagent recipes 
Ethidium bromide solution (100x) 
100 mg ethidium bromide in 10 ml H2O 
 
Lysogeny broth (LB) 
10 g Tryptone 
5 g Yeast Extract 
5 g Sodium Chloride 
Make up to 1 L with H2O – autoclave. 
 
LB Agar 
10 g Tryptone 
5 g Yeast Extract 
5 g Sodium Chloride 
1 2g Agar 
Make up to 1L with H2O – autoclave. 
 
Ampicillin stock (1000x) 
100 mg/ml ampicillin 
Dissolve in 50% (v/v) ethanol/H2O solution 
 
Chloramphenicol stock (1000x) 
34 mg/ml chloramphenicol 
Dissolve in ethanol 
 
Transformation buffer 
15 ml Glycerol 
1.47 g CaCl2.2H2O 
302.4 mg PIPES-HCl 
80 ml H2O 
pH 7 using NaOH, make up to 100 ml with H2O,  filter sterilise 
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Isopropyl β-D-1-thiogalactopyranoside stock (IPTG) – blue/white screening 
100 mg IPTG in 1 ml H2O 
 
5-bromo-4-chloro-indolyl-galactopyranoside stock (X-Gal) 
20 mg X-Gal in 1 ml dimethyl formamide 
 
Protein expression broth 1 L 
5 g Yeast extract 
10 g tryptone 
5 g glycerol 
0.5 g glucose 
0.7 g Na2SO4 
2.5 g NH4Cl 
Autoclave, then add: 
1 mL 2 M MgSO4 
1 mL metals mix* 
 
* Metals mix 100 mL (1000x): 
50 mL 0.1 M FeCl3 dissolved in 0.1 M HCl 
1 mL 1 M MnCl2 
1 mL 1 M ZnSO4 
1 ml 0.2 M CoCl2 
1 ml 0.2 M NiCl2 
46 mL H2O 
 
Isopropyl β-D-1-thiogalactopyranoside 1000x stock (IPTG) – protein expression 
0.47 g in 2 ml H2O 
 
PBS pH 7.4 @ room temperature 1 L  
8 g NaCl 
0.2 g KCl 
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1.44 g Na2HPO4 
0.24 g KH2PO4 
 
Resuspension Buffer A 
50 mM Tris-HCl pH7.4 
1 mM EDTA 
5 mM DTT/TCEP (tris(2-carboxyethyl)phosphine - Sigma). 
1 mM PMSF 
 
Column Buffer A 
100 mM Tris-HCl pH7.5 
100 mM NaCl 
50 mM sucrose 
2 mM DTT/TCEP 
 
Resuspension buffer B 
0.25 mg/ml PMSF (phenylmethylsulfonyl fluoride - Sigma) 
50 mM Tris pH 7.5 at 4oC 
5 mM TCEP (tris(2-carboxyethyl)phosphine - Sigma). 
 
Column buffer B 
5% w/v sucrose 
5 mM EDTA 
50 mM Tris pH 7.5 at 4oC 
2 mM TCEP 
 
Tris-NaCl Buffer (TN Buffer) pH 7.6 
25 mM Tris 
50 mM NaCl 
 
SDS-PAGE gel stain 2 L 
1 g Coomassie Brilliant Blue 
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500 ml isopropanol 
200 ml acetic acid 
1300 ml water 
 
malPEG5000 stock stored at -80oC 
100 mg malPEG5000 in 1 ml DMSO. 
 
Transformation buffer pH 7.0 (stored at -20oC) 
100 mM CaCl2 
10 mM PIPES-HCl 
15% glycerol 
Make up to 50 ml with H2O 
Filter-sterilise and store 
 
Glucose buffer (P1) pH 8.0 
50 mM glucose 
25 mM Tris-HCl 
10 mM EDTA 
 
Lysis buffer (P2) 
0.2 M NaOH 
1% SDS (w/v) 
 
Neutralisation buffer (P3) 
300 ml 5 M potassium acetate 
57.5 ml glacial acetic acid 
142.5 ml H2O 
 
Salt-saturated phenol 
500 g phenol 
100 ml 2M Tris-HCl, pH7.4 
130 ml H2O 
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Dissolve phenol, remove upper aqueous phase (sometimes it is necessary to add more Tris-
HCl solution and H2O) 
Add: 100 ml 2 M Tris-HCl, pH 7.4 
25 ml m-cresol 
1 ml -mercaptoethanol 
500 mg 8-hydroxyquinoline 
Use the upper phase from extraction purposes. 
 
Disassociation buffer 
1.5 M guanidine HCl 
0.5 M LiCl 
50 mM HEPES, pH 7.5 
 
4x Running Buffer for PAGE gels 
1.5 M Tris (pH 8.8) in 200 ml H2O 
 
4x Stacking Buffer of PAGE gels 
0.5 M Tris (pH 6.8) in 50 ml H2O 
 
2x Protein Loading dye 
2.5 ml 4x Stacking Buffer 
4 ml 10% SDS 
2 ml Glycerol 
2 mg Bromophenol Blue 
0.31 g DTT 
Make up to 10 ml H2O 
 
50x Tris Acetate EDTA (TAE) buffer (1L) 
242 g Tris 
57.5 ml glacial acetic acid 
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100 ml 0.5M EDTA 
 
Appendix 3 – Standard Laboratory Protocols 
A3.1 Chemically competent bacteria 
 Inoculate 10 ml LB with 100 l of bacterial stock (glycerol stock or a previously 
prepared competent bacteria aliquot. Some bacterial strains require antibiotics 
during their culture to maintain important plasmids. Incubate the culture over night 
with shaking at 37 oC.  
 Allocate 5 ml of the overnight culture into 45 ml LB. Incubate with shaking at 37 oC 
until the culture has reached an optical density of 0.4 @ 600 nm 
 Pellet bacteria by centrifugation at 1500 × g for 20 minutes at 4 oC, removing the 
supernatant. 
 Resuspend each bacterial pellet in 5 ml transformation buffer (Appendix 2), and 
incubate on ice for 20 minutes.  
 Pellet the bacteria for 10 minutes at 500 × g at 4 oC, remove the supernatant and 
gently resuspend the collected bacteria in 2 ml transformation buffer. 
 Aliquot into 100 l stocks and store at -80 oC 
A3.2 Transformation of chemically competent bacteria 
 Thaw a chemically competent bacterial stock on ice. 
 Add 100 ng – 1 g of DNA to the competent bacteria and gently mix. Place on ice for 
20 minutes. 
 Heat shock the bacteria at 42 oC for 90 seconds and place on ice for 5 minutes 
 Distribute the transformed bacteria on a LB agar plate. 
A3.3 Blue-white screening 
 Prior to distributing transformed bacteria on a LB agar plate, evenly spread 8 l IPTG 
and 40 l X-Gal (Appendix 2) over the agar surface and allow to dry for 20 minutes at 
37 oC.  
 Once the agar surface has dried distribute transformed bacteria over it. Incubate the 
plate at 37oC overnight. 
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 White colonies contain the cloned gene of interest, as the β-galactosidase gene has 
been disrupted. Blue colonies conversely do not contain the cloned gene of interest. 
A3.4 Plasmid extraction 
Preparations of plasmid vary in accordance to the yield of DNA required. The main 
difference in both preparations is the amount of starting culture used. Mini-preps require 
volumes ranging between 2-10 ml of culture, and midi-preps between 100-200 ml of 
culture. 
 Culture overnight 10 ml 200 ml of the respective clone required. Harvest the 
bacterial pellet by centrifugation at 5000 × g for 10 minutes. 
 Resuspend the bacterial pellet in 200 l 10 ml chilled glucose buffer (P1) 
 Add 200 l 10 ml lysis buffer (P2), gently mix by inversion and incubate at room 
temperature for 5 minutes. 
 Add 200 l 10 ml chilled neutralising buffer (P3), gently mix by inversion and 
incubate on ice for 10 minutes. 
 Bacterial debris and precipitate is pelleted by centrifugation at 5000 × g for 10 
minutes at 4 oC. Remove any additional debris by pouring the supernatant through a 
fine cloth (muslin). 
 Add an equal volume of isopropanol to the filtered supernatant, mix and incubate on 
ice for 30 minutes. 
 Centrifugation at 10000 × g for 30 minutes (4 oC) causes the DNA to pellet. 
 Resuspend the pellet in 50 l 600 l H2O, add equal volumes of chloroform and ss-
phenol and briefly vortex. 
 Separate the phases by centrifugation at 14000 × g for 1 minute.  
 Carefully remove the clear upper phase (discard the lower phases) and add an equal 
volume of chloroform, briefly vortex and subject to centrifugation at 14000 × g for 1 
minute. Repeat this step. 
 Remove the upper phase, add an equal volume of isopropanol and 10% of the final 
volume of 3 M sodium acetate. Incubate on ice for 30 minutes or overnight at -20 oC. 
 Pellet the DNA by centrifugation at 14000 × g, 4 oC for 30 minutes. Remove 
supernatant and add 500 l 70% ethanol (v/v), incubate on ice for 10-20 minutes. 
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 Pellet the DNA by centrifugation at 14000 × g, 4 oC for 5 minutes. Remove 
supernatant and dry DNA pellet. Resuspend the pellet in 20-50 l 200 l-1ml sterile 
H2O. 
A3.4 Phenol-chloroform extraction 
 Combine equal parts of DNA suspension, chloroform and salt-saturated phenol. 
 Thoroughly mix samples and centrifuge at max speed (>8000 × g) for 90 seconds. 
  Retain the upper phase and equal volume of chloroform added. 
 Thoroughly mix samples and centrifuge at max speed (>8000 × g) for 90 seconds. 
 Repeat the chloroform wash step. 
 Retain the upper phase and an equal volume of chilled isopropanol added, to this 
add 10% of the total volume 3 M sodium acetate. 
 Incubate on ice for 30 minutes and centrifuge (>8000 × g) for 30 minutes at 4 oC. 
 Remove supernatant and wash DNA pellet with 70% ethanol.  
 Remove supernatant and dry DNA pellet at room temperature.  
 Resuspend the dried DNA pellet in an appropriate volume of distilled water. 
A3.5 Agarose and polyacrylamide gel staining to detect recombinant HBV 
capsids 
 After electrophoresis polyacrylamide gels were stained for two hours in Coomassie 
Brilliant blue stain (Appendix 2) with gentle shaking. Gels were washed in water to 
remove excess stain and then incubated overnight in a destaining solution (80% H2O, 
10% MeOH and 10% AcOH (v/v)). Tissue paper was included during the destaining 
process to aid the extraction of stain from the gel. 
 Agarose gels were stained for 4 hours using a 15-fold dilution of the Coomassie 
Brilliant blue stain. The stain was diluted using destaining solution. Gels were washed 
in water to remove excess stain and then incubated overnight in a destaining 
solution (80% H2O, 10% MeOH and 10% AcOH (v/v)). Tissue paper was included 
during the destaining process to aid the extraction of stain from the gel. The 
destaining process took up to 36 hours for the majority of the stain to be extracted.   
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Appendix 4 
A4.1 Example calculation to determine lysine:ligand mole ratio for conjugation 
 Recombinant c149 capsid concentration is 1 g/l (Mw = 16700 Da) 
 Ligand stock concentration is 100 mg/ml (scPEG Mw = ±5 kDa) 
 100 l of protein stock used 
 Reaction mol ratio 10 ligand : 1 core protein 
If the IL of c149 A80K R82K contains two reactive lysine species then: 
  
 
  
 
  
      
             
 
   
      
             
   
        
      
 
               of core protein (double for the amount of lysines) 
Thus 1.25 x 10-8 mol lysine residues per 100 g core protein 
Similarly, 1 l of scPEG stock contains 100 g, then 
            of scPEG per 1l of stock 
Thus a reaction containing 1 part lysine to 1 part scPEG requires 100 l core protein 
stock and 0.625 l scPEG stock. Similarly a 1 part lysine to 10 parts scPEG reaction requires 
100 l core protein stock and 6.25 l scPEG stock 
 
A4.2 Example calculation to determine cysteine:ligand mole ratio for 
conjugation 
 Recombinant c160 capsid concentration is 1 g/l (Mw = 18200 Da) 
 Ligand stock concentration is 10 mg/ml (gal-mal Mw = 529.58 Da) 
 100 l of protein stock used 
 Reaction mol ratio 10 ligand : 1 core protein 
If the IL of c160 L76C S81C contains two reactive cysteine species then: 
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              of core protein (double for the amount of lysines) 
Thus 1.1 x 10-8 mol cysteine residues per 100 g core protein 
Similarly, 1 l of gal-mal stock contains 10 g gal-mal, then 
              of gal-mal per 1l of stock 
Thus a reaction containing 1 part cysteine to 1 part gal-mal requires 100 l core protein 
stock and 0.58 l gal-mal stock. Similarly a 1 part cysteine to 10 parts gal-mal reaction 
requires 100 l core protein stock and 5.8 l gal-mal stock. 
A4.3 Calculation to determine oligonucleotides (25-mer) required per g of 
capsid 
Porterfield et al.  states: 0.6 Arginine residues required per 1 phosphate molecule 
(RNA/DNA) [245]. 
Thus 1 g of c160 contains approximately: 
  
 
  
 
   
    
             
   
        
    
 
               of core proteins per 1 g 
c160 contains 7 arginine residues in the protamine domain, thus there are 385 pmol Arg 
per 1 g protein.To determine the amount of 25-mer to add; 385 pmol Arg can bind 641.7 
pmol phosphate molecules. If there are 25 phosphate per oligomer, 1 g of capsid can bind 
25.7 pmol oligomer. 
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